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Abstract 
 
Background  
Hyperinsulinemic hypoglycemia (HI) and congenital polycystic kidney disease (PKD) are rare, 
genetically heterogeneous disorders. The co-occurrence (HIPKD) in 17 children from 11 
unrelated families suggested a shared cause.  
 
Methods 
We ascertained the clinical phenotype and performed genetic studies. The effect of the 
identified shared mutation was assessed in vitro. 
 
Results 
All patients exhibited HI and enlarged polycystic kidneys. Whole genome linkage analysis in 
5 informative families identified a single significant (LOD 6.5) locus on chromosome 16p13.2. 
A promoter mutation (c.-167G>T) in PMM2 was found in all patients, either homozygous or in 
trans with PMM2 coding mutations. Yet, typical systemic features of congenital disorder of 
glycosylation type 1a were absent and the diagnostic test of transferrin isoelectric focusing 
was normal. 
The promoter mutation showed decreased transcriptional activity in patient kidney cells and 
impaired binding of the transcription factor ZNF143. In silico analysis suggests an important 
role for ZNF143 for the formation of a chromatin loop including PMM2 that could affect tissue-
specific transcription. In order to investigate this further in a chromatin conformation study a 
HIPKD cell model homozygous for the promoter mutation was generated with CRISPR-Cas9.  
 
Conclusions 
We report a rare disease characterized by the combination of hyperinsulinemic hypoglycemia 
and polycystic kidney disease. Our findings extend the spectrum of genetic causes for both 
disorders, provide insights into gene regulation and implicate glycosylation in the disease 
etiology. The identified promoter mutation appears critical for tissue-specific regulation of 
PMM2 transcription, leading to an organ-specific phenotype and explaining PMM2 pleiotropy. 
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Impact Statement  
 
The work undertaken during this project expands the spectrum of genetic causes for HI and 
PKD, relevant for clinical research and diagnosis. This study also provides critical insights into 
gene regulation and underlines the importance of studying the impact of non-coding variants 
in human disease. Furthermore, it indicates that the higher organisation of the genome 
essentially contributes to correct gene regulation and that extensive research on this topic is 
of great value for both, basic and medical research.  
The initial findings during this PhD have highlighted the dysfunctional gene regulation of the 
PMM2 promoter variant. This substantially has contributed to postulate a hypothesis for the 
potential disease mechanism in HIPKD and eventually has helped to draw the attention onto 
gene regulation and 3D chromatin conformation. In this thesis, the generation of a HIPKD cell 
model with the CRISPR-Cas9 technology will take the project to its next level and will enable 
us to study the 3D conformation in health and disease on the example of HIPKD. Hence, this 
work will provide new important details of the spatial organisation of the human genome in 
general and will help to understand interactions within the genome and how these are affected 
when a mutation lies in a gene regulatory element.  
In fact, about 30 million people in Europe are affected by rare diseases (same number in the 
US). 80% of rare disease worldwide are of genetic cause and often are life-threatening 
devastating disorders which frequently affect children.  
The major issue with rare diseases is the lack of treatment for most of them. Research on rare 
diseases significantly improves the understanding of biology and molecular mechanisms 
within the human body in health and disease, which is crucial for the identification of drug 
targets with the major goal of developing new treatments. These may not only benefit patients 
with the rare disease that led to the identification of the drug, but also for more common 
diseases. Moreover, extensive research on rare diseases can improve diagnosis and thereby 
avoid unnecessary treatments and improve and personalise disease management.  
Studies as conducted during this PhD with the aim to decipher a rare disease mechanism 
significantly contributes to the general understanding of biological processes important for 
human health and in particular the involvement of the non-coding genome and chromatin 
folding in human disease. More than a million enhancer elements are present within the 
human genome. Hence, it is not surprising that non-coding mutations which alter architectural 
modules can cause human disease. However, we are just at the beginning to understand how 
SNPs and structural variants impact genome folding. The combination of Hi-C data and gene 
editing tools such as CRISPR-Cas9 may allow for innovative new therapeutic inventions. 
These could be based on cell-related therapy and the insertion or elimination of architectural 
 6 
modules. Thus, studies which focus on the 3D genome itself and the impact of non-coding 
variants on genome folding are needed to significantly improve diagnostic and potentially 
therapeutic outcomes valid for research, medicine and industry.  
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Abbreviations  
 
3D 3-dimensional 
ABAT 4-Aminobutyrate Aminotransferase 
AC Adenylate cyclase  
ADPKD Autosomal dominant polycystic kidney disease  
AP Action potential 
ARPKD  Autosomal recessive polycystic kidney disease  
ASA Allele-specific assay 
ASN  Asparagine 
ATP Adenosine Triphosphate 
BBS Balanced salt solution  
bp Base pairs 
BSA  Bovine serum albumin 
BSS Balanced salt solution 
cAMP Cyclic adenosin monophosphat, 3,5-cyclic AMP  
CARHSP1 Calcium Regulated Heat Stable Protein 1 
CD Collecting duct  
CDG-1a Congenital disorder of glycosylation Type 1 A  
CDH1 Cadherin 1 
cDNA Complementary DNA 
CHF Congenital hepatic fibrosis 
ChIP Chromatin immunoprecipitation 
CKD Chronic kidney disease  
CNS central nervous system  
CRISPR  Clustered regularly interspaced palindromic repeats 
CRISPR-HDR  CRISPR experiment with HDR donor 
CRISPRed CRISPR edited 
crRNA CRISPR RNA 
CTCF CCCTC-binding factor 
DAG Diacylglycerol 
DCT Distal convoluted tubule  
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
Dol-P Dolichol-P linker  
Dol-P-Man Dolichol-P-Mannose  
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dPCR  Digital PCR 
DSB DNA double strand-breaks  
EMSA Electrophoretic mobility shift assay 
Endo H Endoglycosidase H 
Epac Exchange-protein directly activated by cAMP 
ER Endoplasmic reticulum 
ESKD End-stage kidney disease  
FACS Fluorescence-activated cell sorting 
FAM 6-carboxyfluorescein 
FBS  Foetal bovine serum 
FCS Fetal calf serum 
fg Femtogram 
G1 phase First growth phase in cell cycle 
G2 phase Second growth phase in cell cycle 
GABA Gamma-Aminobutyric acid 
GCK Glomerulocystic kidney disease  
GCK Glucokinase 
GDH Glutamate dehydrogenase  
gDNA Genomic DNA 
gDNA Genomic DNA 
GEA Gene expression assay 
GEA Gene expression assay 
GFP Green fluorescent protein 
GFR glomerular filtration rate 
GlcNAc N-acetylglucosamine  
GLP-1 Glucagon-like peptide 1  
GLP-1R Glucagon-like peptide 1 receptor 
GLUT2 Glucose transporter type 2 
GLUT4 Glucose transporter type 4  
GMO Genetically modified organism 
GPCR G-protein coupled receptor  
gRNA Guide RNA 
GSIS Glucose-induced insulin secretion 
GSIS  Glucose stimulated insulin secretion 
HDR Homology-directed repair 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HI Hyperinsulinemic hypoglycemia/Hyperinsulinism 
HIPKD Hyperinsulinemic hypoglycemia and polycystic kidney 
disease 
HNF4A Hepatocyte Nuclear Factor 4 Alpha 
IEF Isoelectric focusing 
IEQ  One islet equivalent 
IP3 Inositol trisphosphate 
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IP3R IP3 receptor  
iPSC Inducible pluripotent stem cells 
IR Insulin receptor 
IRS Insulin receptor substrates  
KATP ATP-sensitive potassium channel 
kb Kilobase 
kDa Kilodalton 
Kir 6.2  inward rectifying potassium channel 
KRBB  Krebs-Ringer bicarbonate buffer 
LDL Low-density lipoprotein 
LiCl Lithium chloride 
LoH Loop of Henle 
M phase Mitotic phase 
Man-1-P Mannose 1-phosphate 
Man-6-P Mannose 6-phosphate  
MCT-1 Monocarboxylate transporter 1  
MEF Murine embryonic fibroblast 
MGB Minor-groove-binder 
mM Millimolar 
MRI Magnetic resonance imaging 
MUT Mutant 
mV Millivolt 
NFQ 3' nonfluorescent quencher 
ng nanogram 
NHEJ Non-homologous end joining 
nM Nanomolar 
NSB  No sample blank 
nt nucleotide 
OCD Oriented cell division 
ON Over night 
PAM Protospacer adjacent motif 
PBS Phosphate buffered saline 
PC-1 Polycystin 1 
PC-2 Polycystin 2 
PC1 CTT Polycystin 1 C-terminal tail  
PCR Polymerase chain reaction 
PCT Proximal convoluted tubule 
PKA Protein kinase A  
PKC Protein kinase C 
PKC α Protein kinase C α 
PKD Polycystic kidney disease 
PLC Phospholipase C 
pM Picomolar 
PMA Phorbol 12-myristate 13-acetate 
PMM2 Phosphomannomutase 2 
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PNGase F Peptide N-Glycosidase F 
PP Pancreatic polypeptide 
PPIA Peptidylprolyl isomerase A 
PST Proximal straight tubule  
QC1 Quality control 1 
QC2 Quality control 2 
qRT-PCR quantitative reverse transcription PCR 
RD Rare diseases 
RIPA Radioimmunoprecipitation assay buffer 
RNA Ribonucleic acid 
RNPs Ribonucleoproteins 
ROI Region of interest 
RPF renal plasma flow  
rpm Revolutions per minute 
RRP Readily releasable pool 
RT Room temperature 
RyR Ryanodine receptor  
S phase DNA replication (Synthesis phase) 
SBS Specific binding site 
SEM Standard error of the mean 
SGLT2 Sodium-glucose co-transporter 2  
sgRNA Single guide RNA 
SNARE Soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor 
SNP Single nucleotide polymorphism 
SOC Store-operated calcium channels  
ssODNs single-stranded oligodeoxynucleotides (homologous 
HDR DNA repair template) 
SUR1 Sulfonylurea receptor 1 
TADs Topology associating domains 
TALEN Transcription activator-like effector nucleases  
TCA cycle Tricarboxylic acid cycle 
TIDE Tracking indels by Decomposition 
TMEM186 Transmembrane Protein 186 
TRPM2 Transient receptor potential cation channel 2 
TRPP2 Transient receptor potential ion channel 2 
trRNA Trans-activating crRNA 
UCSC University of California, Santa Cruz 
V Volt 
VDCC Voltage-dependent calcium channels   
wt/WT Wildtype 
ZNF  Zinc finger proteins 
ZNF143 Zinc Finger Protein 143 
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Chapter 1: General Introduction  
1.1 The nephron  
The nephron represents the functional unit of the human kidney converting blood into 
urine in a process of filtration, reabsorption, secretion and excretion, which is “cleaning” 
the blood from waste products (metabolic waste, toxins) and maintaining homeostasis of 
blood volume and composition, essential for the human body. About 500,000-1,000,000 
nephrons are present in each kidney. They are composed of two major compartments, 
the renal corpuscle and the renal tubule 1,2.  
The renal corpuscle functions like a blood filter with the glomerulus forming a network of 
capillaries inside, surrounded by the Bowman’s capsule, a bowl-like structure formed of 
epithelial cells, collecting the glomerular filtrate. It is permeable for nearly all components 
of the blood apart from proteins, red and white blood cells and thrombocytes; these are 
restrained by specialised cells, the podocytes, which function as a barrier 3. Around 300 
litres of blood per day are passing through the glomerular capillaries, which derive from 
the afferent renal arteriole and around 180 litres of blood are filtered. The unfiltered blood 
leaves the glomerulus through the efferent arteriole 4. The glomerular filtrate or primary 
urine contains all essential solutes (Ca2+, Na+, K+, Cl-, Mg2+, HCO3-, glucose, amino acids, 
vitamins and H20) and also waste products and enters the lumen of the renal tubular 
system for further processing 5.  
The tubular system is lined with epithelial cells, which function as a barrier between the 
blood and the tubular lumen where they facilitate the reabsorption of the essential solutes 
back into the bloodstream by active, energy-consumptive and passive transport 
processes through a well-orchestrated system of channels, pumps and transporters. The 
renal tubular epithelial cells are polar cells with an apical (lumen) and basal (blood) side. 
The proximal tubule epithelial cells are equipped with an apical brush border formed of 
microvilli, increasing the luminal cell surface dramatically for reabsorption processes.  
The renal tubules are sectioned into different segments with unique functions defined by 
the altering specificity and morphology of the lining epithelial cells. The first segment is 
composed of the proximal convoluted tubule (PCT) and proximal straight tubule (PST) 
followed by the loop of Henle (LoH), distal convoluted tubule (DCT) and the collecting 
duct (CD). Apart from the LoH and the CD, which extends into the renal medulla, all parts 
of the nephron are embedded within the renal cortex, the outer zone of the kidney 6.  
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About 99% of the glomerular filtrate is reabsorbed via the tubular epithelium into the 
circulatory system through the peritubular arterioles located alongside the tubular system 
and are connected with the efferent arteriole. The DCT delivers the final filtrate, the urine, 
to the collecting ducts, which end in the renal collecting system from where the ureters 
drain the final urine to the urinary bladder for excretion 7. Disturbances in these essential 
processes can result in general and specific metabolic imbalances and the study of these 
rare renal disorders help to explain the overall renal physiology. In particular, so-called 
renal tubulopathies have helped to understand the molecular physiology. But there are 
also more common conditions that illuminate the consequences of kidney dysfunction, 
for example chronic kidney disease (CKD), nephrolithiasis (kidney stones) and PKD.  
Figure 1: Anatomical structure of the nephron.  
Blood enters the glomerulus through the efferent arteriole. The glomerular filtrate (primary urine) 
gets collected in the Bowman capsule and passes the renal tubular system for reabsorption of 
essential solutes, which into the circulation via the peritubular capillary network. Starting at the 
proximal convoluted tubule the filtrate passes further down through the loop of Henle and the 
distal convoluted tubule. The final filtrate (urine) finally arrives at the collecting duct for excretion. 
Figure taken from https://biologydictionary.net.   
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1.2 Rare diseases and how they teach us  
Rare diseases (RDs) or also commonly called orphan diseases are typically Mendelian 
disorders. They are often severe, disabling, degenerative and life-threatening disorders 
of multisystemic nature, affecting different organ systems. There is no global agreement 
on when a disease is classified “rare”. In Europe for example, a disease is considered 
rare when less than one in 2,000 individuals are affected, whereas in the US this is the 
case when a disease is concerning fewer than 200,000 people. Worldwide the number 
of individuals affected by a RD was estimated between 350 and 400 million in 2014 8-10. 
Approximately 5,000–8,000 such highly heterogeneous RDs are known and about 80% 
of them identified being of genetic origin.  
At least 150 of known RDs are rare kidney diseases, with 60–80 affected in 100,000 
individuals in Europe and the US. Although such rare renal diseases are usually not 
lethal as good organ-replacement therapy is available, patients often suffer from 
multisystem features and have a poor quality of life, as the kidneys contribute to 
numerous homeostatic processes within the body. Renal replacement therapy, such as 
dialysis or transplant becomes necessary, when kidney function has deteriorated to such 
a degree that it is unable to maintain basic homeostatic function, a condition called end-
stage kidney disease (ESKD). ESKD is due to genetically-caused renal conditions in at 
least 10% of all cases (adults and children) 11,12.  
Figure 2: Anatomy of the renal corpuscle, cross section of the Bowman capsule.  
A tuft of capillaries (glomerulus) surrounded by a single layer of epithelial cells of the bowman 
capsule. Afferent arteriole: Blood flow entering the capillaries of the glomerulus for filtration. 
Macula densa (MD, distal convoluted tubule) and juxtaglomerular cells (JC) regulate blood 
pressure. MD: Sodium detection, triggers contraction of afferent arteriole when sodium is high. 
JC: Renin secretion when sodium is low: Efferent arteriole: Unfiltered blood leaving the 
glomerulus. Proximal convoluted tubule: Tube lined with polar epithelial cells. Glomerular filtrate 
enters the renal tubular system for reabsorption and disposal of urine. Figure taken from 
http://cjasn.asnjournals.org/.  
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RDs cover a broad group and are organised in subgroups according to pathology, these 
for example include: Metabolic, autoimmune or neurodegenerative diseases, rare 
cancers, dysmorphic conditions and congenital malformations 9. While individual RD are 
rare, patients affected by RD are frequent making research into RD an important 
endeavour. Moreover, research into describing their pathomechanisms significantly 
helps to better understand normal human physiology and pathology. The genetic causes 
of RDs are related to monogenic mutations, thus providing a lot of potential relevance in 
research, as the study of the phenotypic contribution of a single gene is easier to conduct 
compared to understanding the multiple genetic influences seen in complex disorders. 
Knowing the disease-causing gene and its protein product helps to decipher the 
principles of genetics, biochemical pathways and physiological processes, equally 
relevant also for common diseases and overall helping to identify potential targets for 
medical treatment and therapy for both, rare and common diseases 13. The development 
of statins is an example for how studying a RD (homozygous familial 
hypercholesterolaemia) has helped to develop a universal drug to lower LDL (low-density 
lipoprotein) cholesterol within hypercholesterolemic conditions 14.  
The small number of patients affected by an individual RD makes the development of 
effective drugs and treatments challenging for researchers, highlighting the importance 
of broad international collaborations and the formation of biobanks to gather clinical and 
genetic data as well as biospecimens. Such biobanks are of scientific and clinical 
relevance, contributing to the understanding of biology, the causes of disease or the 
identification of new disease genes, mutations and biomarkers that can help develop 
improved diagnostic and therapeutic approaches 9,15. Moreover, RDs provide a lot of 
potential for innovative therapy approaches, such as gene therapy or enzyme-
replacement therapy. In 2011 for example, 20% of all innovative products released to 
the market in Europe were specific for the treatment of RDs 16.  
1.3 Cystic kidney diseases  
Cystic kidney diseases are highly heterogeneous and can have genetic, developmental 
or acquired causes. They are often part of a rare syndrome appearing together with 
additional features in other tissues. Interestingly, many mutations causing renal cyst 
formation are often found in genes associated with the cilia centrosome complex and 
ciliary dysfunction is the shared pathomechanism (ciliary hypothesis) of such diseases. 
Therefore, cilia-related cystic kidney diseases belong to the group of ciliopathies. 
However, renal cysts also develop through mutations in other genes encoding for 
proteins which are not directly involved in cilia structure or function 17. The most common 
             Chapter 1 
 25 
ciliopathies are outlined below. Table 1 provides an overview of ciliopathies, their cyst-
causing proteins and where these operate within the body.  
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Table 1: Ciliopathies and their causative genes.  
Encoded proteins and their function. Table modified after Loftus and Ong 17.  
Disease Gene Protein Function 
ARPKD PKHD1 Fibrocystin/Polyductin 
Exact function unknown. Expressed in apical membrane, primary cilia, and 
centrosomes. Interacts with polycystin-2 
ADPKD 
PKD1 Polycystin-1 
Mechanosensitive or ligand-activated receptor; functionally complexed with 
polycystin-2. Expressed in basolateral plasma membrane, cilia, centrosomes 
PKD2 Polycystin-2 
A non-selective Ca2+ channel. Functionally complexed with polycystin-1. Expressed 
in ER, basolateral plasma membrane, cilia, centrosomes 
Nephronophthisis NPHP1-13 
Nephrocystin 2 (Inversin) 
Nephrocystin 3-6 
GLIS2 protein 
Nephrocystin 8-9 
CCCAP 
Meckelin 
IFT139 
IFT144 
Involved in primary cilia function and the cell cycle. Some localize to cell–cell 
junctions or focal adhesions  
Medullary cystic 
kidney disease 
MCKD1  Not known 
MCKD2 
(UMOD) 
Uromodulin 
Possible role in maintaining integrity of thick ascending loop of Henle. Localization to 
cilia and centrosomes 
HNF1 mutations  
Transcription factor 2 
(TCF2) 
Regulates the transcription of several key cystic genes 
Von Hippel-Lindau 
disease 
VHL VHL protein 
Tumour suppressor gene acting through HIF and non-HIF-dependent pathways. 
Localization to cilia and role in cilia length control  
Tuberous sclerosis 
complex 
TSC1 Hamartin Complexes with tuberin to inhibit mammalian target of mTOR 
TSC2 Tuberin Complexes with hamartin. Localizes to primary cilia and regulates cilia length 
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1.3.1 Autosomal dominant polycystic kidney disease 
(ADPKD) 
Inherited ADPKD is the most abundant monogenic kidney disorder and cause for renal 
failure (ESKD) with 1 in 400 to 1 in 1,000 cases in children and adults 18. ADPKD belongs 
to the family of ciliopathies.  
The detailed description of ADPKD shall provide a representative example of the 
complexity of PKD, its genetic causes and pathogenesis. Further examples will be 
outlined in brief.  
1.3.1.1 Phenotype  
Increasing numbers of fluid-filled renal cysts are clinically notable whilst the condition 
progresses with thousands of cysts of different sizes causing a massive enlargement 
and deformation of the kidneys at the advanced stage of disease 19. ADPKD is a systemic 
disorder expressing abnormalities in different tissues, for example cysts developing in 
liver and pancreas, but can also affect the connective tissue (e.g. aortic dissection and 
intracranial aneurysms) and hypertension is a common symptom 20. Studies on cellular 
and biochemical level have revealed that alterations of basement membrane and 
epithelial cells (renal and non-renal) are predominant features in ADPKD and the disease 
is therefore considered a disorder of epithelial cell growth 21,22.  
1.3.1.2 Genetic cause and the encoded proteins  
ADPKD is caused by mutations in either the PKD1 or the PKD2 gene, with mutations in 
PKD1 (MIM 601313) being the most common with about 85% of all cases reported 
compared to 15% in PKD2 (MIM 173910). To date, are 1,273 and 202 pathogenic 
variants known for PKD1 and PKD2, respectively, which are categorised as definitely 
pathogenic, highly likely pathogenic or likely pathogenic in the ADPKD mutation 
database (http://pkdb.mayo.edu/). ADPKD mutations appear with high allelic 
heterogeneity, mainly leading to missense alterations (31% of all PKD1 mutations) 23. 
Overall, the expression of the disease is milder when PKD2 is the cause and also the 
disease onset of PKD2-related ADPKD happens later in life and progression is slower 
until reaching the ESKD state 23,24. A combination of mutations (trans-heterozygosity) in 
both genes are known and develop a more severe form of the disease 21.  
PKD1 encodes for polycystin 1 (PC-1) and is located on the p-arm (short arm) on 
chromosome 16 (1994) whereas PKD2 lies on chromosome 4 (long arm, q-arm) and 
translates into the protein polycystin 2 (PC-2) 25.  
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Polycystin 1 (PC-1)  
PC-1 is a multifunctional protein involved in cell-cell/matrix adhesion, ciliary function and 
cell signalling processes 26,27. It is found in various tissues (e.g. heart, liver) including the 
tubules in the kidney, where it is located in the cilium, the plasma membrane (lateral 
domain), cell-adhesion complexes (tight junctions, adherens junctions, desmosomes) 
and urinary exosomes. PC-1 expression is highest in the fetal epithelium but still 
detectable in the matured tissue 28.  
Polycystin 2 (PC-2)  
PC-2 belongs to the transient receptor potential ion channels protein family and is also 
called TRPP2. It is membrane-associated and found on intracellular compartments 
(endoplasmic reticulum (ER), Golgi apparatus), primary cilia, both apical and basolateral 
plasma membrane of polar epithelial cells and like PC-1 also in urinary exosomes. It acts 
as non-selective ion channel permeable for calcium, potassium and sodium but is 
predominantly present at intracellular compartments for the release of intracellular 
calcium stores 29. Interactions between PC-1 and PC-2 in an ion channel signalling 
complex have been observed suggesting that PC-1 stimulates PC-2 to conduct its ion 
channel capacities 30. Mutations in both genes have led to the disturbance of intracellular 
calcium regulation promoting cell proliferation 31. Figure 3 depict the localisation of PC-1 
and PC-2 in the cell.  
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Function of polycystins  
Mechanosensation and cilia  
Apart from the intercalated cells, all renal tubular epithelial cells within the nephron and 
collecting ducts have a primary cilium on their apical side, which functions as a sensor. 
The cilium is formed of nine nonmotile microtubules. The external part has a microtubule 
core (axoneme) and with the basal body, derived from the intracellular mother centriole 
it is anchored with the cell. It reaches the cell lumen to exert its mechanosensory function 
mediating extracellular signals inside the cell (signal transduction). The cilium responds 
to either mechanical- or fluid flow-based stimulation with bending and this inducing 
calcium influx through PC-2 (TRPP2 calcium channel) 32,33. PC-1 located on the cilium is 
thought to sense such environmental stimuli with its large extracellular domains and after 
conformation change activates PC-2 for calcium influx. This was confirmed in Pkd1 null 
mouse cells and human ADPKD kidney epithelial cells which failed to respond to 
mechanic stimuli 34. In healthy cells the resulting calcium influx then triggers calcium 
release from the intracellular stores and the increasing calcium levels are transduced 
into a downstream Ca2+-signal to control transcriptional activity in the nucleus 35. Hence, 
mutations in any of the polycystins can change their response to fluid flow leading to 
Figure 3: Topology of membrane proteins polycystin-1 (PC-1) and polycystin-2 (PC-2).  
Both proteins are found on the plasma membranes of the cellular adhesion complex (PC-1), apical 
and basolateral membranes, membranes of ER and Golgi (PC-2) and the shaft and basal body of 
the primary cilium of epithelial cells (PC-1 and PC-2). PC-1 (blue) is a 450 kDa protein with 11 
transmembrane domains and a large extracellular N-terminal domain. The short C-terminus tail is 
on the cytosolic side of the membrane PC-1 has different cleavage sides (toothed arrows). PC-2 
(magenta) is a smaller transmembrane protein with 110 kDa spanning the membrane with 6 
transmembrane domains. Both, N-terminal and C-terminal domains face the cytosol. PC-2 functions 
as a calcium channel (TRPP2). With their C-terminal tails PC-1 and PC-2 interact (double-headed 
arrow) with each other exerting distinct regulatory functions. Figure modified after Chapin 2010.  
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dysregulation of target genes and their downstream cellular processes (tissue 
homeostasis, cell proliferation, apoptosis etc.).  
Involvement in signalling pathways  
G-protein signalling: PC-1 has G-protein coupled receptor capacities (GPCR) as some 
domains in its C-terminal tail (PC1 CTT) share sequence homology with GPCR and in 
vitro activate Gi/0proteins 36. G-protein signalling pathways are involved in the regulation 
of cellular processes like fluid secretion, cell proliferation, -polarity and -differentiation 
present in cyst formation 37. Downstream signalling effects of PC1 CTT are found within 
the JNK/AP-1 (c-Jun N-terminal kinase and activator protein-1) and calcineurin/NFAT 
(nuclear factor of activated T-cells) pathways. PC1 CTT has the ability to activate the 
JNK/AP-1 pathway through protein kinase C  (PKC ), small G-proteins (Cdc42 and 
Rac1) and G and G subunits. Cell cycle regulation, cell proliferation and 
differentiation as well as apoptosis are processes controlled by this pathway and many 
of those are subject of PKD pathogenesis 38. In the calcineurin/NFAT pathway PC1 CTT 
activates phospholipase C (PLC) mediated via Gq.  
Gq-coupled PC1 CTT-dependent activation of PLC mediates an increase of intracellular 
calcium and leads to calcineurin (serin-threonin phosphatase) activation. Calcineurin 
eventually dephosphorylates NFAT, inducing its translocation into the nucleus for 
regulation of its target genes with documented involvement in cell development and 
adaptation in many cell types. NFAT and PC-1 are co-expressed in mice renal tubular 
epithelial cells during development and adulthood suggesting a shared role in a 
signalling pathway 39,40.  
Growth regulation/Cell-cycle regulation: PC-1 and PC-2 are directly involved in cell 
cycle regulation. The related signal transduction pathways are described in brief. JAK-
STAT pathway: PC-1 activates the Janus kinase (JAK) and the transcription factors 
STAT1 and STAT3, together causing the upregulation of p21 (kinase), which slows down 
or arrests the cell cycle at G0/G1 phase. Id2: The transcription factor Id2 (helix-loop-helix 
protein, HLH) regulates cell proliferation and differentiation by downregulating p21. 
Phosphorylated PC-2 directly interacts with Id2 and regulates its nuclear localisation, 
thus contributes to the regulation of such cellular processes. PC-1 regulates the 
phosphorylation of PC-2. Id2 is lacking a nuclear localisation signal needs to complex 
with a second HLH protein (E47). PC-2 is able to bind this complex and keeps it outside 
the nucleus, hence p21 transcription promotes cell cycle arrest. In the case of PKD1 or 
PKD2 mutations, PC-2 interaction with Id2 is restricted, explaining increased cell 
proliferation in ADPKD 41. STAT6/P100: PC-1 cleavage is regulated by fluid flow. Under 
normal flow conditions in the renal tubules non-cleaved PC-1 and P100 (co-activator) 
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are co-localised on cilia of epithelial cells. Together PC-1 and P100 translocate the 
transcription factor STAT6 from the nucleus to the cilia preventing STAT6-regulated 
transcription. Under “no flow” conditions (cysts) PC-1 gets cleaved at its C-tail (PC1 
CTT14kDa) and together with P100 translocates STAT6 to the nucleus enhancing 
transcription of STAT6 target genes promoting cell growth. P100 overexpression and 
high levels of nuclear STAT6 have been confirmed in ADPKD patients 42. mTOR: mTOR 
is a kinase and the key  protein in the mTOR pathway stimulating protein synthesis and 
cell proliferation. PC1 CTT interacts with TSC2 (tuberin) a regulator of mTOR. Mutations 
in TSC2 have been described to cause renal cysts (Shillingford et al. 2006). Active 
membrane-bound PC1 CTT has the ability to inhibit phosphorylation of TSC2 which 
retains TSC2 bound to the membrane repressing mTOR signalling. In the case of 
mutated PKD1 the mTOR pathway is active constantly causing uncontrolled cell growth 
43. Wnt pathway: Wnt signalling is involved in the regulation of cellular processes, such 
as embryonic development, cell fate, cell proliferation, cell migration and planar cell 
polarity (cell shape). The latter is subject to the non-canonical (-catenin independent) 
Wnt pathway, the others are regulated during the canonical Wnt pathway (-catenin 
dependent). The major Wnt ligands are glycoproteins. Canonical Wnt pathway: -
catenin is a subunit of the cadherin complex involved in cell-cell adhesion but also 
regulates gene transcription. Binding of Wnt ligands to -catenin promotes its 
translocation into the nucleus activating transcription of its target genes. Cleaved PC1 
CTT binds and co-translocates together with -catenin into the nucleus. Bound in this 
complex -catenin-regulated transcription is inhibited. In ADPKD patients and PKD1 null 
cells Wnt signalling is upregulated and downstream effects enhanced 44. Non-canonical 
Wnt pathway: The non-canonical Wnt pathway regulates planar cell polarity important 
for tubule formation in the kidney. The cell division of renal tubular cells has a pre-set 
parallel direction (oriented cell division, OCD), supporting lengthening rather than 
widening of the tubules. In PKD a loss of OCD is suggested promoting the expansion of 
the tubule diameter, which could mark a precursor-state of cystogenesis 45,46. Another 
interesting model is that urine flow-induced signalling functions as a switch between the 
canonical and non-canonical pathway. Urine flow rates increase the expression of 
inversin, a protein involved in tubular left-right axis development. Upregulated inversin 
reduces -catenin levels, which likely terminates the canonical Wnt pathway to initiate 
the -catenin-independent Wnt signalling for polarisation of the renal epithelial cells 
needed for correct tubule development. In this way the two Wnt pathways could manage 
shape and function of the nephron. In mice, lacking functional inversin cyst formation 
was observed, as a result of unhindered canonical Wnt signalling 47. In ADPKD patients 
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dysfunctional PKD1 potentially prevents the switch between the two Wnt pathways due 
to its inability to repress -catenin-driven transcription resulting in enhanced cell growth. 
Inversin also interacts with nephrocystin proteins and is the causative gene for 
nephronophthisis type II, a disease expressing renal cysts as a major feature. Figure 4 
summarises the signalling pathways PC-1 and PC-2 take part in.  
 
Cystogenesis  
Cyst formation is associated with major cellular processes becoming dysfunctional, such 
as enhanced cell proliferation and apoptosis of cyst-forming epithelial cells, loss of 
epithelial polarity and de-differentiation (regenerative process) and cell/matrix 
interactions. Phenotypic changes are also observed as the cyst-forming epithelial cells 
instead of exerting their absorptive function starting to become secretory.  
In ADPKD, cysts develop from epithelial cells and can arise in any tubular section of the 
nephron due to cell proliferation and inflow of glomerular filtrate. Whilst initially they stay 
attached to their parental tubule, when reaching a diameter of approximately two 
millimetres they detach allowing only cAMP-mediated transepithelial chloride secretion 
into the cystic lumen through the basolateral Na-K-Cl cotransporter and the apical cystic 
fibrosis transmembrane conductance regulator, short CFTR 48,49.  
Growth factors such as the epidermal growth factor (EGF), the EGF receptor (EGFR) 
and the transforming growth factor alpha (TGF alpha) are overexpressed in the cyst-
forming epithelium promoting cell proliferation and hence cyst formation. In healthy 
tissue, cAMP mediates the inhibition of the MAPK/ERK pathway (cell-cycle regulation) 
Figure 4: Signalling pathways with polycystin 1 and polycystin 2 involvement.  
Figure taken from Chapin 2010.  
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restricting cell growth. In cyst-forming cells, it does the opposite. It highly accumulates 
due to reduced intracellular calcium concentrations, enhancing the proliferation of cyst-
forming epithelial cells by activating the MAPK/ERK pathway 50. The knock-out of 
apoptosis-preventing genes and the overexpression of apoptosis-promoting genes both 
also support cell proliferation and cyst formation as mouse models have shown 51. Figure 
5 depicts the process of cytogenesis on all levels.  
 
 
 
On average a human adult kidney hosts about 1 million nephrons, however in ADPKD 
patients, cysts arise from only approximately 1,000 nephrons. If a germline mutation was 
the sole cause for cyst formation, consequently cysts derived from all nephrons would 
be expected. However, on the basis of analysis of PKD1- and PKD2-related cysts, the 
pathogenesis of cyst formation in ADPKD is thought to be a two-hit process (two-hit 
model Figure 6) 52,53. In first place, a heterozygous germline mutation occurs on one 
allele of the ADPKD genes, which is present in all cells but only induces cyst formation 
in a minor number of renal tubular cells. Hence, an additional mutation of somatic origin 
– the second hit – on the other “normal” allele is needed to increase the functional loss 
or dysfunction of the polycystins resulting in extended cystogenesis. The second hit 
affects the wild type (wt) allele of one of the ADPKD genes and causes the loss of 
heterozygosity in those cells 54. Despite being widely accepted the two-hit model is also 
criticised due to the observation, that in up to 60% of PKD1- or PKD2-related cysts a 
second somatic mutation was absent, but this might also be explained by technical 
limitations of the methods used back in the 1990s 23,55.  
Figure 5: Cystogenesis on cellular level, the nephron and entire kidney.  
Gene defect on PKD1 or PKD2 alter transcription changing cell proliferation and ion secretion 
resulting in fluid-filled cysts of different sizes. Cysts protrude from the tubules in different nephrons 
and all together changing the parenchyma of the whole organ. Figure taken from Chapin 2010.  
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Leonhard et al. in 2015, observed cyst formation in an ADPKD mouse model and raised 
the idea of a snowball effect of cyst formation proceeding from one initial cysts, which 
itself originates from a somatic second hit mutation in one cell, prompting the 
development of further cysts due to possible enhanced PKD-signalling 56. Another more 
recent viewpoint of cystogenesis is described by the threshold and dosage-sensitive 
model, initially proposed by Lantinga-van Leuwen et al. in 2004 whilst working with mice 
with hypomorphic PKD1 or PKD2 57. They propose that cystogenesis is not only 
provoked by a combination of a germline and somatic mutation but also might be 
dependent on gene dosage. Meaning, when reduced expression of PKD1 and PKD2 
reaches a certain level this then drives cyst formation (haploinsufficiency) and that 
reduced expression can be induced not only by genetic causes but also due to 
environmental or stochastic (random fluctuations in the expression of individual genes) 
factors 58. To date and despite some variations in available data, the clinical threshold 
level of remaining PC-1 and PC-2 function necessary to maintain cell function is 
estimated at around 40% 59.  
 
 
Figure 6: Two-hit model of cyst formation in ADPKD.  
(a) Renal tubular cells all having the same PKD mutation in heterozygous state (first hit). (b) Somatic 
mutation on the wt allele randomly occurring in one of the cells (second hit). (c, d) Clonal proliferation 
and tubular dilatation of the now compound heterozygous cell (two hits) and cyst development with 
ion secretion into the cyst lumen. Figure taken from Pei 2001 30. 
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1.3.2 Autosomal recessive polycystic kidney disease 
(ARPKD)  
Autosomal recessive polycystic kidney disease is predominantly seen in neonates and 
children with in incident of 1 in 20,000 live births 18.  
Phenotype  
ARPKD typically represents a combination of renal cysts in both kidneys and congenital 
hepatic fibrosis (CHF) or Caroli disease 60. Renal cysts are already notable in the unborn 
child. Fluid-filled cysts form mainly in the collecting duct and stay attached to the parental 
tubule. As a consequence, the collecting ducts in affected individuals elongate and this 
causes poor corticomedullary differentiation resulting from the extension of the collecting 
ducts from medulla to cortex. The cysts in ARPKD are usually quite small, below 3 mm, 
but with increasing numbers the kidneys enlarge 61.  
Histologically the main feature of CHF in ARPKD patients is a ductal plate malformation 
with portal fibrosis, bile duct proliferation and hypoplasia (underdevelopment) of portal 
vein branches with hypertension as a consequence. Liver involvement in form of the 
Caroli phenotype shows cysts within the intrahepatic bile ducts 62.  
Genetic cause and encoded protein 
ARPKD belongs to the group of ciliopathies and is caused by mutations in only a single 
gene, PKHD1, which is located on chromosome 6p12.3-12.2 63. To date, nearly 750 
different mutations have been described (www.humgen.rwth-aachen.de) with severe 
and milder onset depending on the two mutations on the PKHD1 alleles Whereas two 
truncating mutations are lethal usually during the perinatal period, one or two missense 
mutations present a milder form of the disease 64. PKHD1 encodes for the large receptor-
like 450 kDa transmembrane protein fibrocystin (polyductin), with a single 
transmembrane span, a large extracellular N-terminus and its C-terminal domain facing 
the cytoplasm 65.  
Fibrocystin, its function and cystogenesis  
Fibrocystin is found within the kidney in the cortical and medullary collecting ducts, the 
liver in the biliary ducts and pancreas in the pancreatic ducts. In renal epithelial cells it is 
predominantly a ciliary protein and localises to the cilia membrane, the basal body, but 
also the apical plasma membrane as well as the mitotic spindle 65,66. Like other 
cystogenic proteins (e.g. PKD1 and PKD2) this suggests fibrocystin is involved in cellular 
             Chapter 1 
 36 
processes, such as cell proliferation and apoptosis. Mutations are likely to negatively 
influence the regulation of such processes and this may initiate cystogenesis due to 
uncontrolled cell growth as seen in other ciliopathies. However, the exact function of 
fibrocystin is still unknown and its role in the human remains speculative 17,67.  
Besides its ciliary targeting signal, fibrocystin has a nuclear localisation signal (NLS) and 
a polycystin-2 binding domain. This implies a possible translocation into the nucleus as 
well as an interaction with polycystin-2 (PC-2). Both may indicate involvement of 
fibrocystin in nuclear signal transduction, independently or in synergy with PC-2, 
eventually regulating structural cellular processes 68. Evidence of nuclear translocation 
has been described in a study by Hiesberger et al. 69. They were able to show proteolytic 
cleavage within the C-terminal domain of fibrocystin in dependence of intracellular 
calcium levels and protein kinase C (PKC) activity. The cleaved product carries the NLS 
and conclusively should be capable to translocate into the nucleus, suggesting a role in 
signal transduction alike other proteins known from their dysfunction in ciliopathies (e.g. 
PC1 CTT).  
1.3.3 Glomerulocystic kidney disease 
Glomerulocystic kidney disease (GCK) is a rare form of PKD. Glomerular cysts are 
defined as dilatation of the Bowman space more than two to three times the normal size. 
When at least 5% of the kidney is interspersed with glomerular cysts, the phenotype is 
recognised as a renal condition 70. Glomerular cysts are difficult to recognise. To 
distinguish them from tubular renal cysts, the appearance of the glomerular tuft - as long 
as not degraded - within the cysts helps for indication 71. GCK commonly occurs as a 
feature in a genetically caused syndrome and the affected gene often encodes for a 
protein associated with the primary cilium or the centrosome - the very common 
pathogenesis in PKD as discussed above. Dysregulation of transcription in signalling 
pathways controlling renal development seems also to be the mechanism for 
cystogenesis, like seen in typical ciliopathies when GCK is of hereditary nature 72. 
However, the causes and origins to develop GCK are quite heterogeneous and of 
hereditary and non-hereditary origin and are categorised in five subtypes after Lennerz 
et al. 71. Table 2 lists the five subtypes of GCK.  
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Table 2: Categorisation and key features of GCK conditions Lennerz et al. 2010 79.  
Type Name Common feature Subcategories Key features  
I GCK in PKD PKD genes 
ADPKD (PKD1, PKD2) Inheritance pattern: Age, shape, size, bilateral, liver and/or other 
organ cysts ARPKD (PKHD1)* 
II 
GCKD = 
hereditary 
GCK 
GCKD genes 
UMOD 
Inheritance pattern and GCKD specific features HNF1 
NOS 
III 
Syndromic 
GCK 
Recognised 
syndrome, 
absence of 
dysplasia 
Too many to list, please 
see Table 2 in Lennerz et 
al. 2010. 
Malformation syndromes with typical manifestations obstruction 
Localised GCK Unilateral or segmental 
IV 
Obstructive 
GCK (non-
hereditary) 
Urinary tract 
abnormalities 
With dysplasia Smooth muscle cell collarettes, cartilage, IM 
Without dysplasia Urinary tract abnormalities, uni-or bilateral 
V 
Sporadic 
GCK 
No familial 
pattern,  
No dysplasia,  
No syndrome,  
No obstruction 
Ischemic GCK  Vascular changes, unilateral, age 
drug-induced pattern  Bilateral, history of drug exposure 
Abbreviations: ADGCKD: Autosomal dominant glomerulocystic kidney disease; ADPKD: Autosomal dominant polycystic kidney disease; ARPKD: Autosomal recessive polycystic 
kidney disease; FHGCKD: Familial hypoplastic glomerulocystic kidney disease; GCK: Glomerulocystic kidney; GCKD: Glomerulocystic kidney disease, synonymous with 
heritable/familial GCK; GCKD (NOS): Glomerulocystic kidney disease, not otherwise specified; IM: immature mesenchyme; PKD: Polycystic kidney disease; PKD1-2: ADPKD 
genes; PKHD1: ARPKD gene; TCF2: FHGCKD gene encoding hepatocyte nuclear factor–1  (HNF1); UMOD; Uromodulin, ADGCKD gene 
*indirectly due to mutations in HNF1 inhibiting Pkhd1 expression in mice 73.  
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GCK (Type III, syndromic GCK) is presented in at least 43 malformation syndromes. The 
most common of them is tuberous sclerosis, but also Zellweger’s syndrome, nephrotic 
syndrome and von Hippel Lindau disease are well known 71.  
1.4 The Islets of Langerhans of the human pancreas  
The pancreas is one of the key organs of the digestive tract with an exocrine and 
endocrine function in the human body where it plays a major role in nutrient digestion 
and glucose homeostasis (energy homeostasis), respectively. The majority of its mass 
is dominated by the exocrine tissue which harbours the acinar, the exocrine, cells. They 
produce the pancreatic juice, a liquid which contains the digestive enzymes, such as 
amylase, pancreatic lipase and trypsinogen crucial for macro digestion, which they pass 
directly into the small intestine via the pancreatic duct. Within the exocrine pancreatic 
tissue, little cell clusters are embedded, formed of five different hormone-secreting cell 
types representing the endocrine part of the organ 74. They are surrounded by a double-
basement membrane and besides consisting of the endocrine cells also vascular, 
immune and often neuronal cells complete their cytoarchitecture 75. A healthy human 
pancreas accommodates approximately 3.2 million islets with an average diameter of 
110 µm, which in total occupy only 1-2% of the total mass of the pancreas 76,77. However, 
they receive up to 20% of the blood supply 78.  
These cell clusters were first described in 1869 by Paul Langerhans and therefore are 
called the islets of Langerhans but also commonly described as human pancreatic islets. 
Those islets are recognised as highly organised endocrine microorgans which are 
essential for the regulation of glucose homeostasis, sensitively responding to changes 
in blood glucose levels by secreting pancreatic hormones in an endocrine, paracrine and 
autocrine manner 74,79. The total number of cells in an islet equivalent (IEQ, volume of 
150-µm diameter sphere) is estimated being around 1,560. The most prominent and 
most important endocrine cell types for glucose homeostasis hosted by the pancreatic 
islets are the α-cells (glucagon) and β-cells (insulin) with about 20-30% and 60-70% per 
islet, respectively. The remainder is shared by the remaining three cell types, δ-cells 
(somatostatin), PP or γ-cells (pancreatic polypeptide) and the G or ε-cells (ghrelin) 76,80. 
The pancreatic hormones secreted by these cells are associated with a distinct function 
contributing to glucose homeostasis, with insulin and glucagon at the forefront.  
Pancreatic islets are quite variable in terms of their layout and relative population of the 
endocrine cells within one cell cluster, which differs from islet to islet, from individual to 
individual and from species to species. The cellular arrangement within human islets is, 
differently to rodent islets, of a heterogeneous nature with no distinct recognisable 
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pattern. This implies an apparent absence of hierarchy between the different cell types 
80. Moreover, human islets contain numerous blood vessels and the endocrine cells are 
located alongside without a distinct order, in contrast to mice, suggesting that the 
direction of the blood flow does not majorly influence particular interactions 81. β-Cells 
are directly adjoined by α-cells and/or δ-cells and this association is so strong that they 
often remain coupled to the α-cells even when in suspension 82. These observations 
strongly suggest this unique cell arrangement in human islets is of functional nature and 
indicates paracrine cell signalling. Paracrine signalling is depended on a close proximity 
between cells as many signalling molecules otherwise get degraded quite quickly within 
the interstitium and the blood, therefore this process is independent from vascular 
perfusion – both these requirements are fulfilled by the human pancreatic islets 
cytoarchitecture 75,83. Besides the secreted hormones, there are additional signalling 
molecules, mainly neurotransmitters (e.g. glutamate, ATP, acetylcholine and GABA) 
active within the islets, contributing to the paracrine and autocrine processes and adding 
on a complex picture of signalling pathways within these small microorgans.  
Since the early 2000s, islets transplantation is successfully applied to treat type 1 
diabetes mainly due to the insulin-producing potential and functional significance of the 
β –cells 84.  
 
1.5 Peptide hormones secreted by the Islets of 
Langerhans  
1.5.1 Pancreatic glucose homeostasis by insulin and 
glucagon - principle  
Pancreatic islets are glucose sensors which react to changes in glucose concentration 
through a number of metabolic processes accomplished by the endocrine cells. The main 
drivers balancing blood glucose levels are insulin and glucagon, secreted by the β-cells 
and α-cells of the endocrine pancreas, respectively. Whilst glucagon increases the blood 
glucose levels, insulin does the opposite 85. In this way, the optimal blood glucose levels 
are kept within a tight range of 4-6 mM (90 mg/mL). During fasting periods, sleep for 
example or between meals, when glucose levels decrease glucagon gets released by 
the α-cells to guarantee an immediate glucose supply (endogenous glucose) from the 
degradation of glycogen in the liver (hepatic glycogenolysis) to prevent hypoglycemia 86. 
The β-cells, by contrast, respond to increasing blood glucose levels from glycogen 
conversion and food intake with the secretion of insulin 87. Released into the blood, 
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insulin acts on different tissues. It binds to its specific receptors on adipose and muscle 
tissue allowing the uptake of exogenous glucose by these tissues from the blood and 
this in turn lowers the blood glucose levels, preventing the risk of hyperglycemia 88. But 
it also stimulates the liver to produce more glycogen from glucose (glycogenesis) to 
maintain the glycogen stock needed for fasting periods 89. Figure 7 represents the 
principle of insulin- and glucagon-regulated glucose homeostasis.  
 
 
 
The additional hormones released by the δ-cells, γ-cells and ε-cells of the endocrine 
pancreatic cells are modulators of this complex process of the insulin and glucagon-
controlled glucose homeostasis and their role will be discussed more detailed below.  
1.5.2 Insulin and Insulin signalling  
Insulin is exclusively secreted by the β-cells in pancreatic islets. Besides its crucial role 
in glucose homeostasis, Insulin also exerts anabolic functions within the body and is 
involved in carbohydrate metabolism, lipid metabolism and protein synthesis with its 
ability to stimulate glucose uptake by the liver, adipose tissue and skeletal muscle cells 
from the blood 90. In these tissues, insulin is a key mediator for different metabolic 
processes such as, enhancing glycolysis, activating glycogen synthesis, stimulating lipid 
Figure 7: Principle of glucose 
homeostasis regulated by insulin 
and glucagon.  
Red pathway: High blood glucose 
levels stimulate -cells in the 
pancreas to release insulin. Insulin 
prompts tissue cells (adipocytes, 
muscle cells) to take up glucose 
from blood and stimulates 
glycogen conversion from glucose 
stores in the liver. This eventually 
lowers the blood glucose levels. 
Green pathway: Low blood glucose 
levels causing the -cells within the 
pancreas to secrete glucagon, 
which stimulates glycogen 
degradation within the liver to 
produce and liberate glucose into 
the blood stream. This in 
consequence raises the blood 
glucose levels. Figure taken from 
https://physiology-
11.wikispaces.com.  
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synthesis (adipose tissue only) and decreasing lipolysis. The latter resulting in the 
reduction of plasma fatty acid levels. Within the protein metabolism, insulin promotes 
protein synthesis and prevents protein degradation in muscle tissues 90-94.  
Figure 8 shows a simplified scheme of insulin signalling in the human body. The gate for 
glucose uptake by insulin-sensitive cells/tissues is the glucose transporter type 4 
(GLUT4), a transmembrane protein. By binding of insulin to its receptor (IR) on the cell 
surface of the targeted tissues, it activates a complex signal cascade needed for glucose 
uptake into the cytoplasm. On the extracellular side insulin binds to the -subunit of the 
receptor with consequent activation of the -subunits which exert tyrosine kinase activity. 
It autophosphorylates itself and subsequently other intracellular proteins, the so-called 
insulin receptor substrates (IRS) 95. This is where the insulin signal begins to get 
transferred through a kinase-dependent signal cascade (PI3K/AKT pathway), to 
modulate the downstream anabolic processes of insulin stimulation (glycogen synthesis, 
protein synthesis, lipid synthesis), in particular the glucose uptake from blood. In order 
to induce glucose uptake, AKT2 initiates the migration of GLUT4-containing vesicles to 
the cell membrane by phosphorylating SNARE proteins 96. Details around insulin 
secretion are outlined in section 1.6.  
 
 
Figure 8: Overview of insulin signalling.  
Secreted insulin binds to the extracellular domain of the insulin receptor on the surface of insulin-
sensitive cells. Insulin binding initiates a kinase-dependent signal cascade mediating the 
translocation of GLUT4 for glucose uptake and initiates the downstream anabolic processes of 
insulin signal transduction (Glycogen synthesis, lipid synthesis, glycolysis). Figure taken from 
https://courses.lumenlearning.com.  
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1.5.3 Glucagon, glucagon secretion and signalling  
Glucagon exerts its major role in the liver, driving glycogenolysis and gluconeogenesis 
and inhibiting glycogenesis and glycolysis and to prevent hypoglycaemia. It is the 
opponent of insulin and is secreted during hypoglycemic conditions to return blood 
glucose to normal levels. Apart from glycogen break down, glucagon also mediates the 
recruitment of glycerol from adipocytes and amino acids for gluconeogenesis in the liver 
97,98. It also increases fatty acid break down during -oxidation (liver) and the formation 
of ketone bodies when carbohydrates are not available for energy production 99. 
Glucagon also has important functions in the heart and the kidneys. It positively 
influences the cardiovascular performance and it increases the renal plasma flow (RPF), 
glomerular filtration rate (GFR) and electrolyte excretion in the kidneys as a consequence 
of its stimulatory effect on vasodilation (widening of blood vessels) 100,101.  
Glucagon secretion works very similar to the mechanism of insulin secretion. The -cells 
sense low blood glucose levels and become electrically active, encouraging them to fire 
action potentials (APs). Paracrine signalling between -and -cells is thought to be one 
of the factors enabling -cells to sense low insulin levels after lowering blood glucose. 
However, the overall process is related to several factors (e.g. the central nervous 
system) and yet not well understood 102-104.  
Action potential firing is promoted by the opening of voltage-gated sodium channels (Nav 
channels) and subsequently also calcium channels (L-, N-, T-type). This prompts 
additional specific voltage-dependent calcium channels (P/Q-type) to open. The 
increasing intracellular calcium concentration in turn stimulates glucagon granule 
exocytosis allowing the release of glucagon. As blood glucose levels rise, and glucose 
enters the -cell through the sodium-glucose co-transporter 2 (SGLT2) the intracellular 
glucose metabolism consequently raises ATP production, hence inhibiting membrane-
embedded KATP channels (same channel as in -cells). The intracellular potassium 
accumulation results in membrane depolarisation and this likely causes the inhibition of 
Nav and P/Q-type calcium channels due to the, for them, insufficient voltage change, 
potentially lowering the amplitude of APs, thus the inhibition of glucagon release. 
Differently to -cells, it is the P/Q-type calcium channel which predominantly triggers 
glucagon release in -cells. The increase in circulating glucose levels then prompts the 
suppression of glucagon release. However, this process to date is not completely 
understood 105.  
Glucagon signalling pathways are induced by binding of glucagon to its receptor to the 
surface of various cells in different tissues, e.g. liver, pancreas, heart, kidney, brain and 
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smooth muscle. In the following, only the glucagon signal transduction in the liver shall 
be outlined in brief: The glucagon receptor is G-protein coupled and once glucagon is 
bound, the signal gets mediated via G-proteins (Gs, Gq) to activate the adenylate 
cyclase (AC, Gs). AC then boosts cAMP (cyclic adenosine mono phosphate) and 
protein kinase A (PKA, Gq) production, necessary to regulate the activity of the key 
enzymes within the hepatic glucose metabolism to eventually promote glycogenolysis 
and gluconeogenesis 106. Glucose produced from glycogen stores enters the blood 
stream via the glucose transporter 2 (GLUT2) 107.  
1.5.4 Somatostatin 
Somatostatin is known for its extensive inhibitory function, operating in various organs 
and tissues and therefore is considered a key player in homeostatic processes. It acts 
as a neurotransmitter within the central nervous system (CNS) and also as a 
neurohormone inhibiting the release of growth hormone. Within the gastrointestinal tract 
and the exocrine and endocrine pancreas, it regulates processes such as, glandular 
secretion and smooth muscle contractility (e.g., contractility of stomach and intestine) in 
an autocrine, paracrine and neuronal manner and is either secreted by endocrine cells 
or neuroendocrine neurons. 108-111. Somatostatin-producing and -secreting cells are so 
called δ-cells (D-cells), which are predominantly present in the central and peripheral 
nervous system, the gut and the endocrine pancreas. Within the pancreatic islets cluster, 
δ-cells are the third most prominent cell type exerting an inhibitory effect on insulin and 
glucagon secretion with their ability to release somatostatin 112.  
Although not yet completely understood, somatostatin-induced glucagon inhibition 
seems to be glucose-dependent as experiments with mouse pancreatic islets have 
indirectly shown: Whilst somatostatin-deficient mouse islets did not indicate any 
decrease in glucagon secretion under high glucose condition, this was the opposite in 
control wt islets suggesting an inhibitory effect of glucose on the endocrine α-cells 
mediated by somatostatin 113. In terms of β-cells, somatostatin secretion creates a 
negative feedback loop on insulin secretion, mediated by urocortin3 (Ucn3). 
Interestingly, this peptide hormone is co-secreted together with insulin by the pancreatic 
β-cells. Once released, it binds to the Crhr2α receptor (Corticotropin-releasing hormone 
receptor 2 alpha) on the surface of δ-cells promoting the release of somatostatin which 
then can exert its inhibitory function on the β-cells 114.  
The mechanism, how somatostatin finally applies its inhibitory function on α-cell and β-
cells follows the same principle: After somatostatin has bound to its receptor (SSTR2) 
on the human α- and β-cell surface it inhibits the action potential firing and prevents Ca2+-
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influx through VDCCs. These effects together eventually prevent the Ca2+-dependent 
hormone exocytosis in α- and β-cells 115.  
In addition, it was recently described, that ghrelin, the fifth hormone secreted by the 
endocrine pancreas, boosts somatostatin release from δ-cells, which leads to the 
inhibition of insulin release by binding of somatostatin to its receptor on the β-cells 
surface 116.  
Figure 9 depicts a model of Watts et al., 2016 how -, - and -cells interact within the 
process of glucose homeostasis 117.  
 
1.5.5 Ghrelin  
Compared to the other hormones well known to be of pancreatic origin since decades, 
the presence of ghrelin as being one of them has been discovered rather recently. 
Ghrelin is an orexigenic (appetite stimulant) peptide secreted by the endocrine cells 
within the gastric mucosa 118 Shortly after its discovery, scientists provided the evidence 
for its presence and endocrine function within the pancreas whilst performing double- or 
triple-immunostainings with the other four islets hormones 119. Earlier it was already 
reported that ghrelin levels were high during fasting periods, when the demand on insulin 
was low and conversely a decreasing concentration of ghrelin was noted when the 
demand on insulin was high. This helped to come to and verify the conclusion, that it 
acts as an inhibitor of glucose stimulated insulin secretion from β-cells in humans within 
the pancreatic islets 120. As mentioned above (1.5.4), scientist could show, that ghrelin 
affects insulin secretion indirectly by promoting somatostatin secretion and this in turn 
has an inhibiting effect on insulin release. This provides a good example for the complex 
crosstalk between the different cells within the pancreatic islets 116.  
Figure 9: Overview of paracrine regulation 
between -, - and -cells in glucose 
homeostasis.  
Black arrows indicate stimulation. Dashed 
lines indicate inhibition. High glucose levels 
stimulate - and -cells, responding with 
insulin and somatostatin release, 
respectively but inhibits glucagon release 
from -cells. Stimulated - and -cells also 
suppress stimulation of -cells and glucagon 
release. In contrast, glucagon-secretion from 
-cells stimulates -cells and insulin 
secretion. Figure taken from Watts et al. 2016 
127. 
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1.5.6 Pancreatic Polypeptide 
The PP or γ-cells respond to food intake with the release of the pancreatic polypeptide. 
Its role is not completely understood yet, but it is known to be involved in several 
regulatory processes, such as appetite regulation in both directions, anorixigenic and 
orexigenic 121,122 and the inhibition of pancreatic exocrine secretion 123.  
It acts as a mediator between the gastrointestinal tract and the CNS, which are 
connected via the vagus nervus to regulate the energy homeostasis 124 and is part of the 
neurohormonal system, balancing energy accumulation (food intake) and energy 
expenditure 125.  
The predominant stimulus of pancreatic polypeptide secretion comes from the 
parasympathetic vagus nervus (autonomic parasympathetic nervous system) which, 
opposed to the sympathetic nervous system (“fight-or-flight” response), is responsible 
for body functions when at rest, e. g. the stimulation of digestion (energy conservation) 
and the promotion of satiety 126. The secretion is biphasic with a cephalic and 
gastrointestinal phase (peripheral), the first promoting the orexigenic effect on appetite 
whereas the peripheral phase does the opposite. On the cephalic primary level, external 
stimuli, such as taste or smell are recognised by the CNS which responds through vagal 
efferent neurons with the stimulation of pancreatic polypeptide release. On the 
gastrointestinal level (secondary phase), various stimuli induce the secretion of the 
pancreatic polypeptide, such as 1) protein and lipid consumption, 2) gastric distention 
due to food intake and following activation of gut epithelial mechanoreceptors, 3) 
bioactive peptides (e.g. cholecystokinin, CKK) modulating postganglionic efferent 
neurons and also 4) hypoglycemia 127. However, the autonomic neuronal influence on 
human islets is somewhat unclear. Differently to mouse pancreatic islets, human 
pancreatic islets are sparsely innervated, and this rather suggests an indirect influence 
on pancreatic hormone secretion. This could be for example through changing the local 
blood flow or neurotransmitters being spilled over into the islets microcirculation 128.  
 
1.6 The insulin secretion pathway  
1.6.1 Glucose induced insulin secretion pathway 
The glucose-induced insulin secretion pathway is dependent on changing membrane 
potentials. β –cells are sensing changes in plasma glucose and this initiates the insulin 
secretion pathway (Figure 10). Blood glucose enters the cell via the human glucose 
             Chapter 1 
 46 
transporter GLUT2 and gets rapidly metabolised during glycolysis within the cytosol. 
Pyruvate, the product of the glucose breakdown, is then further metabolised in the citric 
acid cycle also known as Krebs cycle and provides the driving force for ATP synthesis. 
The increasing cytosolic ATP concentration causes the closure of ATP-sensitive 
potassium channels (KATP) located in the -cell membrane. These KATP channels are 
membrane protein complexes composed of a Kir 6.2 pore formed of four subunits and a 
regulatory subunit made of four SUR1 (Sulfunylurea receptor 1) subunits 129-132. Kir 6.2 
is encoded by the KCNJ11 gene and SUR1 by the ABCC8 gene, both genes are 
associated with congenital hyperinsulinism 133,134. At a state of low blood glucose levels, 
the KATP channels remain open allowing potassium ions to leak out of the cell constantly 
and this is keeping the -cells hyperpolarised and electrically inactive, with a membrane 
potential of about -65 mV (cell inside negative). The increasing glucose levels and the 
following rise of intracellular ATP concentration affect the activity of the KATP channels 
due to enhanced ATP-binding and this in consequence is leading to channel closure. 
This results in the depolarisation (a temporary accumulation of positive charge inside the 
cell) of the -cell membrane and, in consequence, enables voltage-dependent calcium 
(Ca2+) channels (VDCC) to open upon a certain threshold potential and Ca2+-influx to 
happen. The increasing Ca2+-concentration then finally triggers the release of insulin 
stored in insulin granules via exocytosis (Ca2+-triggered exocytosis) 135,136. Figure 10 
depicts the glucose-induced insulin secretion pathway 137.  
 
 
 
 
 
 
  
             Chapter 1 
 47 
 
1.6.1.1 Biphasic character of insulin release  
Insulin secretion in response to glucose is a biphasic process which can last for hours. 
Biphasic insulin release is glucose-dependent and happens when the extracellular 
glucose concentration increases dramatically from basal levels (3 mM) below the 
physiological range (4-6 mM) to suprastimulatory concentration of 16.7-22 mM (Grodsky 
1972). During the first phase, insulin gets released rapidly and in high concentration 
within the first 5-10 minutes after the stimulus. It is thought that the amount of insulin 
released during the first phase originates form a so-called ‘readily releasable pool’ (RRP) 
stored in insulin granules which are already located close to the plasma membrane. In 
contrast, insulin released during the second phase is stored in granules which are 
located deeper within the cell and first need to be recruited to the cell membrane for 
fusion and exocytosis 138. These granules are called the ‘Newcomer granules’. As the 
process of Insulin secretion lasts for hours, the majority of insulin released derives from 
Figure 10: Glucose-induced insulin secretion pathway in human pancreatic β-cells.  
Glucose molecules bind and enter the cytoplasm via the membrane embedded glucose transporter 
GLUT2. Glucose gets metabolised in glycolysis and Krebs cycle and drives ATP production. The 
raising intracellular ATP concentration promotes KATP channels to close preventing potassium 
efflux. This depolarises the cell membrane and action potential firing causing VDCC to open. The 
increasing calcium concentration triggers insulin granule fusion with the cell membrane and insulin 
release. Figure taken from Castiello 2016.  
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the second phase. Only about 15% of the total insulin released, results from first phase 
secretion during the first hour of stimulation. When this first phase is over the insulin 
release rate drops but is being maintained over hours by the second phase with a lower 
release rate until normal glucose levels are restored 139. Figure 11 depicts a biphasic 
insulin release profile 140.  
 
 
 
 
1.6.1.2 Exocytosis of insulin granules  
The insulin granule exocytosis, particularly during the second phase release, is a 
complex process of intracellular vesicle trafficking and fusion of insulin granules to and 
with the cell membrane 141. It is a SNARE-protein (soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor) mediated process 142. More than 30 types of SNARE 
proteins are found in mammals representing a transmembrane protein family in particular 
located in cell organelles and vesicles, which form SNARE complexes to allow fusion of 
vesicles for exocytosis or intercellular trafficking 143. SNARE proteins are located in the 
vesicle (v) membrane and the target (t) membrane meant to fuse with each other and 
are therefore subdivided into (v)-SNAREs and (t)-SNAREs 144. The transport of the 
insulin granules to the cell periphery is also depended on the cytoskeleton, with 
involvement of the F-actin filament and microtubule network. Long-range movement of 
the insulin granules from the core of the -cell to the periphery happens along 
microtubules and is kinesin-mediated. For the involvement of the F-actin filament, two 
models do exist:  
Figure 11: Glucose-dependent biphasic 
insulin release profile.  
Basal insulin levels are low. With a strong 
glucose stimulus at time point zero (0) a 
rapid and strong insulin release happens 
during the first 10 minutes of stimulation 
(First phase). Insulin secretion rate then 
drop but stays above the basal level for an 
extended amount of time. Figure taken from 
Meloni 2013.  
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The first and older model, the ‘barrier model’ suggests, that the F-actin filament 
undergoes a reorganisation in -cells dependent on the glucose metabolism. It is also 
thought, that a connection between microtubules and the F-actin filament is built at the 
cell margins forming a bridge for the insulin granules which then “walk” along the actin 
tracks to the cell membrane. In this scenario it is supposed, that under basal glucose 
conditions, the densely packed F-actin fibres block the way for the insulin granules to 
reach the plasma membrane and this in consequence prevents the formation of the 
SNARE protein complexes, crucial for vesicle-membrane fusion. In contrast, raising 
cytosolic glucose concentrations, when blood sugar levels are elevated, induce the 
reorganisation of the F-actin network and this allows insulin granules to access the 
plasma membrane, SNARE protein complexes to form and eventually enabling granule 
fusion resulting in the release of insulin as demonstrated in Figure 12 145. Another, more 
recent, model agrees with the barrier function of the actin filament during fasting (low 
glucose) periods to prevent suboptimal insulin release, but claims, that insulin granules 
Figure 12: Model of insulin granule recruitment during the second phase of insulin secretion 
supposed by Wang et al. 154. 
 Glucose enters the cell via GLUT2 when blood glucose levels are high. The changing intracellular 
glucose metabolism drives the rearrangement of the sublaminar F-actin filament (red) to unblock 
the way for SNARE protein complex formation (Syntaxin, VAMP2) between vesicles and cell 
membrane and allows migration of insulin granules first from the cell core along the microtubule 
network (green) to the periphery and then via the f-actin tracks further to the plasma membrane 
for fusion and insulin release. Figure taken from Wang et al., 2009.  
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are transported to the cell membrane directly across microtubules only, independently 
from the F-actin network being reorganised during periods of glucose stimulation 146.  
1.6.2 GLP-1 induced insulin secretion pathway  
The glucagon-like peptide 1 (GLP-1) belongs to the family of incretins (blood glucose 
decreasing metabolic hormones) and has the ability to enhance insulin secretion. It is 
produced and secreted by the L-cells located in the intestine, mainly the ileum and colon, 
upon nutrient intake 147,148. The insulinotropic effect of GLP-1 is glucose dependent. L 
cells are enteroendocrine cells, which sense preferentially carbohydrates and fat rather 
than proteins and respond with GLP-1 release to lower raised blood glucose levels 149. It 
is encoded by the same gene as glucagon and both share the same precursor peptide 
together with further proteins which either have their role in the intestine or the pancreas. 
The maturation of proglucagon to GLP-1 is depended on tissue-specific posttranslational 
processing 150. GLP-1 has also glucagonostatic properties at normal physical conditions. 
However, the inhibiting mechanism on glucagon is not completely clarified but is likely 
an indirect effect due to GLP-1-mediated stimulation of somatostatin 151. Apart from its 
effect on insulin and glucagon secretion, GLP-1 exerts many other functions on different 
organs. For example, it has an influence on gastrointestinal motility as well as a 
presumed protective effect on the heart and the neural system 152,153.  
Depending on the concentration of GLP-1 exposed to -cells or pancreatic islets the 
downstream GLP-1-induced signalling pathway to stimulate insulins secretion differs. In 
experimental settings with isolated -cells or pancreatic islets the effect of both, 
nanomolar (nM) and picomolar (pM) levels of GLP-1 on insulin release have been 
investigated and were summarised in Shigeto et al. 2015 and 2017 154,155: The 
cAMP/PKA-dependent and cAMP/Epac-dependent pathways are induced by nanomolar 
concentrations of GLP-1 and are well established and commonly accepted (Figure 14). 
Rather recently, experiments with GLP-1 concentrations within the physiological 
picomolar range (1-10 pM) have been performed with isolated pancreatic islets or -
cells. The results provide the evidence, that picomolar concentrations of GLP-1 in an 
experimental set up have the potential to depolarise the plasma membrane, increase 
calcium influx and raise insulin secretion in an cAMP/PKA-independent manner 156. This 
pathway is now considered being the major pathway for the stimulation of insulin release 
at physiological GLP-1 concentrations (Figure 13). At this point it should be noted, that 
the physiological GLP-1 levels do not exceed 30 pM even directly after food intake.  
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GLP-1 stimulation of -cells can experimentally be mimicked by PMA (Phorbol 12-
myristate 13-acetate), a phorbol ester which activates PKC 157. It was used in this study.  
 
Figure 14: Model for nanomolar (nM) 
concentration-mediated GLP-1-induced insulin 
secretion pathway.  
cAMP/PKA-dependent and cAMP/Epac-
dependent pathway. PKA-dependent route: 
GLP-1 binds to its receptor on the -cell surface 
and activates the AC. AC uses ATP as a substrate 
to transform it into cAMP (3’5’-cyclic AMP) and 
pyrophosphate. cAMP activates PKA. PKA 
initiates KATP channel closure (depolarisation and 
L-type Ca2+ channel opening), phosphorylates 
IP3R-formed intracellular Ca2+ channels. IP3 and 
Ca2+ together prompt the IP3R-formed Ca2+ 
channel to open (first due to IP3 binding which 
causes conformation change and allows Ca2+ to 
bind and this supports the opening of the central 
pore) and Ca2+ gets released from the store.  
Increasing Ca2+ concentration prompts insulin 
release. After depolarisation PKA also activates 
voltage-dependent potassium channels (Kv) to 
open for repolarisation of the membrane. PKA-
independent route: High cAMP levels also recruit 
Epac to promote insulin secretion. Epac interacts 
with KATP channels, TRPM2 cation channels and 
RyR-Ca2+-channels to initiate depolarisation 
(through cation influx) and intracellular Ca2+- 
accumulation for following insulin release. Figure 
taken from Shigeto 2017.  
Figure 13: Model for picomolar (pM) concentration-
mediated GLP-1-induced insulin secretion 
pathway.  
PLC/PKC-dependent pathway. GLP-1 binds to 
the GLP-1 receptor on the -cell surface and 
induces PLC activity. This results in IP3 and DAG 
production. The raising IP3 concentration induces 
Ca2+ mobilisation from intracellular calcium stores. 
The increasing DAG production activates PKC 
which activates L-type Ca2+ channels promoting 
Ca2+ influx. The raising Ca2+ concentration also 
stimulates Ca2+-dependent TRPM4/5 channels for 
additional cation influx (Na+). GLP-1 also promotes 
KATP channel closure resulting in increased 
intracellular K+ concentration. The raising 
intracellular cation concentration (Ca2+, K+, Na+) 
depolarises the cell membrane which results in 
calcium-dependent insulin release. GLP-1 also 
mediates RyR-based release of Ca2+ stores.  
Figure taken from Shigeto 2017.  
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1.7 Hyperinsulinemic hypoglycaemia (Hyperinsulinism) 
Hyperinsulinism (HI) describes the excessive secretion of insulin by the β-cells of the 
pancreas. HI can originate due to either decreasing insulin sensitivity of glucose 
removing cells (liver and muscle cells) stimulating β-cells to secrete more insulin or the 
hypoglycaemia associated form (Harris 1924) often due to gene mutations affecting the 
insulin secretion pathway. The consequence of HI-related hypoglycaemia bears a high 
risk of a permanent brain damage due to an undersupply with glucose resulting in 
hypoglycaemic brain injury. A variety of clinical symptoms are seen in patients with HI 
with most severe presentation in newborns, having features such as apnea, seizures 
and unresponsiveness. Less severe presentation comes with rather non-specific 
symptoms for example, poor feeding, irritability and lethargy. HI can also be associated 
with cardiomyopathy, hepatomegaly and developmental syndromes 158,159,160.  
1.7.1 Genetic cause, encoded proteins and molecular 
pathomechanism  
The genetic cause for HI is quite heterogeneous with at least eight different mutations in 
key genes regulating insulin secretion being reported affecting adequate insulin release 
from β-cells: ABCC8, KCNJ11, GLUD1, GCK, HADH, HNF4A, SLC16A1 and INSR. The 
encoded proteins are mainly β-cell-associated or associated with insulin-responsive 
cells. The latter being the case for mutations in the insulin receptor gene, INSR (MIM 
609968, Chr19p13.2). HI occurs with an incident of 1 in 50,000 live births in the general 
population and 1 in 2,500 in particular communities with a high rate of consanguinity 161. 
Inheritance of HI mainly is recessive but also some dominate mutations have been 
reported. In total, around 55% of cases presenting HI result from mutations in the above 
listed genes, the remainder is of unknown genetic cause. However, amongst them, 
mutations in KCNJ11 and ABCC8 are the most common cause of inherited HI with 40%-
45% of all cases. Whereas mutations in the remaining genes account for only 5%-10%. 
Successful treatment of HI depends on the causative mutation and the function or 
dysfunction of the encoded protein. HI patients with mutations in GLUD1, HADH and 
HNF4A usually respond well to diazoxide treatment. In contrast, those with mutations in 
ABCC8 or KCNJ11 they often need surgery. Diazoxide acts on potassium channels, 
causing them to open 162.  
The molecular pathophysiology within HI known so far is outlined below in more detail. 
In addition, Figure 15 depicts an overview of molecular disease mechanisms in 
pancreatic -cells affecting insulin secretion in HI.  
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1.7.1.1 KATP channel mutations (KCNJ11, ABCC8)  
KCNJ11 (MIM 161820, Chr11p15.1) and ABCC8 (MIM 600509, Chr11p15.1) encode for 
the subunits of the ATP-dependent potassium channel (KATP) Kir6.2 and SUR1, 
respectively. Located in the -cell plasma membrane the KATP channel functions like a 
mediator between glucose metabolism and electrical membrane potential crucial for 
insulin secretion. HI is associated with loss-of-function mutations in these genes. Under 
healthy circumstances, high glucose levels increase the intracellular ATP concentration 
and ATP-binding initiates channel closure with subsequent membrane depolarisation 
resulting in calcium influx and eventually the coupled insulin release. Kir6.2 opening and 
closure is regulated by intracellular ATP and ADP concentrations via two different 
nucleotide binding sites. ATP exerts an inhibitory function to the channel and stimulates 
channel closure once bound. ADP has a stimulatory effect on the channel prompting it 
to open in a magnesium-dependent manner, allowing potassium efflux. Hence, when 
intracellular magnesium (Mg) is absent, only the inhibitory effect is accomplished. 
Mutations in KCNJ11 prevent MgADP-binding to Kir6.2 causing permanent membrane 
depolarisation and excessive insulin release independently from blood glucose 
concentrations. Mutations in the ABCC8 gene occur with a much higher frequency 
compared to those in KCNJ11 163,164. Since SUR1 and Kir6.2 are co-expressed for correct 
channel formation, mutations in The SUR1 gene (ABCC8) triggering abnormal protein 
maturation, defective assembly of the SUR1 -subunits forming the channel or also 
wrong protein trafficking to the cell surface can result in the absence of Kir6.2, as well 
leading to continuous membrane depolarisation and insulin secretion 165.  
1.7.1.2 Glutamate dehydrogenase mutations (GLUD1)  
The glutamate dehydrogenase (GDH) is encoded by the GLUD1 gene (MIM 606762, 
Chr10q23.2) and mutations are causative for a gain of protein function in protein-
sensitive HI. GDH is leucin-sensitive and involved in amino acid-stimulated insulin 
secretion in the mitochondrion and stimulates -ketoglutarate formation from glutamate 
in a GTP/ADP ratio-dependent manner. Low glucose levels (high ADP) and leucine 
activate GDH (leucine-sensitive state) resulting in the increase of intracellular ATP from 
glutamate metabolism, thus prompting KATP channel closure. High GTP levels reverse 
GDH-sensitivity to leucine (leucine-insensitive state) preventing an effect on KATP 
channels and related insulin release. GLUD1 mutations can change the sensitivity of 
GDH to high GTP levels making it unresponsive, preventing its inhibition and this leads 
to excessive secretion of insulin 162,166.  
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1.7.1.3 Glucokinase mutations (GCK)  
The glucokinase is encoded by the GCK gene (MIM 602485, Chr7p13) and is one of the 
key enzymes in glucose metabolism. It catalyses the phosphorylation of glucose to 
glucose-6-phosphate after glucose uptake through the membrane transporter GLUT2 in 
-cells and contributes to KATP channel activating ATP levels. Mutations in GCK are 
enhancing the enzymes’ affinity to glucose and consequently the glycolysis rate, 
resulting in exorbitant insulin release independently from its demand 167.  
1.7.1.4 Solute carrier family 16, member 1 mutations (SLC16A1)  
Mutations in the SLC16A1 gene (MIM 610021, Chr1p13.2) are causative for exercise-
induced HI due to the accumulation of lactate and pyruvate and the consequent increase 
of ATP levels – eventually resulting in excessive insulin release during elaborate 
exercise. SLC16A1 encodes for the monocarboxylate transporter 1 (MCT-1), which sits 
in the mitochondrial membrane promoting lactate and pyruvate transport into the lumen. 
Although, its expression in -cells is limited to reduced levels under normal conditions, 
mutations in SLC16A1 promote gain-of-function and cause increased expression on the 
-cell surface, enhancing its response to extracellular lactate and pyruvate levels 168.  
1.7.1.5 HNF4A and HADH mutations  
The exact molecular pathophysiology of HI mutations causing excessive insulin release 
due to mutations in the HNF4A (MIM 600281, Chr20q13.12) and HADH (MIM 609975, 
Chr4q25) genes are unknown to date. The transcription factor HNF4A Hepatocyte 
nuclear factor 4A) has multiple regulatory functions within the pancreatic islets on the 
transcriptional level, causing loss-of -function mutations 169. HADH encodes the 
hydroxyacyl-coenzyme A dehydrogenase. HADH is a key enzyme in mitochondrial -
oxidation catalysing the penultimate reaction before Acetyl-CoA is generated to enter the 
Krebs cycle. However, the exact dysregulation responsible for elevated insulin secretion 
is yet not understood 170.  
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1.8 Congenital disorders of glycosylation  
Congenital disorders of glycosylation (CDG) are inherited metabolic disorders based on 
mutations affecting the biosynthesis (Type I) or processing (Type II) of glycoconjugates 
(glycoproteins, glycolipids). The transfer of polysaccharides (glycans) onto proteins or 
lipids are either N-linked, via the amide group of asparagine or O-linked, via the hydroxyl 
group of a serine or threonine at the N-terminus. N-linked glycosylation (please refer to 
section 1.8.1.3 for details) is a much more complex process happening in the cytoplasm, 
the endoplasmic reticulum (ER) and the Golgi, compared to O-linked glycosylation, 
which starts at the Golgi.  
Several hundred enzymes and transporters are involved in posttranslational protein 
glycosylation pathways, which are potential targets for a glycosylation defect and CDG. 
To date, only 28 CDGs caused by mutations in different genes are known, with in total 
16 N-linked CDGs, 6 O-linked CDGs, 4 CDGs with both N- and O-linked defects and 2 
with defects in lipid glycosylation. CDGs are highly heterogeneous ranging from mild to 
Figure 15: Molecular mechanisms in pancreatic -cells underlying hyperinsulinemic 
hypoglycaemia.  
Mutations in the KCNJ11 and SUR1 genes, encoding the KATP channel cause loss-function 
mutations. Mutations in GCK, SLC16A1 and GLUD1 cause gain-of-functions mutations in the 
encoded proteins glucokinase, MCT-1 and glutamate dehydrogenase, respectively. The molecular 
mechanisms of mutations in HNF4A and HADH (Hydroxyacyl-coenzyme A dehydrogenase) 
causing excess secretion of insulin are unknown. Figure taken from Flanagan 2011.  
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severe diseases with multisystem features to types with abnormalities only in a single 
organ. Major features within CDGs are of neurological nature due to significant brain 
damage, such as psychomotor retardation, ataxia, eye abnormalities, structural brain 
abnormalities and hyporeflexia to name a few 171,172.  
The most powerful screening test for a N-linked glycosylation defect and the diagnosis 
of CDG is the assessment of serum transferrin levels in patients analysed in an 
isoelectric focussing assay. An example is represented in Figure 16.  
 
 
 
Deficiencies in the phosphomannomutase 2 (PMM2) characterising the CDG subtype 
CDG-1a is the most common variant within CDGs and is described below in more detail.  
1.8.1 Congenital disorder of glycosylation Type 1 A  
The congenital disorder of glycosylation Type 1 A (CDG-1a) is by far the most frequent 
form of CDG, with more than 700 affected individuals known worldwide in 2010 173.  
It was first reported in 1980, as a well-described rare autosomal recessive disease due 
to coding mutations within the PMM2 gene 174. Commonly also named PMM2-CDG or 
Phosphomannomutase 2 deficiency, it is characterised by the defective post-
translational glycosylation of N-linked Glycoproteins due to the defective synthesis of 
mannose-1-phosphate 175,176.  
Most reported cases are due to compound heterozygous PMM2 mutations, only a few 
present a homozygous genotype (N216I) 177, Y106F 178. Homozygosity for complete loss-
of-function mutations is lethal suggesting that a minimum of residual enzymatic PMM2 
activity might be crucial for survival 179.  
Figure 16: IEF of serum transferrin of CDG-1 and CDG-
2. (1) wt control. (2) CDG1 and (3) CDG2. Figure taken 
from Jaeken and Carchon 2001.  
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1.8.1.1 The phenotype within CDG-1a 
Initially, after being identified CDG-1a was characterised as a combination of 
developmental delay, distinct fat pads, cerebellar hypoplasia and inverted nipples. A few 
years later, the application of the transferrin screening (isoelectric focussing analysis) 
helped to develop a broader view on the consequences of functional PMM2 mutations. 
In contrast to what was thought in the beginning, it became evident, that within CDG-1a 
any organ system can be affected and it became obvious that CDG-1a presents a 
multisystem disorder with multiple features in a highly variable manner ranging from mild 
to very severe expression 180,181 . At the neonatal stage, infants commonly present with 
muscular hypotonia, inverted nipples and abnormal subcutaneous fat pads, but also 
additional dysmorphia like large protruding ears or a high forehead or feeding problems 
(anorexia, vomiting and diarrhea) can be the case – however any of these symptoms 
can also be missing 181. Overall, predominant features in CDG-1a are of neurological and 
dysmorphic nature. Kidney (e.g. tubular microcysts, proximal tubulopathy), liver features 
(e.g. Hepatomegaly, liver fibrosis) and hyperinsulinism have also been reported 175.  
The disease progress was categorised in four stages by Hagberg et al.: 1) Multisystemic 
stage (Babies), 2) Ataxia-mental retardation stage (Childhood), 3), Leg atrophy 
(Teenagers) and 4) Hypogonadal stage (Adulthood) 182. This pattern still applies to most 
cases, given the patients survive the early years of life as the mortality is quite high with 
20% of those patients presenting the “visceral” form of CDG-1a, a combination of 
neurological and non-neurological features often lethal due to organ failure 183. Table 3 
provides a summary of the different features present in CGD-Ia.   
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Table 3: Clinical features noted in CDG-1a patients. Taken from Grunewald 181.  
Neurology  
Axial hypotonia; peripheral neuropathy; hyporeflexia; 
developmental delay; seizures; stroke-like events; 
micro- and macrocephaly; myopathy  
Gastroenterology/hepatology  
Failure to thrive; vomiting; protein-losing enteropathy; 
liver dysfunction; hepatomegaly; chronic diarrhea 
Neonatology 
Hydrops; ascites; pleural effusions; multiorgan failure; 
failure to thrive; floppy baby 
Haematology 
Thrombocytopenia; coagulopathy; thrombosis; 
anaemia; leukocytosis 
Endocrinology 
Hyperinsulinaemic hypoglycaemia; hypothyroidism; 
hypergonadotropic hypogonadism; growth retardation 
Clinical genetics  Mild dysmorphic facial features; inverted nipples 
Orthopaedics 
Osteopenia; joint contractures; kyphosis/scoliosis; 
short limbs; arthrogryposis 
Ophthalmology 
Abnormal eye movements; squint; cataract; retinitis 
pigmentosa; nystagmus; (transient) cortical blindness 
Radiology 
Small cerebellum, olivopontocerebellar hypoplasia; 
delayed myelinisation 
Histology 
Liver fibrosis; liver cirrhosis; lamellar inclusions in 
hepatocytes; renal microcysts 
Dermatology Abnormal fat distribution 
Nephrology 
Nephrotic syndrome; tubulopathy; cystic kidneys, 
enlarged kidney 
Immunology Recurrent infections; hypogammaglobulinaemia 
Cardiology 
Cardiomyopathy; pericardial effusions, cardiac 
ischemia, cardiac tamponade 
Biochemistry 
Hypoalbuminaemia; elevated transaminases; low 
cholesterol, triglycerides; decreased antithrombin III; 
decreased factor VIII, IX and XI; decreased protein C 
and S; elevated FSH, LH and prolactin; low free T4, 
increased ferritinaemia 
 
 
Although hyperinsulinism and renal cysts have been observed in CDG-1a, this is only 
the case in a subset of patients and associated with the typical additional features. 
Moreover, nephromegaly and glomerular cysts, the renal phenotype in HIPKD, has not 
been described in CDG-1a.  
Aside from CDG and CDG-1a, several congenital disorders are described which are 
caused by defective N-glycosylation, e.g. LAD II, Galactosemia type I-III or the Ehlers-
Danlos syndrome 184, reflecting its importance within biological processes.  
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1.8.1.2 Genetic cause – The PMM2 gene  
The PMM2 gene is relatively small, with eight exons, and is located on chromosome 
16p13.2 as identified by Matthijs et al. in 1997 185,186. Two years before, in 1995, 
Schaftingen et al. 187 were able to report, that CDG-1a (MIM#212065) underlies a 
phosphomannomutase deficiency. They concluded from results of transferrin analyses 
of CDG-1a patients an early defect during the N-glycosylation pathway as the 
glycosylation pattern on transferrin blots were normal but overall reduced in patient 
samples, indicating decreased mannosylation of targeted proteins 187.  
Matthjis et al. have found eleven more different missense mutations in PMM2 and 
defined the gene as “the” causative gene for the congenital disorder of glycosylation type 
1a 188,189. To date, more than 100 pathogenic variants of CDG-1a have been reported, 
including missense, nonsense and frameshift mutations, splicing defects and exon-
skipping mutations within PMM2, with the c.G425A (Arg141His) transition being the most 
common, PMM2 variant with 75% 190-192.  
1.8.1.3 Function of PMM2 – N-linked glycosylation  
The encoded enzyme, phosphomannomutase 2 (PMM2) is an isomerase and a key 
enzyme within posttranslational N-linked glycosylation, which catalyses the 
isomerisation of mannose 6-phosphate (Man-6-P) to mannose 1-phosphate (Man-1-P), 
a precursor to GDP-mannose 185.  
Posttranslational modifications (PTM) are enzyme-catalysed additions of functional 
groups (e.g., glycosylation, phosphorylation, methylation, acetylation) onto proteins after 
protein biosynthesis. Many proteins undergo PTMs to fully develop their structural and 
functional maturation 193. More than half of all naturally occurring proteins are 
glycosylated 194 including various types of proteins such as structural and functional 
(enzymes, receptors, hormones) proteins, protective proteins (Mucin) or proteins of the 
immune system (Immunoglobulins), to fulfil their function within the cell, on its surface or 
beyond 195.  
The involvement of PMM2 in N-glycosylation is placed very early within this 
posttranslational pathway. The enzyme catalyses the isomerisation of mannose 6-
phosphate (Man-6-P) to mannose 1-phosphate (Man-1-P), a precursor of GDP-mannose 
(nucleotide sugar) necessary for the synthesis of the lipid-linked glycan Dolichol-P-
Mannose (Dol-P-Man), the carrier and donor of oligosaccharides for transfer onto 
nascent proteins in this pathway 209. The assembly of N-glycans starts on the cytosolic 
side of the rough ER (RER) membrane with the formation of Dol-P-Man: The dolichol-P 
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linker (Dol-P) sits in the RER membrane and functions as an acceptor for mannose 
sugars attached to GDP-mannose (mannose donor substrate), which before were 
transferred from Man-1-P – after conversion through PMM2 action – onto GDP. Prior to 
receiving mannoses two molecules N-acetylglucosamine (GlcNAc) are attached to Dol-
P through a pyrophosphate linkage (GlcNAc2-PP-Dol) – the first assembly step. The 
GlcNAc2-PP-Dol precursor glycan then is ready for elongation starting with the reception 
of one mannose sugar obtained from GDP-mannose and is further build up to a 
biantennary structure with, in total, five mannose sugars (Man5-GlcNAc2-PP-Dol) 
building the core glycan. Five mannosyltransferases (I-V) are catalysing these reactions. 
At this point, the core glycan gets “flipped” across the RER membrane facing now the 
luminal side for further modifications and elongations with glucose and mannose sugars 
to form the final glycan (Glc3Man9GlcNAc2-PP-Dol). In the case of CDG-1a when PMM2 
performance is dysfunctional, the formation of the core glycan with its tree build of five 
mannose sugars remains absent due to disturbed Man-6-P to Man-1-P conversion 196. 
The early stage and PMM2 action of posttranslational N-glycosylation is depicted in 
Figure 17.  
 
 
 
Once on the luminal side of the RER, the final glycan gets then transferred onto an Asn 
residue of the growing protein due to the cleavage of the phosphate bond between 
dolichol and the second GlcNAc (oligosaccharyltransferase-catalysed). After some 
additional trimming of the oligosaccharide branches, the glycoproteins are ready for 
Figure 17: Early stage of posttranslational N-linked glycosylation.  
Involvement of PMM2 and impairment in the case of CDG-1a are included. Black arrows indicate 
enzyme activity. In CDG-1a PMM2 function is impaired and affects the conversion of Man-6-P to 
Man-1-P, crucial for GDP-mannose formation, the mannose donor to build the core glycan dolichol-
P-mannose (Dol-P-Man). Orange ellipse: Dolichol-linker. Grey circles: Phosphate. Blue squares: 
N-acetylglucosamine. Red circles: Mannose sugar. Figure taken from Marquardt 2003.  
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vesicular transport to the cis-Golgi where further modifications take place. These include 
the partial or complete removal of mannose to finally allow the completion of the three 
major N-glycan residues (medial Golgi): High mannose glycans (2 GlcNAc + many 
mannose residues), complex glycans (2 GlcNAc + any number of other sugar residues) 
or hybrid glycans (2 GlcNAc + mannose and other sugar residues). Those mature N-
linked glycoproteins are then finally transferred from the trans-Golgi to the plasma 
membrane, where they are either embedded or secreted 196,197. Figure 18 shows an 
overview of the process after forming the core glycan.  
 
 
1.9 The CRISPR-Cas9 system – an overview  
Since its discovery and first application in early 2013, the CRISPR-Cas9 system has 
revolutionised the scientific world as being the simplest and most cost-effective gene 
editing tool known so far, which allows for manipulation of nearly any DNA sequence in 
a diverse range of cell lines and organisms. CRISPR (clustered regularly interspaced 
Figure 18: Posttranslational N-linked protein glycosylation.  
The core oligosaccharide or glycan (Man5-GlcNAc2-PP-Dol) forms on the cytosolic side of the 
membrane of the rough ER (RER). It gets “flipped” across the membrane to the RER lumen 
where more mannose and three glucose units are added to form the final glycan, which eventually 
gets attached to an Asn-residue of the nascent protein. Grey hexagons: GlcNAc. Orange 
hexagons: Mannose molecules. Blue hexagons: Glucose molecules. Figure taken from 
https://wikispaces.psu.edu.  
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palindromic repeats) sequences were discovered in some bacterial strains and identified 
as being part of the adaptive immune system in many bacterial and archaeal genomes 
against invading viruses and pathogens 198. Those strains are able to incorporate short 
sequences of the foreign DNA in their genome and upon reoccurring infection by the 
same pathogen, the bacterial genome “memorises” the invading DNA and the CRISPR 
sequences get transcribed into crRNAs activating the CRISPR system to eventually 
silence the harmful DNA 199. Different CRIPSR-Cas systems of bacterial and archaeal 
origin are known of which the CRISPR-Cas9 system from Streptococcus pyogenes is 
the most widely used and best understood 200.  
The active CRISPR-Cas9 complex is formed of three major components: The Cas9 
endonuclease which acts as a pair of genomic scissors, the trRNA:crRNA duplex (gRNA) 
which guides the Cas9 protein to an individual target site and the protospacer adjacent 
motif (PAM), the recognition site for Cas9 within the genome, crucial for its cutting 
activity. The working principle of the system relies on DNA double strand-breaks (DSB) 
created by Cas9 at precise genomic loci due to the target-specific nature of the gRNA. 
This gRNA is a short 20 nt long piece of RNA, which can be individually designed 
according to the targeted genomic region 199, thus making CRISPR-Cas9 such a versatile 
gene editing tool. Since its discovery it has been undergoing a rapid development and 
nowadays is an indispensable gene editing tool across many fields of biological research 
and industries, including the human health and agricultural sector 201.  
1.9.1 DNA repair after CRISPR-Cas9 cleavage  
In eukaryotic cells, DNA damage can occur at any locus, any time and can potentially 
result in genomic inaccuracies, which can have a significant impact on the function and 
behaviour of a cell. In order to prevent the occurrence of such harmful DNA alterations, 
eukaryotic cells have developed so called checkpoints (G1/S, G2/M) between the 
phases of the cell cycle to detect and repair DNA double strand breaks. 202. Cas9-induced 
double strand breaks (DSBs) also activate these cellular DNA repair mechanisms within 
the nuclei of the targeted organism and can follow two possible repair pathways, called 
non-homologous end joining (NHEJ) and HDR, the latter following the principles of 
homologous recombination (Figure 19). NHEJ DNA repair takes place mainly during the 
G1 phase 202. The simplest and most abundant mechanism of the two DNA repair 
mechanisms is the error-prone NHEJ repair pathway which randomly introduces indel 
mutations at the target site. This often results in the formation of DNA frameshifts and 
premature STOP codons causing gene knock-outs 203. The HDR repair is of rare nature 
but highly precise and allows the introduction of specific nucleotide modifications ranging 
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from a small single nucleotide substitution to the insertion of an entire gene. The supply 
of a DNA repair template homologous to the target site and carrying the desired mutation 
enables biologists to introduce the specific DNA alterations of choice into the genome in 
a scarless manner 204. These DNA repair templates, also called HDR donor template or 
just single-stranded oligodeoxynucleotides (ssODN), are composed of two homology 
arms compatible to the CRISPR site, flanking the desired insertion. In the case of large 
insertions plasmid donors, which should at least have 1-2 kb of sequence homology for 
stable repair, are commonly used. For smaller changes, ssODNs are more sufficient 205. 
Studies observing HDR rates at different stages in the cell cycle revealed, that HDR 
events are most efficient during the S-phase (39x higher than in M-phase, 24x higher 
than in G1/G0 phase). This is likely to be explained by the presence of the sister chromatid 
which can be used as a template for DNA repair. Studies have shown that the 
intracellular DNA repair mechanism, instead of recruiting the homologous chromosome, 
preferentially uses the sister chromatid for DSB repair. The efficiency of HDR is generally 
low (<10%) and the CRISPR activity generally high, the majority of DSBs will be repaired 
after the NHEJ pathway, as has been reported 206. Hence, each CRISPR-Cas9 
experiment will result in a genomically mixed population of cells with combinations of wt 
alleles, NHEJ-repaired alleles, the desired HDR-edited alleles and also heterozygous 
versions of these options. To date, many human cell lines and organism have been 
successfully modified with the CRISPR-Cas-9 system, either by introducing specific 
changes into the genome or via gene knock-outs 207.  
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Figure 20 demonstrates Cas9 and donor template DNA binding after creating the DSB 
at the CRISPR target site. This model is based on studies by Richardson et al. 208 who 
aim to explain the biophysics of the interaction between Cas9, sgRNA and the DSB to 
improve homology-directed genome editing.  
 
 
Figure 19: DNA repair mechanisms after CRISPR-Cas9 cleavage.  
Target-specific crRNA (Spacer, green) and universal trRNA (Scaffold, yellow) build a RNA-duplex 
establishing the mature gRNA which forms a ribonucleoprotein complex with the Cas9 
endonuclease. Led by the specific crRNA sequence, the mature gRNA guides the Cas9:gRNA 
complex to the specific target site on the genomic DNA. Cas9 protein recognises the PAM site 
(purple) and cuts the DNA three to four nucleotides upstream of the PAM. The CRISPR-induced 
DNA double strand break (DSB) activates the cellular DNA repair mechanism which can follow 
two routes. A NHEJ: Indels form as a result of randomly occurring insertions and deletions at the 
cut site to fix the cleavage often causing frameshifts and premature STOP codons, which lead to 
the disruption of the gene (knock-out). B HDR: In presence of a homologous DNA repair template 
which has a desired DNA change incorporated in its sequence, this attaches to the flanking regions 
of the target site with its left and right homology arms. It covers the cleavage allowing the DSB to 
be repaired accordingly and the desired DNA modification gets introduced simultaneously. The 
PAM site on the template usually gets mutated to prevent the CRISPR-Cas9 complex to bind and 
cleave it. Figure taken from blog.addgene.org.  
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According to their findings after measuring Cas9 dissociation rates from the DNA target 
site the following process can be explained:  
After Cas9 has produced the DSB, it releases the 3’-end of the leading strand, upstream 
of the cut first but remains attached to the 5’-end of the leading strand downstream of 
the cut and also to both ends of the reverse strand. This allows the single-stranded donor 
DNA to anneal complementary to the freely available 3’-end of the leading strand, whilst 
the tight complexation between Cas9:sgRNA duplex and the other three ends is 
maintained. This prevents the re-annealing of leading and reverse strand. A bit later 
Cas9 detaches and releases the 5’-end of the leading strand. The DNA now starts 
opening on this side and allows the HDR donor to anneal there as well. The HDR donor 
now bridges the gap on the site of the leading strand completely, which then gets 
repaired (DNA-Polymerase) and elongated (5’->3’) according to the sequence of the 
DNA donor template, harbouring the desired change (e.g. SNP). When the elongated 
leading strand meets its 5’-end, the ends get ligated (ligase). The reverse strand then 
gets repaired according to the edited leading strand and the genomic change is 
introduced successfully.  
Figure 20: Cas9 and donor DNA interaction at the CRISPR site.  
Target strand refers to the strand targeted by the complementary sgRNA. A: Binding of Cas9 to 
the cleaved DNA. The Cas9 (grey) and sgRNA (blue) complex binds tightly to three of the four 
ends of the DSB. The 3’-end of the nontarget strand distal of the cut is free. Red triangles indicate 
the nuclease domains of Cas9 performing the cut. PAM site (yellow) is proximal to the cut site on 
the nontarget strand. B: Interaction of the DNA donor template with its complimentary (non-target) 
strand and the Cas9:sgRNA complex. The donor DNA first binds to the 5’-end of the nontarget 
strand released from the Cas9:sgRNA complex which gets elongated whilst the three remaining 
ends of the DSB are still in tight complexation with the Cas9:sgRNA duplex. Figure taken from 
Richardson 2016 and http://blog.addgene.org/.  
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1.10 Aims  
This study focuses on HIPKD, a novel rare kidney disease caused by a promoter 
mutation in the PMM2 gene which clinically is characterised by cystic kidneys, 
hyperinsulinism and in some cases also presents with liver malformations. As the 
disease is triggered by a newly recognised promoter mutation in the PMM2 gene, 
dysfunctional gene regulation and expression are implicated as the molecular causes for 
HIPKD.  
Overall, this work shall contribute to disclose the molecular mechanisms within HIPKD, 
to better understand why the phenotype settles in three distinct organs in this individual 
case. In particular, this PhD has focused on the functional consequences of the promoter 
mutation, both with respect to PMM2 gene regulation as well as assessing the effect of 
altered glycosylation on insulin secretion to confirm and extend the results obtained 
previously 209. In addition, it was of interest to generate a HIPKD cell model with the 
promoter mutation integrated in homozygous state using CRISPR-Cas9.  
Aim 1: Investigate how the c.-167G>T promoter mutation affects PMM2 gene 
expression. 
Differences in gene and allelic expression levels on the basis of the c.-167G>T 
promoter variant were assessed in primary renal cells of one of the compound 
heterozygous patients using quantitative digital PCR. The genes (TMEM186, 
CARHSP1, ABAT) surrounding PMM2 and two additional control genes (PPIA, 
CDH1) were also included in the gene expression assay to investigate whether 
their expression is also affected in HIPKD.  
Aim 2: Investigate the effect potentially impaired N-glycosylation on insulin 
secretion.  
Enhanced insulin secretion in HIPKD is assumed to be linked to defective 
protein N-glycosylation. To prove this, human pancreatic islets were used to 
mimic a glycosylation defect as assumed in HIPKD patients and were deployed 
in two sets of insulin secretion assays to enable subsequent measurements of 
the insulin levels.  
Aim 3: Development of a HIPKD cell model to enable further investigation of the 
3D chromatin conformation in HIPKD and to prove the hypothesis of 
altered chromatin loop formation.  
As the promoter is poorly conserved through evolution, a human cell model for 
HIPKD was needed. To this end, HepG2 cells were genome edited using the 
CRISPR-Cas9 technology. As part of this, a homologous DNA repair template 
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was provided to allow the cells to follow the homology directed repair pathway 
for integration of the HIPKD variant in homozygous state.  
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Chapter 2: Materials and Methods  
2.1 Cell culture methods  
All cell culture methods were performed under sterile conditions working under a Class 
II laminar flow hood.  
2.1.1 Primary renal cells for digital PCR assays 
2.1.1.1 Obtaining and culturing primary renal cells from 
compound heterozygous patient  
Primary renal cell cultures were obtained from the renal cortex of a compound 
heterozygous patient including the c.-167G>T PMM2 promoter mutation (c.-
167G>T/c.422G>A) and a control kidney, kindly provided by Dr Jill Norman (UCL Centre 
for Nephrology). Cortical tissue was minced into explants <1 mm3. Explants were plated 
into pre-wetted flasks (Corning) with multiple explants in each flask and cultured in a 
minimal volume of 4.5 g/L D-Glucose DMEM GlutaMax™-I (Gibco) supplemented with 
10% fetal calf serum (FCS) (Sera Laboratories International Ltd), 1% antibiotic-
antimycotic (Sigma) at 37°C, 5% CO2. Explants were left undisturbed for at least one 
week to maximise attachment and the initiation of cellular outgrowth. Thereafter the 
medium was changed every 4-5 days taking care not to dislodge the explants from the 
substrate. At confluence, cellular outgrowth and explants were trypsinised and cell 
suspension plated in new flasks. Cells were cultured under standard conditions (37°C, 
5% CO2) with the medium changed, every 4-5 days. Cells were passaged at confluence 
and split 1:3.  
Primary renal cells were further maintained in 4.5 g/L D-Glucose DMEM GlutaMax™-I 
(Gibco) with 10% fetal bovine serum (Gibco), 2.5 µg/mL Amphotericin B (PAA 
laboratories) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin, Gibco) at 
37°C, 5% CO2 and grown until about 80% confluence with a regular medium change 
every three to four days.  
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2.1.2 Human pancreatic islets for deglycosylation studies 
2.1.2.1 Human pancreatic islets: Samples and culture  
Two batches of human pancreatic islets, which were deemed unsuitable for 
transplantation, were obtained from the Oxford consortium for islet transplantation 
(OXCIT, University of Oxford). The following information was provided for batch 1: Islets 
originated from a 54-year-old female donor (BMI: 31). Islet purity and viability determined 
was 50% and 65%, respectively. Islets were supplied three days after isolation in a 
suspension (~50mL) containing a total number of 13,000 islets, an equivalent of 21,000 
IEQs. IEQ is considered a unit for pancreatic islets and refers to an islet volume with a 
diameter sphere of 150 µm. Batch 2 was obtained from a 59-year-old female donor with 
a BMI of 27. Purity and viability accounted for 76% and 70%, respectively. In total, 20,000 
IEQ were provided one day after isolation in a 50 mL suspension. Human pancreatic 
islets were maintained in 5.6 mM D-Glucose CMRL 1066 transplant media without 
phenol red supplemented with 10% purified human albumin, 20 mM HEPES, 1% 
penicillin/streptomycin and 1 mM glutamine (OXSOP 5.2.7). Islets culture medium was 
prepared at the OXCIT and kindly provided for usage throughout the experiments. If 
islets were meant to be kept in culture, they were seeded (100 µL/100 IEQ seeding 
density) in non-coated T75 flask (Corning) for maintenance at 37°C, 5% CO2.  
2.1.2.2 Krebs-Ringer bicarbonate buffer (KRBB buffer)  
Insulin secretion studies according to Assay 1 (2.3.1) were performed in KRBB (modified 
after 210). Like other salt solutions, KRBB buffer maintains the physiological pH and 
osmotic balance and provides cells with water and inorganic ions. In one litre of ultrapure 
water, HEPES (25 mM), NaCl (115 mM), NaHCO3 (24 mM), KCl (5 mM), MgCl2 x 6 H2O 
(1 mM), BSA (0,1%), and CaCl2 x H2O (2.5 mM) were combined under continuous 
stirring. The pH of 7.3-7.5 was adjusted with 1 M NaOH and 1 M HCl and the solution 
then filter sterilised, aliquoted and stored at 2 - 8°C. Prior to the experiment, KRBB buffer 
was supplemented with 2.8 mM and 28 mM glucose for low and high glucose-stimulated 
insulin secretion, respectively.  
2.1.2.3 Balanced salt solution (BBS) after Gey and Gey 1936  
For insulin secretion studies (2.3.2) with Batch 2 of human pancreatic islets a 
physiological BBS after Gey and Gey 211 was prepared. The following ingredients were 
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added to 500 mL of ultrapure water and dissolved one by one under continuous stirring 
conditions: Sodium chloride (128.56 mM), potassium chloride (4.96 mM), sodium 
bicarbonate (27 mM), magnesium chloride hexahydrate (1 mM), disodium hydrogen 
phosphate dehydrate (0.84 mM), potassium dihydrogenphosphate (0.22 mM) and 
magnesium sulfate heptahydrate (0.28 mM). After the salts had dissolved the solution 
was supplemented with calcium chloride dihydrate (2 mM) and BSA (0.25 g). It was 
important to add the calcium chloride dihydrate bit by bit as it is a difficult to dissolve 
compound. The complete dissociation of all ingredients and for adjustment of a 
physiological pH of 7.3-7.5 the salt solution was gas-flushed with CO2 before and after 
filter-sterilising (0.2 cellulose acetate filter) the solution. 40 mL aliquots of the balanced 
salt solution were aliquoted in 50 mL tubes and stored at 4°C. The different solutions 
needed for the assay were prepared prior to the experiment on the basis of the balanced 
salt solution and either supplemented with 2 mM glucose or 20 mM glucose. For 
deglycosylation, 4000U/mL Peptide N-Glycosidase F (PNGase F) and 4000U/mL 
Endoglycosidase H (Endo H) were added to a part of the 2 mM glucose solution and half 
of the 20 mM glucose solution was supplemented with PMA.  
2.1.2.4 Radioimmunoprecipitation assay buffer (RIPA buffer)  
Human pancreatic islets were lysed in radioimmunoprecipitation assay buffer (RIPA lysis 
buffer) composed of Tris-HCl pH 8 (50 mM), NaCl (150 mM), NP-40 (1%), Sodium 
deoxycholate (0.5%), SDS (0,1%), Protease inhibitor and combined in ultrapure water 
for intracellular insulin measurement.  
2.1.3 HEK293T cells and HepG2 cells for genome editing 
with CRISPR  
2.1.3.1 HEK293T cells  
Culture of HEK293T cells  
HEK293T cells (Davies lab) were routinely cultured in T25 flasks in MEF medium 
composed of DMEM high glucose (Sigma) supplemented with 10% FCS (Gibco), 1x L-
Glutamine (Sigma) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin, 
Sigma) and maintained at 37°C and 5% CO2 fumigation. Cells were subcultured every 
two days with a subcultivation ratio of 1:3 cells per T25 flask. After carefully aspirating 
the medium, cells were washed ones with 1x PBS and incubated with 1 mL 0.05% 
Trypsin-EDTA (Sigma) per T25 flask for 2 minutes for detachment. To stop the reaction 
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4 mL of MEF medium were added and the cell suspension was pelleted for 5 minutes at 
1,000 rpm in 15 mL conical tubes. Cells were suspended in MEF medium, composed of 
DMEM supplemented with and seeded after counting with a hemocytometer. For 
cryopreservation, cell culture medium was supplemented with 10% dimethylsulfoxide 
(DMSO, Sigma) and cells were stored in Nunc® CryoTubes at -80°C. When taken from 
cryostocks, HEK293T cells were thawed quickly in a water bath at 37°C for 90 seconds 
and immediately transferred into culture flask containing MEF cell culture medium and 
kept at 37°C, 5% CO2.  
Semi-reverse transfection of HEK293T cells 
The assessment of two CRISPR-Cas9 expression constructs (Table 12), each carrying 
a target-specific gRNA and the Cas9 gene, was first tested in HEK293T cells, as these 
cells are known to be “easy to transfect”. The constructs were delivered to the cells in a 
semi-reverse transfection whilst cells are in suspension using the FuGENE® HD 
transfection reagent (Promega).  
Beside the two CRISPR constructs to test, three controls were incorporated. The GFP-
expressing plasmid pCAGFP 212, a CRISPR construct which was used successfully in a 
previous, independent experiment and non-transfected to compare as a negative control. 
Transfections were carried out in 24-well plates (Corning). After detaching the cells, 
80,000 cells per well in a total volume of 500 µL MEF medium without antibiotics were 
transfected with 550 ng of plasmid DNA and DNA:FuGENE® HD ratio of 1:5. The 
transfection mix was prepared in serum-free Opti-MEM™ medium (Gibco) in sterile 1.5 
mL reaction tubes and plasmid DNA and Opti-MEM™ together were made up to a final 
volume of 25 µL. To prewarm the FuGENE® HD reagent, 2.5 µL were added to the Opti-
MEM™ and incubated for 5 minutes prior of adding the plasmid DNA. To promote 
FuGENE® HD and plasmid DNA complexation the content was gently mixed by flicking 
the tube and then incubated for 15 minutes at RT. Meanwhile, the cells were prepared 
and seeded in the 24 wells and the transfection mix then added dropwise to the cells. 
Transfected HEK293T cells were incubated 48 hours at 37°C and 5% CO2 before lysis 
(s. 2.4.1.2.).  
2.1.3.2 HepG2 cells  
Culture of HepG2 cells 
HepG2 cells (ATCC® HB-8065™) were routinely cultured in T25 flasks in α-MEM 
medium with ribonucleosides and desoxyribonucleosides (Gibco) supplemented with 10-
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20% FCS, antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin, Sigma), 1x non-
essential amino acids (Sigma), 1x GlutaMAX™ Supplement (Gibco), 1x L-Glutamine 
(Sigma), 25 mM D-Glucose (Sigma), 50 µg/mL Linoleic acid bovine serum albumin 
(Sigma), 0.4 µg/ml Hydrocortisone (Sigma), 0.04 µg/mL Thyroid Releasing Hormone 
(Sigma), 10 µg/mL Insulin (Sigma) and 0.002 µg/mL Sodium Selenite (Sigma) and 
maintained at 37°C with 5% CO2. HepG2 cells were passaged every 3-4 days with a 
seeding density of 750,000 cells per T25 flask. For detachment, cells were washed twice 
with 1x PBS (Gibco) and treated with 1.5 mL 0.25% Trypsin-EDTA (Gibco) per T25 flask 
for 4-7 minutes. The reaction was terminated by adding the double amount of cell culture 
medium containing serum. In order to obtain a single cell suspension and to avoid 
clumping, cells were passed through a 21G needle before seeding. Cell culture medium 
was changed 24 hours after subculturing. For cryopreservation, cell culture medium was 
supplemented with 5% DMSO and cells were stored in Nunc® CryoTubes at -80°C. 
When taken from cryostocks, vials with cells were thawed quickly in a water bath at 37°C 
for about 90 seconds, transferred into a 15 mL conical tube containing 9 mL of HepG2 
culture medium and spun for 5 minutes at 1,000 rpm. Immediately after, the cell pellet 
was resuspended in HepG2 cell culture medium and cells were transferred into a T25 
culture flask containing a total of 7 mL HepG2 cell culture medium and kept at 37°C, 5% 
CO2. HepG2 cells were tested negative for mycoplasma contamination.  
 
Semi-reverse transfection and co-transfection of HepG2 cells 
In order to create the desired SNP (PMM2 c.-167G>T) in HepG2 cells, the CRISPR-
Cas9 expression construct of choice and a specifically designed ssODN were delivered 
to the cells in a semi-reverse co-transfection.  
Semi-reverse transfections and co-transfections were done using the FuGENE® HD 
transfection reagent and the protocol was optimised for HepG2 cells. At first, different 
amounts of the CRISPR plasmid DNA (550 ng, 800 ng and 1 µg) only were transfected 
to assess the right proportion of plasmid DNA to add. Later on, different amounts of 10 
µM ssODN working stock (800 ng, 400 ng, 320 ng and 200 ng) were delivered to the 
cells together with the CRISPR plasmid in semi-reverse co-transfection experiments. For 
both, semi-reverse transfections and co-transfections, experiments were performed in 
24 well plates. Cells were trypsinised and separated as described before and 250,000 
cells were seeded per transfection in a total volume of 500 µL HepG2 culture medium 
without antibiotics. The transfection mix was added immediately after plating the cells.  
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The optimal DNA:FuGENE® HD ratio to use was 1:6. A total amount of 1 µg plasmid 
DNA were used per transfection and combined with 6 µL of FuGENE® HD. The 
transfection mix was prepared in serum-free Opti-MEM™ medium (Gibco) in sterile 1.5 
mL reaction tubes. Plasmid DNA and Opti-MEM™ together were made up to a final 
volume of 25 µL. Before adding the plasmid DNA to the mix, 6 µL of the FuGENE® HD 
reagent were added to the Opti-MEM™ and incubated at RT for 5 minutes to prewarm 
the reagent. After adding the right amount of plasmid DNA, the transfection mix was 
gently mixed by flicking the tube and then incubated for additional 15 minutes at RT. In 
case of a co-transfection, 400 ng (1 µL) of the 10 µM ssODN were added to the mix 
additionally, prior the 15-minute incubation. In the meantime, the cells were seeded onto 
the wells and the transfection mix then added dropwise to the cells. Transfected HepG2 
cells were incubated 48 to 72 hours at 37°C and 5% CO2. During each experiment, at 
least one sample of cells got transfected with the GFP-expressing plasmid 
pCAGFP213213213213213213213213213213213 to serve as a positive control and one or two wells 
of non-transfected cells were used as a negative control (MOCK). Both controls were 
also used to set up the FACS cell sorter later on.  
2.1.4 Monitoring transfection efficiency of GFP-expressing 
cells 
GFP expression of delivered plasmids to HEK293T and HepG2 cells and CRISPR 
constructs was monitored 24–72 hours after semi-reverse transfections and co-
transfections using the ZOE Fluorescent Cell Imager (Bio-Rad). Pictures were taken 
from the brightfield and the green fluorescent channel, to be able to compare cell density 
and GFP-signal.  
2.1.5 Electroporation of HepG2 cells (CRISPR-RNP 
approach)  
When the CRISPR/Cas9 system was delivered to HepG2 cells as ribonucleoproteins 
(RNPs) together with the ssODN, electroporation was used. RNPs and HDR donor were 
transferred into the cells with the Neon® Transfection System (ThermoFisher) using the 
NEON® 10 µL electroporation tips provided by the Kit. In total, four samples were 
incorporated in the experiment: The sgRNA/Cas9 complex and the ssODN were 
delivered to the cells in duplicate next to a control electroporation with the GFP plasmid 
pCAGFP 213 only and a MOCK sample of non-electroporated cells.  
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Three to four days after passaging, HepG2 cells were harvested as described previously. 
For each electroporation ~1.4*106 HepG2 cells were used and plated afterwards onto 24 
wells in 500 µL – 1 mL of HepG2 culture medium without antibiotics. The 24-well plate 
was prepared beforehand and put in the cell culture incubator (37°C, 5% CO2) to 
prewarm the medium and adjust the pH. For each electroporation, a transfection mix was 
prepared in 1.5 mL tubes consisting of ~1.1 µg sgRNA (0.6 µL), 20 µM Cas9 protein (1 
µL) and 4.4 µL Buffer R and the mix was then incubated for 15 minutes at RT to allow 
RNP complexes to form (RNP mix). Meanwhile, the ssODN, HepG2 cells and 
electroporator were prepared. First, 3 µL of the ssODN (100 µM stock) were diluted in 7 
µL Buffer R. The NEON® pipette station was put under the laminar flow hood and the 
NEON® tube (contains electrode) was inserted. 3 mL of Buffer E were then added to the 
NEON® tube and the electroporation programme set to the following parameters: 1500 
V, 30 ms, 1 pulse. Next, HepG2 cells were counted and the adequate number of cells 
per experiment needed was collected at 1,000 rpm for 5 minutes and the pellet dissolved 
in the right amount of Buffer R (7 µL per electroporation plus 1x excess) provided by the 
Neon® kit. This was done just before electroporation, to keep cell stress as low as 
possible. Suspended cells had to be kept on ice prior to usage. When the 15-minute 
incubation time was up, 1 µL of the ssODN dilution was added to each RNP mix and 7 
µL cell suspension were added to this mix. With the electroporation pipette and the 
NEON® 10 µL electroporation tip, the cell/RNP/ssODN mix was mixed carefully (2-times 
up and down) and the whole volume then taken. Here, it was crucial to avoid bubble 
formation inside the NEON® tip. The tip was placed inside the NEON® tube containing 
Buffer E and the programme was started. Immediately after electroshocking, the cells 
were seeded in one well of the previously prepared 24-well plate and the plate put in the 
incubator at 37°C, 5% CO2. After 3 days of incubation, CRISPRed HepG2 cells were 
harvested as described previously and three-quarters put in cryopreservation at -80°C 
as a backup. The remainder was used to extract gDNA to assess the cutting efficiency 
and overall success of the experiment (s. 2.4.6). In addition, 3x 5,000 cells were seeded 
in ultra-low density on 10 cm dishes and incubated at 37°C, 5% CO2 for about two weeks, 
to obtain single cell colonies (s. 2.4.7) for genotyping (s. 2.4.8).  
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2.2 Quantitative digital PCR methods  
Using quantitative digital PCR (dPCR), a series of gene expression assays (GEA) and 
an allele-specific assay (ASA) were performed. For both sets of experiments, cDNA 
obtained from primary renal cell cultures from a compound heterozygous patient and a 
healthy person (control) was used as a template in dPCR. For further details regarding 
primary renal cell culture and origin, RNA isolation and cDNA synthesis please go to 
sections 2.2.1, 2.2.2 and 2.1.1.  
Quantitative differences in the overall PMM2 gene expression of the HIPKD patients 
were analysed by GEA. Besides PMM2, the expression levels of three additional genes, 
TMEM186, CARHSP1 and ABAT, the neighbour genes of PMM2, were analysed to 
explore whether these are affected by the PMM2 promoter mutation. In addition, the 
expression of two housekeeping genes, CDH1 and PPIA was measured as well.  
In addition to the c.-167G>T SNP on one allele within the PMM2 promoter, the compound 
heterozygous patient also carries a SNP within the coding region of PMM2 (c.422G>A; 
Ref.-Seq.: NM_000303.2) located on the opposite allele controlled by the wt PMM2 
promoter. The nature of these two mutant PMM2 alleles (Allele 1 and Allele 2) in the 
compound heterozygous patient was used to design an allele specific assay (ASA) for 
dPCR. This has allowed the investigation of potential alterations in expression levels of 
the two PMM2 alleles due to the c.-167G>T promoter mutation on Allele 2. Here, also 
cDNA served as the input material. Quantification was implemented using two specific 
differently labelled probes, both spanning nt position c.422 (Ref.-Seq.: NM_000303.2) 
on both alleles. To distinguish between the two PMM2 alleles, the SNP c.422G>A was 
used and incorporated in the probe design (Table 5) for the respective allele (Allele 1). 
Figure 21 shows how the two ASA TaqMan® probes were designed to bind at the PMM2 
target locus c.422G>A.  
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Absolute quantification of differential gene expression in primary renal cells was 
implemented and analysed using the chip-based QuantStudio™ 3D Digital PCR system 
(ThermoFisher) and the QuantStudio™ 3D Analysis Suite Cloud Software 
(ThermoFisher). All specific TaqMan® Genotyping assays were purchased from Thermo 
Fisher Scientific, Paisley, UK. The TaqMan® probes are covalently labelled with a 
fluorophor (FAM™or VIC®) at the 5’-end for detection. One allele-specific assay and six 
gene expression assays were included in this study (Table 7).  
2.2.1 RNA isolation from primary renal cells  
In order to perform quantitative digital PCR gene expression experiments, RNA was 
isolated from primary renal cell cultures, derived from a patients’ and a control (wt) kidney 
at different passages and days (Table 4) using TRIzol® (ThermoFisher) according to the 
manufacturer’s protocol for adherent cells. RNA was dissolved in ultrapure DEPC-
treated Water (Sigma). The concentration of isolated RNA (Table 4) was determined 
using the NanoDrop ND1000 spectrophotometer (ThermoFisher). RNA was stored at 
-80°C.  
2.2.2 cDNA synthesis from RNA samples 
Each of the RNA isolates was transcribed into cDNA by a one-step reverse transcription 
(RT) reaction using the iScript™ Reverse Transcription Supermix for RT-qPCR Kit (Bio-
Rad). A total RNA input of 1,000 ng per RNA sample was transcribed into cDNA resulting 
in a total cDNA amount equivalent to 50 ng/µL of RNA per RNA sample. As suggested 
Figure 21: Scheme depicting TaqMan® probe-binding for allele specific discrimination (ASA) in a 
compound heterozygous patient.  
The red asterisk indicates the PMM2 promoter SNP G>T at position c.-167 on Allele 2 (MUT 
promoter) of the PMM2 gene. The blue bar indicates probe binding overspanning the wt version 
of position c.422G (Allele 2 with MUT promoter). The green bar specifies probe binding to allele 1 
(WT promoter) carrying the G>A SNP at position c.422. The blue and green asterisks mark probe-
labelling with the two fluorophores FAM™ (green) and VIC® (blue). MUT = mutant. WT = wildtype. 
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by the manufacturers’ protocol a pooled no reverse transcriptase control for patient and 
control and a no template control (for ASA) were used as negative controls. cDNA 
samples were stored at -20°C until usage in digital PCR experiments.  
 
Table 4: Patient (grey) and control (white) primary renal cell samples used for RNA isolation 
Sample Kidney Passage RNA concentration Assay used 
Patient 1 (P1) Passage 4 151.9 ng/µL ASA/GEA 
Patient 2 (P2) Passage 3 171.4 ng/µL ASA/GEA 
Patient 3 (P3) Passage 3 200.6 ng/µL ASA/GEA 
Patient 4 (P4) Passage 1 423.6 ng/µL ASA/GEA 
Control 1 (C1) Passage 4 319.7 ng/µL GEA 
Control 2 (C2) Passage 4 278.5 ng/µL GEA 
Control 3 (C3) Passage 4 318.8 ng/µL GEA 
 
2.2.3 TaqMan® assays  
2.2.3.1 Allele specific assay  
Allelic discrimination was implemented using a target-specific Custom TaqMan® SNP 
Genotyping Assay (ThermoFisher) designed through the Thermo Fisher TaqMan® 
Assay Design Tool. The assay contains a primer/probe mix for amplification and 
detection of the targets. For allelic discrimination two differently fluorophore-labelled 
probes were present in the assay. ASA probe and primer sequences and probe labelling 
are listed in Table 5 and Table 6.  
 
Table 5: TaqMan® assay used for allele specific assay in dPCR setting 
Assay ID Target gene Sequence 5’-3’ 
Fluorophore at 
5’-end (Dye) 
AHGJ9ED 
PMM2 CCAAGAAGAACGCATTGA-3’-NFQ-MGB FAM™ (green) 
PMM2 CCAAGAAGAACACATTGA-3’-NFQ-MGB VIC® (blue) 
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The following primer set was part of the allele specific assay for amplification in dPCR.  
 
Table 6: Primer contained in TaqMan® assay AHGJ9ED used for allele specific assay  
Target Direction Sequence 5’-3’ 
PMM2 Forward GTGTCCCCTATTGGAAGAAGCT 
PMM2 Reverse CTTTTGTCTTATATTTTCTTTTTTATCGAGTTCGTAGA 
 
2.2.3.2 Gene expression assay  
TaqMan® gene expression assays used for expression studies (Table 7) were ordered 
predesigned. More detailed information regarding approximate probe-binding motif 
within the gene of interest can be ascertained through the assay IDs.  
 
Table 7: TaqMan® assays used for quantitative dPCR gene expression assays  
Target gene Assay ID Fluorophore at 5’-end (Dye) 
PMM2 Hs00756707_m1 FAM™ 
TMEM186 Hs01049388_m1 FAM™ 
CARHSP1 Hs00183933_m1 FAM™ 
ABAT Hs00609436_m1 FAM™ 
PPIA Hs04194521_s1 VIC® 
CDH1 Hs01013955_m1 FAM™ 
 
2.2.4 Control sample for allele specific assay  
As a control, two linearized plasmid constructs [pcDNA™3.1(-) PMM2_wt.dna; 
pcDNA™3.1 (-) PMM2_mut.dna] were used in a 1:1 ratio, mimicking the two PMM2 
alleles of a patient being heterozygous for the c.422G>A SNP but both being under 
control of a wt promoter (done by Dr Daniela Iancu, UCL Centre for Nephrology).  
2.2.5 Digital PCR sample preparation  
For the final reaction, cDNA samples and master mix were prepared separately for each 
assay. All cDNA/plasmid samples were made to a volume of 6 µL using nuclease free 
water (Sigma). The master mix contained the Quantstudio® 3D Digital PCR Master Mix, 
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20x TaqMan® assay and nuclease-free water and were made up to the number of chips 
to be loaded per sample. Then, cDNA sample and master mix were combined and a total 
volume of 14.5 µL was loaded on each chip according to the manufacturer’s 
recommendations (ThermoFisher).  
2.2.6 PCR program 
All dPCR reactions were performed using the GeneAmp PCR system 9700 
(ThermoFisher) and samples were amplified with the following conditions: Initial 
denaturation at 96°C, 10 mins followed by 39 cycles of 60°C, 2 mins and 98°C for 30 sec 
and final 2 mins at 60°C for extension.  
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2.3 Insulin secretion assays with human pancreatic 
islets  
The effect of deglycosylation on the function of human pancreatic islets was examined 
by, firstly, conducting two different deglycosylation assays (Assay 1 and Assay 2) using 
two batches of human pancreatic islets to then measure insulin secretion in a human 
insulin ELISA assay. Both assays had two main stages, a deglycosylation period evoked 
due to the addition of glycosidases and a glucose-stimulated insulin secretion series 
(GSIS). The main differences between the assays were 1) the order in which the two 
treatment periods (Deglycosylation and GSIS) took place, 2) for the second assay (Assay 
2) the PKC activator PMA (phorbol-12 myristate-13 acetate) to enhance insulin secretion 
was used in addition and 3) the process itself. Whereas during the first assay (Assay 1), 
the islets were exposed to the different stimuli in a flowing sequence (transfer from well 
to well) and each sample had passed all the different treatment stages, in the second 
assay islets were split in three parts and kept separately, one group for each condition 
of the GSIS part. Figure 22 and Figure 23 illustrate the principle and performance of both 
assays. During the first assay (2.3.1) deglycosylation took place after a series of glucose-
stimulated insulin secretion (2.8 mM glucose and 28 mM glucose) with Peptide N-
Glycosidase F (PNGase F, NEB). In the second assay (2.3.2), deglycosylation was 
evoked by using two glycosidases, PNGase F and the more specific Endoglycosidase H 
(Endo H) and was conducted before glucose stimulation testing three conditions (2 mM 
glucose, 20 mM glucose, 20 mM glucose plus PMA).  
2.3.1 Assay 1: Glucose-stimulated insulin secretion (GSIS) 
and PNGase F treatment  
The glucose-stimulated insulin secretion and subsequent PNGase F treatment series 
was performed using human pancreatic islets Batch 1. After arrival, the islet suspension 
was placed in the incubator for islets settlement. Then islets were suspended in 5 mL 
medium and 1,500 IEQ (volume calculated) were seeded in a 10 cm non-coated petri 
dish containing 15 mL of islets culture medium. Subsequently, islets were incubated ON 
at 37°C, 5% CO2 prior to start the experiment. The remaining islets were kept in culture 
as described in section 2.1.2.1. The experiment was done in 24-well plates (NUNC) with 
Millicell® cell culture inserts (Merck Millipore) for islets transfer. Before islets seeding, 
the 24-well plates were prepared as shown in Figure 22. KRBB buffer and previously 
prepared KRBB glucose solutions were filled in 24-wells (1.3 mL per well) and those then 
equilibrated for 60 mins at 37°C and 5% CO2 to adjust the pH and temperature of the 
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bicarbonate-containing KRBB buffer. In total, four samples (3x experimental condition, 
1x control) were assayed. The ON culture was harvested in a 15 mL tube. After islets 
settlement on the bottom of the tube, the majority of the medium was removed and only 
1.5 mL were left. In this way an islets concentration of 100 IEQ/100 µL was achieved to 
precisely place the desired number of IEQs (300 IEQ/300 µL per insert) in Millicell® cell 
culture inserts. Prior to the assay, seeded islets were washed and equilibrated in the 
KRBB 2.8 mM glucose solution for one hour at 37°C and 5% CO2. For GSIS, all four 
samples were incubated in 1) low (2.8 mM), 2) high (28 mM) and again 3) low glucose 
(2.8 mM). For the last condition to test (4), three islets samples were exposed to 2,000 
U PNGase F in KRBB buffer without the addition of glucose (0 mM glucose). The fourth 
sample was used as a control. Before adding it to the wells, PNGase F was mixed with 
100 µL of its dedicated enzyme buffer (10x GlycoBuffer 7 “G7”, 500 mM Na3PO4) and 
subsequently added to the three wells containing KRBB buffer only (1:10 dilution). The 
control sample was supplemented with the G7 enzyme buffer to keep conditions 
consistent. Each treatment lasted for 60 mins under known culture conditions (37°C, 5% 
CO2) and when the time was up, islets were transferred into the next well. For 
measurement of secreted insulin, medium samples were taken before (T0, 300 µL) and 
after the 60-minute incubation (T60, 1 mL).  
Finally, islets were harvested in 1 mL radioimmunoprecipitation assay buffer (RIPA 
lysis buffer, 50 mM Tris-HCl pH 8; 150 mM NaCl; 1% NP-40, 0.5% sodium 
deoxycholate; 0,1% SDS; Protease inhibitor; 18.2 MΩ H2O) for intracellular insulin 
measurement. Cell lysates and medium samples were stored at -80°C and -20°C, 
respectively for analysis with ELISA later on (2.3.3).  
  
                     Chapter 2  
 82 
 
2.3.2 Assay 2: Deglycosylation assay with PNGase F and 
Endo H for insulin secretion studies 
Insulin secretion studies following deglycosylation with PNGase F and, in addition, Endo 
H were done using human pancreatic islets Batch 3. Differently to the previous set up, 
the deglycosylation of human pancreatic islets took place prior to glucose-stimulated 
insulin secretion during this experiment. In total, six independent islets samples were 
treated with deglycosylating enzymes in a first experimental stage. In parallel, another 
six independent non-deglycosylated islets samples were used as a control group for 
direct comparison. During the second stage of the assay both sets of islets, 
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Figure 22: Experimental set up for human pancreatic islets Batch 1 (Assay 1).  
Plate preparation and experimental process for glucose-stimulated insulin secretion and PNGase 
F treatment assay. Low Glu: KRBB buffer plus 2.8 mM glucose (1.3 mL/well). High Glu: KRBB 
plus 28 mM glucose (1.3 mL/well). PNGase F (2000 U in 10x G7 enzyme buffer, 500 mM Na3PO4) 
in KRBB without glucose (1.3 mL/well). G7: 10x G7 enzyme buffer only in KRBB without glucose 
(1.3 mL/well). RIPA: Grey arrows indicate the transfer of the islets throughout the experiment. 
Blue arrow: Total amount of time of islets stimulation. 
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deglycosylated and non-deglycosylated, were split in three groups for glucose 
stimulation, testing islets response to the following three conditions: 1) 2 mM glucose for 
basal islets stimulation, 2) Exposure to 20 mM glucose for enhanced stimulation and 3) 
Exposure to 20 mM glucose plus PMA to boost enhancement of insulin secretion 
additionally. For each condition, two independent samples of deglycosylated islets and 
two independent samples from the control group were available, allowing subsequent 
insulin measurements in duplicate. The assay was performed in 24-well plates which 
was prepared as shown in Figure 23 and 1 mL of the previously prepared glucose 
solution added per well. Before seeding the islets, the plate was equilibrated for one hour 
in the cell culture incubator (37°C and 5% CO2).  
After collection, islets were maintained in a non-coated T75 flask in their dedicated 
culture medium ON (2.1.2.1). Prior to the experiment, 24-well Millicell cell culture inserts 
(Merck) were placed in 24 well plates. Human pancreatic islets were then seeded onto 
the polycarbonate membrane of the insert at a density of 150 islets/well. To 
deglycosylate cell surface proteins the cells were incubated at 37°C for 120 minutes, in 
balanced salt solution (2.1.2.3) prepared after Gey and Gey, supplemented with 2mM 
glucose in the presence or absence of 4000U/mL PNGase F and 4000U/mL Endo H. 
Immediately following deglycosylation the cells were washed and transferred into the 
next wells for glucose-stimulated insulin secretion. Islets were exposed to three different 
conditions as mentioned above. Islets were incubated for 60 minutes (37°C, 5% CO2) in 
balanced salt solution supplemented with 2mM glucose, or 20mM glucose, or 20mM 
glucose plus the protein kinase C activator PMA (500 nM). After incubation, the medium 
of each well was collected and stored at -20C for the measurement of secreted insulin 
with ELISA. In order to determine the intracellular insulin content, all islets samples used 
in this assay were harvested in RIPA cell lysis buffer (2.1.2.4) after the experiment was 
finished and carefully sonicated (Hielscher) on ice (3x 12 pulses, 60% amplitude) to 
ensure the breakdown of the cells. Islets lysates were frozen at -80C for intracellular 
insulin measurements.  
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2.3.3 ELISA assay for Human insulin measurement  
The medium samples and lysates collected from both glucose-stimulated insulin 
secretion and deglycosylation assays with human pancreatic islets Batches 1 and 2 
(2.3.1, 2.3.2) were analysed in an enzyme-linked immunosorbent assay (ELISA) using 
the Human Insulin ELISA Kit (Millipore). The sample volume always accounted for 20 
µL. Blanks (NSB, RIPA buffer) and standards (2, 5, 20, 50, 100, 200 µU/mL) were 
measured in duplicates (20 µL) and used for correction of sample absorbance values 
after reading. To guarantee accuracy of the measurement two low and high insulin 
quality controls, QC1 (concentration range: 7.3-15 µU/mL) and QC2 (concentration 
range: 19-39 µU/mL), were measured in parallel. Each sample (secreted and 
intracellular) and also the quality controls were measured once. The assay was 
performed according to the manufacturer’s instructions and read at 450 nm (Beckman 
Coulter, DTX 880). When outside of the range of the standard curve, samples were 
Figure 23: Experimental set up for human pancreatic islets Batch 2 (Assay 2).  
Plate preparation and experimental process for deglycosylation studies with PNGase F, Endo H 
and subsequent glucose-stimulated insulin secretion with PMA. All solutions were prepared in 
balanced salt solution (BSS) and 1 mL were added per 24-well. +: with PNGase F and Endo H. -
: Without PNGase F and Endo H. A: Deglycosylation. 150 IEQ/well were seeded in BSS 
containing 2 mM glucose with PNGase F and Endo H. B: Control (non-deglycosylated). 150 
IEQ/well were seeded in BSS containing 2 mM glucose without PNGase F and Endo H. Rows A 
and B were incubated for 120 minutes at 37°C and 5% CO2. After incubation, islets were 
transferred into rows C and D. C and D 1-2: Glucose-stimulated insulin secretion condition 1 
(Basal stimulation). BSS containing 2 mM glucose with (+) or without (-) PNGase F and Endo H. 
C and D 1-2: Glucose-stimulated insulin secretion condition 1 (Basal stimulation). C and D 3-4: 
Glucose-stimulated insulin secretion condition 2 (Enhanced stimulation). BSS containing 20 mM 
glucose with (+) or without (-) PNGase F and Endo H. C and D 5-6: Glucose-stimulated insulin 
secretion condition 3 (PMA-enhanced stimulation). BSS containing 20 mM glucose and 500 nM 
PMA with (+) or without (-) PNGase F and Endo H. Rows C and D were incubated for 60 minutes 
at 37°C and 5% CO2.  
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diluted accordingly prior to measurement. Differences in insulin secretion between 
treatment groups were assessed by one-way or two-way ANOVA and post hoc 
Bonferroni or student’s t-test, respectively.  
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2.4 CRISPR-Cas9 genome editing methods 
To generate the desired HepG2 cell line, a CRISPR/Cas9 vector-based strategy was 
chosen for scarless gene editing. In order to be able to track and select transfected cells, 
the Cas9 expression vector pSpCas9(BB)-2A-GFP (Addgene plasmid # 48138, PX458) 
203, kindly provided by Feng Zhang, was used. The CRISPR vector contains the hSpCas9 
gene (insert) from S. pyogenes and an EGFP at the C-terminal site of the insert. Due to 
digestion of the vector with BbsI, the target-specific gRNA oligonucleotides could simply 
be ligated into the backbone by adding matching 5’-overhangs. BbsI is a Type II 
restriction enzyme which cuts a few nucleotides upstream its recognition sites and 
therefore got replaced by the inserted double-stranded gRNA oligo. Figure 24 depicts a 
schematic overview of the cloning strategy when working with the Cas9 expression 
vector pSpCas9(BB)-2A-GFP (PX458).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Schematic overview showing the insertion of the target-specific gRNA oligo using the 
Cas9 expression vector pSpCas9(BB)-2A-GFP (pX458).  
Top: Double-stranded guide oligo composed of the individual target-specific 20-nt guide 
sequence (blue Xs), an additional guanine (blue g), if not present naturally and a matching 5’-
overhang complementary to BbsI cut site in pX458 for ligation. Middle: Guide oligo insertion site 
and universal sgRNA scaffold sequence. Bottom: pSpCas9(BB)-2A-GFP with all its features from 
left to right: U6 promoter, BbsI guide oligo ligation site, Cbh promoter, 3x FLAG tag, NLS nuclear 
localisation signal, S. pyogenes Cas9 gene, viral 2A self-cleaving peptide, green fluorescent 
protein GFP, NLS, bovine growth hormone polyadenylation signal (bGH pA). Taken from Ran et 
al., 2013  
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2.4.1 Molecular biology methods for genome editing with 
CRISPR-Cas9 
2.4.1.1 DNA sequences and primer design 
Human PMM2 promoter sequence was obtained from the UCSC genome browser 
(https://genome.ucsc.edu/) and corresponds to the human genome assembly 
GRCh38/hg38. Primers were chosen directly from the DNA sequence and analysed 
using the Thermo Fisher Tm calculator (https://www.thermofisher.com/uk/en/home.html) 
for appropriate annealing conditions.  
2.4.1.2 Genomic DNA extraction from HepG2 and HEK293 cells  
Genomic DNA (gDNA) was obtained from pooled or clonal single cell populations in order 
to sequence verify and genotype the PMM2 CRISPR site to evaluate either the overall 
outcome of the CRISPR gene editing (cell pool) or to identify positive clones (single cell 
colonies) post-transfection. When the cells reached a decent confluency, lysis buffer 
(0.1% SDS, 400 µg/mL Proteinase K, 40 µg/mL RNAse A) was either added directly to 
96 well plates or cells were harvested beforehand and lysed in reaction tubes. In both 
cases, cell lysis took place ON at 37°C. For precipitation, 1/10 volume of an 8 M LiCl 
solution and one volume isopropanol were added and lysates were mixed thoroughly. 
Samples or 96 well plates were spun for 10 to 15 minutes at 13,000 rpm, the supernatant 
removed, gDNA pellets then washed 1x with 500 mL 70% ethanol and spun again under 
previous conditions. Pellets were placed at 37°C for 5 to 10 minutes to evaporate 
remaining ethanol. gDNA was resolved in 10 to 50 µL ultrapure water, depending on the 
size of the pellet, quantified using NanoDrop and stored at -20°C.  
2.4.1.3 Hot-Start PCR 
For amplification of the PMM2 CRISPR site in HepG2 cells (and also HEK293T cells) 
and genotyping of picked single cell HepG2 colonies, a Hot-Start PCR protocol was 
chosen, using the IMMOLASE™ DNA Polymerase Kit (Bioline, Cat. No. BIO-21046) to 
increase DNA yield and purity. IMMOLASE™ is a heat-activated thermostable DNA 
polymerase which is inactive at room temperature. It provides extremely high yields of 
DNA and significantly reduces non-specific products (primer-dimers, mis-primed 
products) compared to standard polymerases. All reactions were supplemented with Q-
solution (Qiagen), a substance which additionally improves the PCR reaction by 
modifying the melting behaviour of the DNA. This is in particular beneficial when working 
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with GC-rich templates or templates with a high degree of secondary structure. The 
formulation of Q-Solution is unknown.  
All reactions were carried out in dedicated thin-walled PCR microcentrifuge tubes in a 
thermocycler (VWR Quattrocycler) for DNA amplification. The cycle conditions 
(Denaturation, primer annealing, elongation) were adjusted specifically to primer set 
used and amplicon length. PCR reactions were performed in a total reaction volume of 
20 μL containing 1 µL of gDNA (10 – 300 ng) or 2 µL of gDNA when extracted from single 
cell colonies, 2 µL of 10X ImmoBuffer, 0.6 µL of MgCl2 (50 mM), 0.4 μL of forward and 
reverse primers (10 µM), 0.4 µL of dNTPs (10 µM), 0.2 µL of IMMOLASE DNA 
Polymerase, 4 µL of Q-Solution (5x) and 11 µL of sterile ultrapure water. The 
amplification of gDNA was carried out using the following conditions: Hot start incubation 
at 95°C for 10 mins to activate the IMMOLASE DNA Polymerase, followed by 35 cycles 
of denaturation (94°C, 30 s), primer annealing (temperature primer depended, 30 s) and 
elongation (72°C, 30 s). A final elongation at 72°C for 2 min completed the DNA 
amplification. PCR products (5 µL) were analysed on 2% agarose gel. Table 8 lists primer 
sequences used in Hot-Start PCR.  
 
Table 8: PCR primer used to amplify genomic CRISPR site within PMM2 in HepG2 cells 
Name Target Direction Sequence 5’-3’ 
Amplicon 
length 
PMM2 For3 PMM2 Forward CCGACCCCAAAGAGCATCAC 
296 bp 
PMM2 Rev3 PMM2 Reverse CAAGACACGTTGGCACGAGGAAC 
ChrY For TTTY14 Forward CCTGAACCCTGTCCTCTTGG 
420 bp 
ChrY Rev TTTY14 Reverse GGACTTCCTAAGGGCTGTGT 
 
The annealing temperature of the PMM2 For3/Rev3 primer pair was 56°C and the one 
for ChrY For/Rev 60°C. Primers were purchased from either Integrated DNA 
Technologies or Thermo Fisher Scientific.  
2.4.1.4 Agarose gel electrophoresis 
PCR and restriction digest products were analysed on 1-2% agarose gels in TAE (Tris-
acetate-EDTA) buffer, depending on the size of the DNA products to analyse. Usually 5 
µL per PCR sample were mixed with the 5X Orange G loading dye and brought to a total 
sample size of in total 19 µL. Restriction digests were complemented with 5X Orange G 
loading dye before loading. 100 bp or 1 kb molecular weight standards (NEB, see Figure 
75, Figure 76) were run alongside each electrophoresis and DNA was visualised by 
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adding 0.25 mg/mL ethidium bromide to the gel. Electrophoresis took place at 120-130 
V for 35-45 minutes.  
2.4.1.5 Gel purification of DNA 
If it was needed, DNA bands were extracted and purified from gel using the GeneJET 
Gel Extraction Kit (ThermoFisher) according to the manufacturer’s instructions. Cut 
bands were transferred into a 1.5 mL reaction tube and 100 µL/0.1 g gel of binding buffer 
were added. In the case of 2% gels the volume of binding buffer was doubled. Gel bands 
were put at 55-60°C on a heating block for 10-20 minutes to melt. Up to 800 µL of molten 
DNA gel bands were transferred onto the GeneJET purification column and spun in a 
centrifuge for 1 minute at 13,000 rpm and RT. The flow-through was discarded. This step 
was repeated if the total sample volume exceeded 800 µL. If low DNA amounts were 
expected an additional binding step was introduced by adding additional100 µL of 
binding buffer onto the column silica membrane and the sample was spun as previously 
described. Next, the bound DNA was washed with ethanol-containing wash buffer (700 
µL) and again spun under same conditions. After discarding the flow-through the column 
was spun one more time to completely remove residual wash buffer. The DNA then was 
eluted in 15-50 µL sterile ultrapure water, depending on the DNA concentration 
expected. DNA concentrations were quantified using NanoDrop and stored at -20°C.  
2.4.1.6 ExoSAP treatment of PCR products  
For the enzymatic clean-up of amplified PCR products, prior to sequencing, samples 
were treated with a combination of exonuclease I and shrimp alkaline phosphatase 
(ExoSAP, Affymetrix). This allowed the removal of excess primer and nucleotides in the 
samples which potentially can disturb downstream reactions such as sequencing. Per 
PCR sample, 0.075 µL exonuclease I, 0.75 µL shrimp alkaline phosphatase, 10X SAP 
buffer and 0.675 µL dH2O were added and. Usually, these components were combined 
in a master mix and 2.2 µL of it added to each PCR sample. Samples were incubated 40 
minutes at 37°C, followed by 5 minutes at 80°C and stored at 4°C in a thermocycler.  
2.4.1.7 Sanger Sequencing  
Sequencing of PCR products or CRISPR constructs (Table 12) was outsourced and 
completed by Eurofins Genomics using the Mix2Seq Kit. Samples were prepared in 
provided barcoded tubes. Plasmids were sent in a total reaction volume of 17 µL 
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containing 850 ng of plasmid in ultrapure water and 2 µL of the respective primer (10 
µM) (Table 9). ExoSAP-treated PCR products were diluted 1:20 with ultrapure water and 
15 µL of the diluted PCR product were mixed with 2 µL of a 10 µM primer (usually only 
forward primer) and sent for sequencing.  
 
Table 9: Sequencing primer used for verification of PMM2 ROI, CRISPR constructs and gene 
editing 
Name Target Direction Sequence 5’-3’ Template 
PMM2 For3 PMM2 Forward CCGACCCCAAAGAGCATCAC PCR product 
U6-F 
U6 
promoter 
Reverse GAGGGCCTATTTCCCATGATT  Plasmid 
 
2.4.1.8 Analysing Sanger Sequencing 
All Sequencing data were analysed in ABI format. Electropherograms showing 
sequencing traces were reviewed with the free available software SnapGene Viewer 
(http://www.snapgene.com/). To confirm insertions and deletions (Indels) in 
heterozygous sequences after gene editing, the web-based tool TIDE (Tracking of Indels 
by DEcomposition, https://tide-calculator.nki.nl/) was used.  
2.4.2 TIDE  
TIDE (Tracking indels by Decomposition) is an easy to use and cost-effective online tool, 
which allows for quantification of gene editing events generated by CRISPR-Cas9, 
TALENs or ZFNs by determining sequence alterations and their frequency in a precise 
manner. The input material needed for a TIDE analysis were two simple Sanger 
sequencing traces obtained from the edited HepG2 or HEK293T cell pool or later single 
cell colonies and a wt control sample after PCR amplification of extracted gDNA. It aligns 
sample and control sequence and then calculates the percentage of the overall efficiency 
the individual gene editing tool has altered the targeted DNA with. In the case of the 
CRISPR-Cas9 system, this is significantly dependent on the gRNA target sequence 
chosen, as gRNA performance can vary tremendously. It also provides the individual 
indel spectrum showing the resulting predominant deletions and insertions as well as it 
models the aberrant sequence signal including the predicted cut site. 214.  
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2.4.3 Plasmid-based CRISPR gene editing methods 
2.4.3.1 CRISPR gRNA design  
Guide RNA’s were designed using the molecular biology software SnapGene 
(http://www.snapgene.com/) and two CRISPR design tools, CRISPOR 
(http://crispor.tefor.net/) 215 and CHOPCHOP v2 (http://chopchop.cbu.uib.no/index.php) 
216. gRNA target regions were chosen directly from the human PMM2 promoter sequence 
region of interest to ensure closest proximity to the target site (c.-167), crucial for a 
CRISPR HDR gene edit. Mandatory for a S. pyogenes Cas9 driven approach, the gRNA 
target sequence has to be 20 nt in length and precedes a 5’-NGG PAM site. Potential 
gRNA target sequences were chosen and cross referenced with the two CRISPR design 
tools mentioned above for uniqueness and specificity. Only those gRNAs were used, 
which have provided a specificity score of above 50 in CRISPOR 217 and above 0.5 in 
CHOPCHOP. The gRNA sequences chosen to target the PMM2 promoter are shown in 
Table 10.  
 
Table 10: gRNA DNA target sequences specific to the CRISPR site within PMM2 in HepG2 cells 
to clone into PX458. 
Name Target Vector Direction Sequence 5’-3’ PAM 
gRNA hPMM2*_1 PMM2 PX458 Forward GCGTGATCTGCGTTGCACCC TGG 
gRNA hPMM2*_2 PMM2 PX458 Reverse TTCCTGGACCGCAACTCCCA GGG 
*human PMM2  
 
For cloning into the target vector PX458, gRNA oligonucleotides were designed 
according to the sequences shown in Table 11.  
 
Table 11: gRNA oligonucleotide sequences for cloning into CRISPR plasmid PX458.  
BbsI recognition sites are highlighted in blue.  
Name Target Direction Sequence 5’-3’ 
gRNA hPMM2_1 PMM2 Forward CACCGCGTGATCTGCGTTGCACCC 
gRNA hPMM2_1 PMM2 Reverse AAACGGGTGCAACGCAGATCACGC 
gRNA hPMM2_2 PMM2 Forward CACCgTTCCTGGACCGCAACTCCCA 
gRNA hPMM2_2 PMM2 Reverse AAACTGGGAGTTGCGGTCCAGGAAc 
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In order to enable ligation into the target vector via BbsI restriction sites, 5’-overhangs 
(CACC-/AAAC-) had to be added to the oligonucleotide sequences. The Cas9 
expression plasmid used is controlled by a U6 promoter, which needs a guanine (G) at 
the transcription start site at the 5’ end. A “G” was added to the 5’ end of gRNA 
oligonucleotides when required.  
2.4.3.2 Annealing of gRNA oligonucleotides 
gRNA oligonucleotides (Table 11) were suspended in ultrapure water and brought to a 
stock concentration of 100 µM (100 pmol/µl). For annealing, 2 µL of 100 µM forward and 
reverse primer stock was mixed with 16 µL of TE buffer and the reaction was incubated 
at 100°C for 5 minutes on a heating block. After a short spin, the reaction tubes were 
placed back onto the heating block to gradually cool down to RT.  
2.4.3.3 Cloning of CRISPR-Cas9 expression constructs 
Each gRNA oligo duplex (Table 10) was cloned into the Cas9 expression vector pX458. 
A Golden Gate inspired approach was used for the cloning procedure, which allowed 
restriction and ligation in one reaction step 218. In a final reaction volume of 20 µL, 1 µL 
of plasmid DNA PX458 (150 ng), 1 µL of annealed gRNA oligo pairs, 1 µL BbsI-HF (20 
U), 1 µL T4 DNA ligase (400 U) and 10x T4 Ligase buffer were combined. The reaction 
was incubated in a thermocycler under the following conditions: A sequential incubation 
at enzyme-specific temperatures (37°C, 5 minutes for BbsI-HF and 16°C, 10 minutes for 
T4 DNA Ligase) was repeated during 10 cycles, followed by two final 5 min incubations 
at 50°C and 80°C. The reaction was cooled down to 4°C and then used for transformation 
into E. coli DH5. Both CRISPR constructs had a total size of about 10 kb.  
2.4.3.4 Bacterial transformation culturing of positive E. coli 
clones  
Plasmid DNA (Table 12) was transformed into E. coli DH5 via heat shock. 5 µL of each 
CRISPR-Cas9 expression construct were mixed with 100 µL of thawed E. coli DH5 and 
incubated on ice for 20 minutes, following a heat shock at 42°C for 90 seconds and put 
back on ice for additional 5 minutes. Transformed bacteria were then plated directly on 
LB agar plates containing 100 µg/mL ampicillin for selection of positive clones ON at 
37°C. 1-3 colonies per transformation were picked, inoculated into 2 mL of ampicillin 
containing LB medium and shaken ON at 37°C for harvest the next day.  
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2.4.3.5 Plasmid DNA preparation  
Plasmid DNA was extracted and purified according to the GeneJET Plasmid Miniprep 
Kit (ThermoFisher). Transformed E. coli DH5 ON cultures were transferred into 1.5 mL 
reaction tubes and spun at 8,000 rpm for 2 minutes at RT. Pelleted bacteria were then 
resuspended in 250 µL of RNase A containing chilled resuspension solution and 250 µL 
of lysis solution were added and the mixtures was thoroughly mixed by inverting the tube 
4-6 times resulting in a clear, viscous solution. To separate the vector DNA from gDNA, 
proteins and cell debris, 350 µL of the neutralisation buffer were added per miniprep and 
tubes, again, were inverted 4-6 times prior to a 5-minute centrifugation at 13,000 rpm. 
The plasmid DNA containing supernatant was then added onto the GeneJET Spin 
columns to harvest plasmid DNA by spinning for 1 minute at 13,000 rpm. The flow-
through was discarded and the columns were washed twice with 500 µL of ethanol-
containing wash solution, which was removed by centrifugation under conditions 
mentioned. The columns were placed in new, sterile 1.5 mL collection tubes and plasmid 
DNA was eluted in 40 µL of sterile, ultrapure water. DNA concentrations were measured 
using NanoDrop and samples were stored at -20°C.  
Table 12: PMM2 target-specific CRISPR constructs generated with pSpCas9(BB)-2A-GFP 
(pX458) 
 Name gRNA Sequence 5’-3’ PAM 
Construct 1 pX458_hPMM2_1 GCGTGATCTGCGTTGCACCC TGG 
Construct 2 pX458_hPMM2_2 TTCCTGGACCGCAACTCCCA GGG 
2.4.3.6 Plasmid-Safe treatment  
Purified CRISPR constructs (Table 12) were treated with an ATP-dependent Plasmid-
Safe Nuclease (Epicentre) to remove contaminating chromosomal bacterial DNA. The 
entire cloning reaction was incubated with 1 µL of 10 mM ATP (Epicentre) and 1 µL 
Plasmid Safe nuclease (10 U) for one hour at 37°C in a thermocycler.  
2.4.3.7 Verification of CRISPR-Cas9 expression constructs 
Purified plasmids (Table 12) were verified by restriction double digest with EcoRV and 
BbsI-HF, both purchased form New England Biolabs, and verification was confirmed by 
Sanger sequencing.  
Double restriction digest helped to distinguish between successfully cloned CRISPR 
construct and failed cloning due to the loss of the BbsI site when the gRNA target 
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sequence was inserted into the CRISPR plasmid pX458. Restriction digests were 
performed in a final reaction volume of 10 µL. 1 µg of plasmid DNA were digested with 
5 units of both EcoRV and BbsI-HF in 10X CutSmart buffer and sterile ultrapure water. 
The results were analysed on a 1% agarose gel alongside a 1 kb DNA ladder (Figure 
76) Successfully digested CRISPR constructs were sent for sequence verification using 
the U6-F forward primer (Table 9) as described in section 2.4.1.7.  
2.4.4 Single-stranded donor oligonucleotide design for 
CRISPR-HDR 
To enable a directed HDR-repair after CRISPR, the homologous ssODN which 
harboured the desired SNP at position c.-167 was synthesised by Eurogentec and co-
delivered to the cells. The ssODN was designed according to the leading strand of the 
target region within the PMM2 promoter and has a total length of 139 nt with the desired 
SNP (c.-167G>T) in the centre, flanked by 69 nt long homology arms (Table 13).  
 
Table 13: Sequence of ssODN used for CRISPR/Cas9 co-transfection and electroporation.  
Desired SNP highlighted in red.  
Target Direction ssODN Sequence 5’-3’ 
PMM2 Forward 
ACCGGCCCCCGGAACCCCTAAGAGCGCATGCTCGAATGTACAAG
GCGGGCGTGATCTGCGTTGCACCCTTGGAGTTGCGGTCCAGGAA
TCGTGGCTGCCGCTACTCCCAGGCGTTATGGGAACGGAGTCCCC
TCCTCTT 
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2.4.5 RNP-based CRISPR gene editing methods  
2.4.5.1 sgRNA DNA oligo design  
In order to work with CRISPR RNPs, a DNA oligo template (Figure 25) for sgRNA 
synthesis of gRNA hPMM2_2 (s. Table 10) was designed using the EnGen™ sgRNA 
Template Oligo Designer according to the target sequence:  
5’-TTCCTGGACCGCAACTCCCA-3’.  
 
 
2.4.5.2 sgRNA synthesis and purification  
sgRNA hPMM2_2 was synthesised using the EnGen™ sgRNA synthesis kit (NEB) under 
RNAse-free conditions according to the manufacturer’s protocol. For synthesis in a 20 
µL reaction, the target-specific DNA oligo template 1 µM (5 µL) was combined with 
nuclease-free water (3 µL), EnGen™ 2x sgRNA Reaction mix (10 µL) and the EnGen™ 
sgRNA enzyme mix in a PCR reaction tube. The reaction was mixed well, incubated for 
2.5 hours at 37°C in a thermocycler and put on ice afterwards. The reaction was brought 
to 50 µL with nuclease-free water for DNAse I treatment and 2 µL of DNAse I were added 
(15 minutes, 37°C). After incubation, the reaction was either stored at -20°C or sgRNA 
was purified straight away.  
sgRNA was purified by adding 500 µL phenol-containing TRIzol® reagent 
(ThermoFisher) to the tube. After mixing, 100 µL of chloroform were added, the mixture 
inverted several times and spun for 15 minutes at 13,500 rpm to promote phase 
separation. The RNA-containing aqueous phase was collected carefully in a new 1.5 mL 
Eppendorf tube and the equal volume of isopropanol was added (pipette up and down). 
The mixture was then incubated either at -20°C ON or at -80°C for 1 hour to commence 
Figure 25: Sequence and transcribed sequence of target-specific DNA oligo template for sgRNA 
hPMM2_2 synthesis.  
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precipitation of sgRNA. Following centrifugation at 13,500 for 10 minutes, the 
isopropanol was discarded and the pelleted sgRNA washed with 70% ethanol and again 
spun as previously. The ethanol was discarded under sterile conditions (cell culture 
hood) and the pellet dried for about 20 minutes on ice. The sgRNA was mixed with 30 
µL of water (water for embryo transfer, Sigma) and dissolved for 10 minutes on ice. A 
few µL were taken to a new tube to measure sgRNA concentration with the NanoDrop 
spectrophotometer. The quality of sgRNA was determined by running 1 µg on a 2% 
agarose gel. sgRNA was diluted to obtain a concentration of 680 ng/µL (20 µM) and 
stored at -80°C.  
2.4.6 Assessment of cutting efficiency after CRISPR and 
CRISPR-HDR transfection and electroporation  
To assess the overall success of each CRISPR experiment in HEK293 and HepG2 cells, 
about 30% of an edited cell population was lysed and gDNA was extracted as described 
previously (s. 2.4.1.2) and used as a template for PCR with PMM2 specific primers (s. 
2.4.1.3, Table 8). The approximately 300 bp amplicon was then sent for sequencing to 
detect whether Indels due to CRISPR/Cas9 activity are visible or not in the resulting 
electropherogram. In addition, sequences were analysed in TIDE (s. 2.4.1.8) and 
differences, compared to a control wildtype sequence, quantified. Experiments with an 
overall CRISPR efficiency below 20% were not considered being successful and have 
been rejected for further use. CRISPRed cells of a successful experiment were divided 
in two parts after reaching a decent confluency. One part was used to seed cells in low 
density to obtain single cell colonies and the rest served as a backup and was kept in 
culture and later on put in long term storage at -80°C.  
2.4.7 Obtaining single-cell colonies from CRISPR-HDR 
targeted cell populations 
CRISPR-HDR targeted HepG2 cells with an overall sufficient editing efficiency were 
seeded in low density in 10 cm tissue culture dishes to obtain single-cell colonies for 
genotyping. To guarantee a well separated single cell suspension, cells were split as 
described previously (s. Culture of HepG2 cells) using a 21G needle and seeded in 10 
mL of HepG2 cell culture medium. Although the numbers of cells seeded per 10 cm 
tissue culture dish varied, a well scattered population was always controlled by 
microscopy. Low density plates were incubated at 37°C and 5% CO2 with regular 
medium changes every 4-5 days. After 10-14 days, single cell colonies were picked using 
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a microscope (stereomicroscope with transillumination) under sterile conditions and 
each clone was transferred to a separate well of a 96 well plate containing 200 µL of 
HepG2 cell culture medium for further growth at 37°C and 5% CO2 for 7-9 days.  
2.4.8 Genotyping of HepG2 single cell colonies after 
CRISPR-HDR 
In order to genotype CRISPR-HDR single cell clones, those were first split 
asymmetrically by transferring 20-30% onto a new 96 well plate. These plates were 
maintained in culture to have a backup of each clone. The remainder population of each 
clone on the “old” 96 well plate was used for genotyping after a few more, usually 2-3 
days, in culture. When the single clones in each well reached a confluency of at least 
70%, cells were lysed in 100 µL of lysis buffer ON and gDNA was extracted directly on 
the 96 well plate to simplify the process. Lysis and gDNA extraction conditions used 
previously (s. 2.4.1.2) were adjusted to the dimensions of a 96 well plate as follows: 10 
µL (1/10th) of the 8 M LiCl solution and 100 µL of isopropanol (molecular grade) were 
added subsequently to each lysate. The plate was then mixed for at least 10 minutes on 
a microplate shaker at 700 rpm and RT. The DNA was then precipitated by spinning for 
20 minutes at 2,500 rpm in a centrifuge. The supernatant was removed by inverting the 
plate over a basin and blotting it onto a dry tissue. DNA was washed with 200 µL per well 
of a 70% ethanol solution and the plate again spun for 20 minutes at 2,500 rpm. The 
ethanol was removed as previously described and the plates then put at 37°C for 15-30 
minutes to assure complete evaporation of the alcohol. The DNA per well was eluted in 
30 µL of sterile ultrapure water and dissolved whilst at least one hour of shaking at 250 
rpm and 37°C or during an ON incubation at 4°C prior to usage in downstream reactions.  
To genotype each clone, 1 µL of each gDNA extract were put in a genotyping PCR as a 
template and amplification was performed according to the protocol described in section 
2.4.1.3 using the PMM2 For3/Rev3 primer pair (Table 8). As a quick and easy first check 
whether CRISPR-HDR repaired clones are present, all amplicons were digested with 
StyI (also called Eco130I). The desired G>T SNP at position c.-167 within the PMM2 
promoter coincidentally creates an additional restriction site for StyI (ThermoFisher), 
which is usable to distinguish between HDR and non-HDR clones as cutting results in 
different band patterns within the region of interest Figure 26.  
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Each restriction digest reaction was done in a total volume of 20 µL. 5 µL of each PCR 
product were combined with 15 µL of a previously prepared master mix composed of 2 
µL of the enzyme-specific 10X Orange buffer (ThermoFisher), 0.2 µL of StyI (2 units) 
and 12.8 µL of sterile ultrapure water per reaction. Volumes for the master mix were 
multiplied according to the number of samples digested. The restriction digests were 
incubated for at least one hour at 37°C and analysed on a 2% agarose gel (2.4.1.4).  
Positive clones were further analysed using Sanger sequencing (s. section 2.4.1.7) to 
confirm the desired gene edit.  
2.4.9 Expansion of positive CRISPR-HDR HepG2 single cell 
clones  
Positive clones were expanded from the backup 96 well plates kept in culture after 
asymmetric splitting. Clones were maintained in HepG2 culture medium and when due 
to split transferred onto 24 wells. When ready to split, one half of cells was used to extract 
gDNA for characterisation to ensure the clones taken are the desired ones and the other 
half was transferred onto a 6-well plate for further expansion. From there, one part of 
each positive clone was transferred into a T25 flasks for maintenance and growth and 
the other part was put in cryopreservation at -80°C. From this point, clones were further 
expanded and kept in culture and several backups were deep-frozen at -80°C to 
generate an adequate stock of each clone for future experiments.  
Figure 26: Expected band pattern after digesting CRISPR-HDR targeted single clone amplicons 
from genotyping PCR with StyI.  
Left: Bands (250 bp, 50 bp) show pattern as expected when the desired SNP is not introduced at 
nucleotide position c.-167. Right: Bands (150 bp, 100 bp, 50 bp) show expected band pattern when 
desired SNP (c.-167G>T) is introduced via CRISPR-HDR.  
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2.4.10 Checking for off-target effects  
In order to investigate whether the gRNA used has created any off-target effects in 
different regions within the HepG2 genome was tested with PCR (2.4.1.3) and 
subsequent Sanger sequencing analysis. Those off-targets being predicted most likely 
by CRISPOR and CHOPCHOP were considered and primers were designed 
accordingly, spanning a region of 400-500 bp and the PCR products sent for sequencing 
after the clean-up with the ExoSAP Kit.  
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Chapter 3: Project background  
3.1 Introduction 
This chapter shall summarise the beginning of this project and the work included before 
this PhD was started. This mainly involves clinical observations characterising the 
phenotype of the patients, genetic studies, some functional assays and bioinformatic 
analysis, which eventually helped to describe HIPKD as a new polycystic kidney disease 
with involvement of the pancreas and the liver. This work was done by our group at the 
Centre for Nephrology in London and in collaboration with colleagues working in 
universities and hospitals in Spain, Germany, UK, US and Qatar and published in The 
Journal of the American Society of Nephrology (JASN) in April 2017 209.  
3.2 The aims of this chapter  
▪ Presentation of the clinical phenotype and the patients  
▪ Identification of the mutation  
▪ Functional studies of the disease variant 
▪ Genomic region from bioinformatics point of view  
▪ Hypothesis for disease mechanism  
3.3 The patients and the clinical phenotype  
The project was born when patients with an ARPKD-like phenotype in combination with 
an hyperinsulinemic phenotype of unknown origin were seen in clinics. Although, a 
substantial number of patients underwent genetic testing focussing on mutations in 
causative gene(s) for ARPKD (PKHD1) and hyperinsulinemic hypoglycemia (ABCC8, 
KCNJ11), no pathogenic mutations were identified, and the genetic cause of the 
phenotype remained unclear at that point.  
To date, we know 21 patients from 13 unrelated families with Caucasian background 
showing the phenotypic combination of PKD and HI (HIPKD). Four of them are offspring 
of a consanguineous family. From the pedigrees of five of the affected families we could 
conclude an autosomal recessive inheritance of the disease as shown in Figure 27 and 
which was compatible with the inheritance in the remaining families (data not shown).  
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The physical manifestations of the disease in all patients were restricted to the kidneys 
and the pancreas and in some patients also in the liver. In all patients, enlarged and 
cystic kidneys were clearly identified (Figure 28 A–G). The morphologic appearances of 
the kidneys typically prompted an initial clinical diagnosis of ARPKD before the genetic 
testing was done. Histology was available in one patient only and showed cysts 
predominantly or perhaps even exclusively of glomerular nature consistent with a 
glomerulocystic disorder (Figure 28 H and I). This excluded a diagnosis of ARPKD, as 
cysts in this disorder exclusively localise to the collecting duct. Since histology is only 
available in one patient it is currently unclear whether all patients have glomerular cysts, 
or whether this was unique to this particular patient.  
In addition to the renal malformations an excess secretion of insulin was noted in all 
patients. In eight patients, small liver cysts were also seen. Of note, one patient without 
detectable liver cysts on imaging had a liver biopsy performed. This was done at the time 
to investigate the suspected diagnosis of ARPKD, which has obligated liver involvement 
in the form of ductal plate malformation, a developmental abnormality of the intrahepatic 
bile ducts. Interestingly, the biopsy indeed showed ductal plate malformation. Since this 
biopsy was done in a patient without apparent liver abnormalities on routine liver imaging, 
it raises the question whether ductal plate malformation is also an obligate manifestation 
of HIPKD, or whether this patient was an exception. Figure 28 and Figure 29 represent 
the appearance of kidneys and liver in HIPKD on MRI, ultrasound and histology images.   
Figure 27: Pedigrees of five informative families included in the study showing the origin of nine 
patients with HIPKD.  
Dark symbols indicate affected individuals. Empty symbols indicate unaffected individuals. 
Circles: Female. Squares: Male. A small dot above the left-hand corner of the symbols indicates 
confirmed carrier status of the promoter mutation in PMM2 c.-167G>T.  
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Figure 28: Renal phenotype in patients with HIPKD.  
A-C: Ultrasound of three cystic kidneys. A: Left kidney, patient 11 years old. B: Right kidney, 
patient 4 years old. C: Right kidney, patient 2 years old. D-E: MRIs of two cystic kidneys. D: Axial 
MRI, patient 11 years old. E-F: Axial and coronal MRIs (without contrast), patient 2 years old. G: 
Nephrectomy specimen of enlarged, cystic HIPKD kidney, patient 2 years old. H and I: Histology 
(hematoxylin and eosin staining) of the same kidney showing multiple cysts lined with a thin 
epithelium and some enclosing the glomeruli.  
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The children often presented hypoglycemic seizures as a consequence of 
hyperinsulinism, which was diagnosed at an age of 10 months on average. There was 
no evidence for the involvement of other organs.  
3.4 Identification of the disease-causing mutation and 
description of the locus  
An elaborate genetic analysis was done in order to find the HIPKD-causing mutation and 
the results are shown in Figure 30. To be able to identify the precise locus of the mutation 
within the genomes included, a whole-genome multipoint parametric linkage analysis 
was performed. The analysis was done on the basis of the five pedigrees shown in Figure 
27 detecting a distinct single locus on chromosome 16p.13.2 at 2.3 Mb with a combined 
LOD score of 6.5. With next-generation sequencing we finally identified a point mutation 
within the promoter region of PMM2, encoding the phosphomannomutase 2. The 
mutation is a guanine to thymine single nucleotide polymorphism (SNP) located 167 
nucleotides upstream (c.-167G>T) of the start codon, which has not been reported in 
Figure 29: Hepatic phenotype in HIPKD.  
Note that liver abnormalities are not expressed in all patients. A: Axial MRI of HIPKD liver with 
multiple small cysts, patient 11 years old. B: Ultrasound of HIPKD liver showing a cyst, 4 years 
old. C-D: Histology (hematoxylin and eosin staining) showing ductal plate malformation, patient 1 
year old. No liver cysts were noted in this patient.  
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any database yet. The point mutation was shared by all 17 patients as confirmed with 
Sanger sequencing (Figure 30 B), either in homozygous state, as it was the case for the 
four patients descending from the consanguineous family, or in compound heterozygous 
state. The latter was found in all other 13 patients with PMM2 coding mutations on one 
allele, known to be causative for the severe multisystem disorder CDG-1a described 
previously 1.8.1.  
 
 
Knowing the mutation lies within the non-regulatory part of PMM2, we were able to 
investigate this further. The literature provided us with some insightful information around 
the PMM2 promoter. A major characteristic of this promoter is its bidirectionality making 
it responsible for the regulation of two genes, PMM2 and TMEM186. To drive its 
regulatory function the PMM2 promoter hosts specific binding sites (SBS) were 
transcription factors bind to activate or block the transcription of the genes. In this 
context, Anno et al. have described the existence and functional importance of three 
SBSs (1-3) within the PMM2 promoter and have shown reduced expression levels of 
both genes when any of the SBS was deleted. They also described ZNF143, a 
Figure 30: Genetic studies identifying the HIPKD 
causing mutation.  
A: Parametric multipoint linkage analysis. Single 
peak on chromosome 16 with combined LOD 
score of 6.5. B: Sequencing result of the linked 
region showing the PMM2 promoter mutation c.-
167G>T. Depicted are Sanger sequencing 
traces from position c.-173_-161. Top: 
Homozygous patient. Middle wt control. Bottom: 
Heterozygous parent.  
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ubiquitously expressed protein, as being an essential transcription factor for bidirectional 
transcription, having strong affinity to bind at SBS1 within the PMM2 promoter 219. Our 
group analysed the SBS independently and localised the c.-167G>T promoter SNP 
within SBS 1, which contains a binding motif for ZNF143.  
3.5 Functional studies of the PMM2 promoter variant  
We were able to confirm ZNF143 binding to SBS1 within the PMM2 promoter and most 
importantly we could show significantly reduced binding of ZNF143 to its binding motif 
when the PMM2 promoter mutation was present. This was confirmed by a densitometry 
analysis of the two bands appearing in the immunoblot representing ZNF143 binding. 
The intensity of the band resulting from ZNF143 binding to the mutant promoter was 70% 
reduced compared to the band from ZNF143 interaction with the wt promoter. The results 
are shown in Figure 31.  
 
ZNF143 and PMM2 promoter interaction was assessed with an electrophoretic mobility 
shift assay (EMSA). ZNF143 was generated in vitro in a cell free system (TNT T7 Quick 
Coupled Transcription/Translation System, Promega) with an expression vector and two 
Figure 31: EMSA assay demonstrating ZNF143 binding to mutant and wt PMM2 promoter.  
Black arrow indicates ZNF143 binding. Lane 1: ZNF143 binding to the wt PMM2 promoter 
(labelled probe). Lane 2: Competition with excess of wt unlabelled probe. Lane 3: ZNF143 binding 
to the mutant PMM2 promoter (labelled probe). Lane 4: Competition with excess of mutant 
unlabelled probe. Lane 5: Negative control without ZNF143, with empty vector and wt labelled 
probe. Lane 6: Negative control without ZNF143, empty vector and mutant labelled probe. B: 
Densitometry analysis comparing band intensities (Lane 1 vs. Lane 3) in percent.  
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biotinylated oligonucleotide probes containing either the wt or mutant PMM2 promoter 
sequence c.150_-178 were used to provide the ZNF143 binding site for the assay.  
To address the expression levels of PMM2 in HIPKD patients, we expected these to be 
reduced due to the promoter mutation and have tested this experimentally in vitro 
performing a luciferase assay using two commercially available cell lines; the human 
renal proximal tubular cell line RPTEC/TERT1 (LGC standards, ATCC-CRL- 4031, UK) 
and the human pancreatic -cell line 1.1B4 (Sigma Aldrich/ECACC, 10012801-1VL, UK). 
The Renilla luciferase gene on a promoter reporter construct was under control of either 
wt PMM2 promoter, mutant PMM2 promoter (c.-167G>T) or SBS1-deleted PMM2 
promoter (c.-163_-180del). The targeted cell lines were transfected with these 
constructs. The results are shown in Figure 32.  
 
 
 
In both cell lines the luciferase expression was significantly reduced when the gene was 
regulated by the mutant and SBS1-deleted PMM2 promoter. The latter turned down 
luciferase expression even more in -cells whereas expression with mutant promoters 
in kidney cells remained the same.  
Figure 32: Luciferase assays showing luciferase expression controlled by the PMM2 promoter.  
Light grey bars: Luciferase activity with wt promoter (c.-167G). Black bars: Luciferase activity with 
mutant promoter (c.-167G>T). Crosshatched bars: Luciferase activity with ZNF143 binding site 
deleted in promoter (c.-163_-180del). A: Pancreatic human -cell line. B: Human kidney cell line. 
Asterisk indicates statistical significance (P<0.01) of wt compared to mutant/Promoter. 
Luminescence in arbitrary units.  
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3.6 PMM2 and Congenital disorder of glycosylation 
The finding of mutations in PMM2 as the cause of HIPKD was surprising, as PMM2 
encodes a key enzyme in N-glycosylation and is a recognised disease gene for CDG-
1a, a severe multisystem disorder caused by biallelic PMM2 coding mutations as 
described in the introduction. In contrast, our patients appeared to have isolated 
involvement of kidneys, pancreatic beta cells and liver. The standard clinical test to 
assess for CDG-1a is isoelectric focusing of transferrin. Transferrin is an iron-binding 
blood plasma protein predominantly produced in the liver and a major distributor of iron 
to all tissues in the body 220. It is normally strongly N-glycosylated and defects in 
glycosylation thus result in a shift of the isoelectric point, which is detectable 221. 
Interestingly, this test was normal in patients with HIPKD (Figure 33 C) arguing against 
a systemic defect in N-glycosylation. The transferrin N-glycosylation pattern of three 
HIPKD patients tested did not differ to the normal control Figure 33 C.  
We therefore hypothesised that the promoter mutation in PMM2 causes an organ-
specific defect in glycosylation in kidneys, pancreatic -cells and liver only, in contrast to 
biallelic coding mutations in PMM2 which cause a generalised defect in glycosylation, 
affecting all organ systems. This would be consistent with the concept of pleiotropy: that 
mutations in one gene can cause two or more different disorders as is the case for 
example for the OCRL gene 222. To prove this hypothesis, we aimed to assess 
glycosylation status of affected tissue. The only available patient material from affected 
organ systems were cells grown in primary culture and derived from the end-stage kidney 
of a patient who had nephrectomies performed at the time of transplant. We assessed 
the N-glycosylation status of TRPP2 immunoprecipitates from patient cells used in a 
deglycosylation assay with PNGase F and Endo H by western blot. TRPP2 (transient 
receptor potential channel 2, PKD2 gene) is a non-selective cation channel in the kidney 
which is heavily N-glycosylated. Mutations in TRPP2 are found in ARPKD, some of which 
can affect aminoacids that represent N-glycosylation sites (Asn-X-Ser/Thr; X can be any 
amino acid but prolin), consistent with the idea that abnormal TRPP2 glycosylation can 
cause cystic kidney disease 223. The results of these assays are shown in Figure 33 A 
and B.  
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Differently to heterologous expressed TRPP2, endogenous TRPP2 appears with two 
distinct bands on western blot as was observed before 223. The bands of 
immunoprecipitated, normally glycosylated TRPP2 for patient and control sample run at 
around 120 kDa and just below 100 kDa consistent with the results of Hofherr et al. As 
it was expected, immunoprecipitates after deglycosylation with Endo H and PNGase F 
run lower in the blot at around 105 and 80 kDa due to the removal of N-glycans (Figure 
33 A). However, in both cases no shift between patient and control samples was 
detectable and this confirmed an overall glycosylation defect being absent in HIPKD. 
This was also confirmed by isoelectric focussing of TRRP2 in HIPKD patient compared 
to control cells with no difference in the band pattern being detected (Figure 33 B). This 
result was inconsistent with our hypothesis of organ-specific dysfunction of glycosylation. 
Our current best explanation is that the cells which were obtained from an end-stage 
kidney do not represent healthy kidney tissue but mostly fibrotic scar tissue and therefore 
are not representative. Further investigations are needed to conclusively prove or 
disprove our hypothesis.  
Figure 33: Glycosylation levels of TRPP2 and serum transferrin in HIPKD patient primary cells.  
A: Enzymatic deglycosylation of endogenous TRPP2 immunoprecipitates with either Endo H or 
PNGase F from HIPKD patient cells compared to control primary kidney cells and HEK cells on 
western blot detected with an anti-TRPP2 antibody. HEK: HEK293T transfected with TRPP2. Ctrl: 
Endogenous expressed TRPP2 in control primary kidney cells. Pat: Endogenous expressed TRPP2 
in HIPKD patient primary kidney cells. 150: 150 kDa. 100: 100 kDa. Left panel: Western blot of non-
glycosylated TRPP2. Middle panel: Western blot of TRPP2 treated with Endo H. Right panel: Western 
blot of TRPP2 treated with PNGase F. B: Isoelectric focusing (IEF) of TRRP2 in control primary kidney 
cells (Ctrl) and patient primary kidney cells (Pat). C: IEF of serum transferrin of three patients 
compared to three controls. P1-P3: Patients 1-3. NC: Normal wt control. CDG: Congenital disorder 
of glycosylation. N: Deglycosylated Control (PNGase F & EndoH). 
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3.7 Impact of impaired glycosylation on insulin 
secretion  
Knowing PMM2 plays a major in N-glycosylation, it was expected that impaired PMM2 
expression has an effect on insulin secretion based on a dysfunctional performance of 
PMM2 in HIPKD patients. As an excess secretion of insulin has been observed in 
affected children, it was of interest to investigate whether deglycosylation enhances 
insulin secretion. This was tested in a glucose-stimulated insulin secretion assay using 
the murine -cell line MIN6. The cells were treated with two glycosidases, Endo H and 
PNGase F, beforehand to provoke deglycosylation of extracellularly accessible proteins. 
This was meant to mimic PMM2 dysfunction.  
Glycosidase-treated MIN6 cells were compared to a control group not treated with any 
of the enzymes. Cells were split in three groups and after enzyme-incubation either 
stimulated with very basal glucose levels (2 mM), or high glucose levels (20 mM) or high 
glucose (20 mM) in combination with the PKC-enhancer PMA. Secreted insulin was 
assessed using a human insulin ELISA. Figure 34 shows the insulin measurement.  
 
 
Insulin release was significantly higher from deglycosylated cells when treated with PMA 
at high glucose concentrations compared to the control group and providing a relation 
between glycosylation and insulin secretion.  
Figure 34: Insulin secretion of 
deglycosylated MIN6 -cells.  
Stimulation with different glucose 
concentrations (2 mM, 20 mM, 20 mM 
+ PMA). Light grey bars: Control group 
non-deglycosylated. Black bars: 
Deglycosylated cells treated with Endo 
H and PNGase F. Insulin secretion 
levels are provided in fold over basal. 
Asterisk indicates statistical 
significance (P<0.01) of 
deglycosylated cells at 20 mM glucose 
+ PMA compared to the control group. 
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3.8 Bioinformatic analysis of the PMM2 promoter region 
The fact that the HIPKD mutation lies within the regulatory region of PMM2 and is located 
in a transcription factor binding motif for ZNF143 gave rise to look into the genomic region 
on chromosome 16 in more detail. Our bioinformaticians conducted an elaborate in silico 
analysis within the UCSC genome browser (Hg19) and identified a chromatin loop of 
about 220 kb that includes PMM2 and three additional genes (TMEM186, ABAT, 
CARHSP1) and is limited by CTCF motifs. Chromatin segmentation and transcription 
factor binding sites were assessed within that predicted looping region in different human 
cell lines. These data sets (ChIP-Seq, Hi-C and ChIA-PET) were extracted from 
ENCODE (Encyclopedia of DNA elements). In particular, binding sites for CTCF, 
ZNF143 and HNF4A were of interest, as 1) CTCF motifs are known for their loop limiting 
function 224 and 2) to confirm the previous results of ZNF143 binding to the PMM2 
promoter. HNF4A was of certain interest, because of its predominant expression in 
kidney, pancreas and liver – the three affected organs in HIPKD – consistent with the 
idea of a tissue-specific pathomechanism in HIPKD.  
Figure 35 shows the result of the in silico analysis. CTCF motifs at the outer part mark 
the loop and face each other – a typical feature of CTCF motifs 225. A strong ZNF143 
binding site within the PMM2 promoter matches the EMSA data nicely and there are 
several clusters of HNF4A sites of different strength towards the outer part of the 
chromatin loop. Interestingly, the chromatin throughout the looping region is active 
exclusively in HepG2 cells, which is a liver carcinoma cell line with the PMM2 promoter 
located almost in the centre. In the other five cell lines the chromatin seems to be 
generally active only downstream of the PMM2 promoter.  
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3.9 Summary of project background and conclusion  
HIPKD is a combination of polycystic kidney disease, hyperinsulinism with partial liver 
involvement and of autosomal-recessive inheritance, that had not been described 
before. The disease-causing mutation was identified to be a G to T substitution (c.-
167G>T) in the regulatory promoter region of the PMM2 gene, located within a 
transcription factor binding site for ZNF143 – a ubiquitously expressed protein known to 
be crucially involved in 3D chromatin conformation 226. The affected patients all share 
this noncoding mutation either in homozygous or compound heterozygous state. 
Impaired ZNF143 binding to the mutant promoter and reduced gene expression when 
under control of the same promoter were confirmed in vitro. The absence of an overall 
glycosylation defect in our patient and the distinct manifestation in three organs clearly 
separate the HIPKD phenotype from the well-described CDG-1a due to biallelic coding 
mutations in PMM2. However, based on the HIPKD phenotype there is strong evidence 
that glycosylation has a major impact on cyst formation and increased insulin release – 
the latter was experimentally confirmed with MIN6 -cells.  
The fact that HIPKD is caused by a noncoding PMM2 mutation clearly implied, that the 
disease mechanism is a gene regulatory problem. Knowing of ZNF143 and its function 
and impaired binding to the PMM2 promoter in HIPKD raised the idea of an altered 3D 
chromatin conformation in our patients. In silico analysis confirmed the presence of 
convergent orientated CTCF motifs flanking the active chromatin in HepG2 cells, 
indicating possible anchors for a chromatin loop 227. It is well established, that ZNF143 
mediates chromatin loop formation by interacting with CTCF motifs and gene promoters 
228 suggesting, that ZNF143 facilitates a change of the loop formation by binding to both, 
the PMM2 promoter and CTCF motifs simultaneously to allow interactions between 
promoter with distal regulatory elements at the anchors of the loop. Moreover, knowing 
of HNF4A and its predominant expression in kidney, liver and pancreas we linked these 
facts and suspect a possible distinct 3D chromatin conformation that affects regulation 
of PMM2 expression by HNF4A and therefore creating the limitation of the phenotype to 
these three organ systems. Thus, in HIPKD, the promoter mutation causes impaired 
ZNF143 binding to the promoter, preventing this particular loop formation to happen, 
consequently disturbing HNF4A-mediated PMM2 transcription in kidney, liver and 
pancreas. Figure 36 depicts this proposed disease mechanism.  
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3.10 Next steps  
The absence of a suitable cell or tissue model motivated us to develop such to facilitate 
the investigation of chromatin structure and looping. To address this and to investigate 
whether our hypothesis is right or wrong, a HIPKD cell model was to be generated with 
CRISPR-Cas9. In addition, it was of interest to show dysfunctional PMM2 expression in 
human. For this purpose, gene expression studies with patient cells from one of the 
compound heterozygous patient were performed to confirm the gene expression results 
obtained in vitro. These cells also allowed us to measure the expression level of each 
Figure 36: Simplified cartoon demonstrating tissue-specific chromatin loop formation with wt and 
mutant PMM2 promoter.  
A: Wt promoter. A big structural loop is formed with the PMM2 promoter (green) on top and limited 
by CTCF motifs (yellow). ZNF143 binding to the PMM2 promoter pulls down the loop, changing its 
3D architecture and allowing close proximity to CTCF (functional loop) and interaction with HNF4A 
(black). B: Mutant promoter: ZNF143 binding to the PMM2 promoter is impaired preventing 
functional loop formation and interaction of ZNF143 and promoter with CTCF and HNF4A causing 
disturbance of PMM2 gene regulation/transcription.  
A 
B 
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PMM2 allele separately in an allele-specific assay to investigate whether the expression 
of the allele under control of the mutated promoter was reduced. Furthermore, the effect 
of impaired glycosylation in HIPKD was investigated using human pancreatic islets to 
confirm the result obtained from mouse pancreatic -cells. All this work was addressed 
during this PhD.  
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Chapter 4: The expression of PMM2 in HIPKD  
4.1 Introduction  
This chapter focusses on PMM2 expression levels in cells in primary culture from the 
nephrectomy specimen of a compound heterozygous patient (c.-167G>T/c.422G>A), to 
investigate whether the promoter mutation has an influence on PMM2 expression in 
HIPKD or not. In addition to the promoter mutation (c.-167G>T) located on one allele, 
this patient also carries a point mutation within the coding region of PMM2 at nucleotide 
position c.422G>A (p.Arg141His) on the other PMM2 allele.  
In particular of interest was to determine the overall gene expression of PMM2 in HIPKD 
patients compared to controls, but also the expression of the individual PMM2 alleles 
(mutant vs. wildtype promoter) in comparison to each other. In addition, the expression 
of the neighbouring genes of PMM2, TMEM186, ABAT and CARHSP1 and two control 
genes (PPIA, CDH1) were also included in the study.  
TMEM186 encodes for a potential transmembrane protein (RefSeq NM_015421) and 
not much more is known about it, except that is shares the promoter with PMM2. ABAT 
encodes the enzyme 4-aminobutyrate amino transferase (RefSeq NM_020686) and 
converts the neurotransmitter gamma-aminobutyric acid (GABA) into semialdehyde. 
GABA primarily exerts inhibitory functions within the central nervous system. ABAT is 
active in about one third of synapses in the human body and expressed in several 
tissues, predominantly in the liver 229. Mutations in the gene cause GABA-transaminase 
deficiency, a neurological disorder presenting with psychomotor retardation, hypotonia, 
hyperreflexia and seizures 230. CARHSP1 translates into the calcium regulated heat 
stable protein 1 (RefSeq NM_001042476), a cytoplasmic protein which enhances mRNA 
stability. Using the example of tumour necrosis factor  (TNF-) transcription, CARHSP1 
is presumed to prevent mRNA degradation, indirectly promoting translation by enabling 
the mRNA to re-enter the translational pool 231.  
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4.2 The aims of this chapter  
▪ Performing gene expression studies with quantitative digital PCR  
▪ Measure whether there is allelic discrimination detectable between expression 
levels of the two mutant allele variants of PMM2 in the compound heterozygous 
patient  
▪ Study the expression levels of PMM2 and surrounding genes in specific gene 
expression assays  
4.3 Results  
4.3.1 Allelic discrimination of the PMM2 variant alleles  
The expression levels of the PMM2 alleles in the compound heterozygous patient were 
measured in an allele specific discrimination assay (ASA) using quantitative dPCR. 
Expression levels of the PMM2 alleles in patient and control samples were determined 
using a custom allele specific dPCR assay (Assay-ID: AHGJ9ED, (2.2.3.1).  
In this case, two probes were needed to discriminate the PMM2 alleles and both were 
part of the TaqMan® Assay used. The probes were differently labelled with a fluorophore 
(FAM™ or VIC®) for discrimination of the expression levels of each PMM2 allele (Alleles 
1 and 2). Both probes were designed to span the nucleotide position 422 (Ref.-Seq.: 
NM_000303.2) of PMM2 within the cDNA of patient and control. In this way, 
discrimination of the two PMM2 alleles was possible due to a variant (c.422G>A) on the 
allele (Allele 1) not carrying the promoter mutation, whereas the allele having the 
promoter mutation (c.-167G>T, Allele 2) is wildtype for this variant (c.422G). Therefore, 
the FAM™-labelled probe was used to detect the allele with the promoter mutation (Allele 
2) and the VIC®-labelled probe was specific for the allele carrying the c.422G>A genetic 
variant (Allele 1).  
Prior to the actual experiment, defined amounts of patient (10ng, 25 ng) and control 
cDNA (20 pg-100 fg) were tested to assess the required amounts to be within the desired 
range of target sequence (200-2,000 copies/µL). Based on this, a final input of 25 ng and 
200 fg of patient cDNA and control construct mix, respectively (data not shown), was 
used. Negative controls (No reverse transcriptase patient control, no template control, 
control constructs 1 and 2 individually) were included to assess assay specificity. This is 
reflected by Figure 37, showing the allele fraction (%) of the two constructs measured 
individually.  
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To assess allelic discrimination, each cDNA sample was measured once (n=3) and for 
the control, the 1:1 construct mix was prepared three times independently (n=3), each 
also measured once. A ratio based on the fluorescent signals (FAM™ or VIC®) detected 
for each allele in patient and control samples divided over the total fluorescence (FAM™ 
+ VIC®) measured was calculated to identify differences in expression levels of the 
PMM2 alleles in percent (Allele fraction, Figure 38). The values plotted are means±SEM.  
 
 
 
 
 
 
 
 
Figure 37: Allele fraction (%) of control constructs 1 and 2 determined by quantitative dPCR.  
The percentages of the fluorescent signals detected for the expression of each construct over the 
total signal measured are shown. Grey bars indicate the detection of Control construct 1 (mimics 
PMM2 Allele 1) carrying the c.422G>A SNP (VIC®-labelled probe). Black bars indicate the 
expression of Control construct 2 (mimics PMM2 Allele 2), wt at nucleotide position 422 (Ref.-
Seq.: NM_000303.2) (FAM®-labelled probe). Each construct was measured once with a total input 
of plasmid DNA of 200 fg/sample.  
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Overall, the expression levels of the PMM2 alleles in the patient are clearly unequal 
compared to the control (1:1 plasmid construct mix) Figure 38. As it was expected, in the 
control sample alleles 1 and 2 were expressed in equal amounts with 51% and 49%, 
respectively. In contrast, the total expression in the patient measured for Allele 1 (wt 
promoter) accounted for 58±0.33% versus 42±0.33% of that determined for the allele 
under control of the mutated promoter (Allele 2, MUT promoter). In relation to each other, 
this implies a 29% reduction of expression levels due to the promoter mutation in Allele 
2 compared to Allele 1 of PMM2 in the compound heterozygous patient. A two-tailed and 
unpaired student’s t-test verified the significance of the described allele expression 
differences statistically (p-value < 0.05).  
 
 
Figure 38: Allelic discrimination of PMM2 alleles determined by quantitative dPCR.  
The percentages of the fluorescent signals detected for the expression of each allele over the total 
signal measured for control (1:1 construct mix) and patient cDNA samples are shown (Allele 
fraction). Grey bars indicate the detection of Allele 1 negative for the promoter mutation (VIC®-
labelled probe). Black bars indicate the expression of the PMM2 Allele 2 carrying the promoter 
mutation (FAM®-labelled probe). Three patient cDNA samples (equal to 25 ng total RNA) were 
measured 1x (technical replicates, n=3). The control (1:1 construct mix, 200 fg) was assayed 3x 
individually (technical replicates, n=3). Samples were within the appropriate range of target 
numbers (200 – 2,000 copies/µL). Values are means±SEM. *p-value < 0.05.  
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4.3.2 Gene expression of PMM2 and its neighbours in 
compound heterozygous HIPKD patient and wildtype 
cells  
To evaluate the overall expression levels of the genes of interest, PMM2, TMEM186, 
CARHSP1 and ABAT, a dPCR gene expression assay was performed. In addition, two 
control genes, PPIA and CDH1, which are not in the neighbourhood of the promoter and 
thus expected to be expressed equally in patient and control, were also assayed for 
direct comparison to the results of the four genes of interest.  
For detection and quantification of the six genes, specific TaqMan® gene expression 
assays containing forward and reverse primers and fluorophore-labelled probes were 
used (Table 7). Absolute quantification was measured and provided by the dPCR system 
as copies/µL and analysed and processed as such. The plotted data are the 
means±SEM of two to four (n = 2, n = 3, n = 4, Figure 39) cDNA samples for both, patient 
and control (2.2.2), each measured in duplicate (ABAT, CDH1) or triplicate (PMM2, 
TMEM186, CARHSP1, PPIA). Statistical significance was assessed with a two-tailed 
and unpaired student’s t-test.  
Optimal cDNA input was also assessed prior to the final dPCR gene expression series 
(Data not shown). This suggested a final cDNA input per sample (per chip) and assay 
equivalent to 25 ng total RNA for all genes aside from TMEM186 (50 ng) and ABAT (200 
ng). A no reverse transcriptase (RT) negative control for each assay was tested in 
parallel for both, patient and control cDNA to successfully exclude possible DNA 
contamination (Data not shown).  
Figure 39 represents the expression levels of all six genes. Expression levels of PMM2, 
TMEM186, PPIA and CDH1 were not significantly different in the patient compared to 
the control. Yet, PMM2, TMEM 186 and CDH1 show a trend for lower expression in the 
patient. As expected, PPIA was equally expressed, with about 1,000 copies/µL in both 
groups tested. Even though ABAT expression was not significantly different as well, its 
expression trended towards a decrease in the control sample. CARHSP1 instead, was 
the only gene within the chromatin loop assayed, which showed significantly reduced 
expression in the patient, with a decrease of approximately 30% (913 copies/µL in control 
versus 540 copies/µL in patient).  
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In general, there clearly is some variation in the average expression levels of the genes 
tested, as is evident from the controls. PMM2 and TMEM186 are expressed the lowest, 
with 500 and 200 copies/µL, respectively, followed by CARHSP1 and ABAT being 
expressed much higher with values in the range of 900 to 950 copies/µL and finally PPIA 
and CDH1 slightly surpass the two previous ones with copy numbers of 1,000 to 1,100 
per micro litre.  
4.4 Discussion  
Gene expression studies based on quantitative PCR are a well-established tool within 
functional genomics to quantify RNAs. It covers a broad range of applications in many 
fields of research including the quantification of gene transcription by measuring mRNA 
levels of particular genes 232. The significant advantage of qPCR is its high sensitivity 
and precision, making the detection of very small RNA amounts possible. Besides, its 
utilisation is relatively simple and screening of large sample numbers and different genes 
Figure 39: Expression levels of PMM2, TMEM186, CARHSP1, ABAT, PPIA and CDH1 in patient 
and control samples determined by quantitative digital PCR.  
Absolute quantification (copies/µL) of the expression levels of PMM2, TMEM186, CARHSP1, 
ABAT, PPIA and CDH1 in patient (Black bars) and control (Grey bars). cDNA input was equal to 
25 ng (PMM2, CARHSP1, PPIA and CDH1), 50 ng (TMEM186) and 200 ng (ABAT) of total RNA 
for patient and control samples. In total four patient (n=4) and three control (n=3) cDNA samples 
for PMM2, TMEM186, CARHSP1 and PPIA were measured three-times each and the means were 
taken. ABAT and CDH1 were determined using two cDNA samples for patient and control, each 
measured twice and the means were taken (n=2*). Values are means±SEM. *p < 0.05.  
                         Chapter 4 
 121 
in the same experiment is possible, providing higher flexibility compared to more 
traditional techniques, such as Northern blot and in-situ hybridisation where input/output 
relation (dynamic range) is more limited 233.  
Apart from the well-established real-time qPCR for quantification of DNA/RNA 
sequences, a novel approach has settled in modern research, improving the possibilities 
of qPCR due to the ability of “digital” measurements 234. Quantitative dPCR simply counts 
the number of a gene transcript at a given time precisely and with excellent sensitivity 
and specificity. It provides absolute values and higher accuracy compared to classic real-
time qPCR. The high precision and accuracy dPCR results from diluting and partitioning 
the sample into thousands of separate reaction chambers so that each contains one or 
no copy of the target sequence. Hence, positive and negative partitions can simply be 
counted resulting in exact copy numbers (absolute values) and absolute quantification is 
guaranteed making the use of reference genes of known concentration redundant. 
Furthermore, dPCR allows the detection of 30% or smaller differences in expression 
levels. It can determine whether a variant occurs in five out of six copies and it can detect 
one different allele within thousands. Thus, dPCR is helpful where qPCR has its 
limitations, being unable to distinguish expression differences or copy number variants 
below two-fold 235.  
First tested and applied by Vogelstein and Kienzler in 1999, they successfully could 
identify the KRAS mutation causative for colorectal cancer in a stool specimen. They set 
a genetic hallmark for early detection of tumorgenesis in a mixed cell population 236, 
reflecting the opportunities dPCR has in modern molecular research and especially 
clinical applications to detect rare mutations at an early stage crucial for diagnosis and 
treatment 237 as well as the quantitative measurement of allelic imbalances 238,239 . The 
ability to detect genetic variants expressed in very low copy numbers makes digital PCR 
a powerful tool in clinical diagnostics and optimally meets the requirements for the here 
described study.  
As expected, a reduced expression of the PMM2 allele with the mutant promoter was 
demonstrated by the allelic discrimination assay (Figure 38). The data repeatedly 
demonstrate significant reduction in expression levels of the PMM2 allele under control 
of the mutant promoter, which fundamentally strengthens our hypothesis of a 
dysfunctional PMM2 gene regulation causative for the disease. Yet, the overall 
expression of PMM2 and also TMEM186 turned out to be not as clear after differential 
expression analysis (Figure 39). However, a trend for a reduction in expression levels of 
both genes in patient compared to control (wt) samples could be detected, thus 
supporting the hypothesis of disturbed bidirectional promoter activity of the promoter 
variant.  
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The results for the additional genes tested in the gene expression analysis are difficult 
to interpret. We tested all genes considered to be located within the chromatin loop 
containing PMM2 (Figure 35) to get a first overall picture of this region. Furthermore, to 
get an idea of what might be happening on the regulatory level with respect to the PMM2 
promoter mutation.  
As outlined above (Figure 36), according to our loop hypothesis, bioinformatical 
predictions and ChIP-Seq data pointed towards the existence of HNF4A binding sites 
close to the linked CTCF motifs suggesting ZNF143 binding to the PMM2 promoter is 
crucial to bring promoter and HNF4A into close proximity to activate PMM2 and 
TMEM186 expression. In contrast, we concluded, that CARHSP1 and ABAT expression 
was independent from PMM2 promoter activity. This in turn implied equal expression 
levels of these genes in patient and control. However, CARHSP1 and ABAT expression 
revealed a different expression pattern in patient and control, although this was 
statistically significant only for CARHSP1. In addition, the results generated in the same 
experiment for PPIA and CDH1, used as reference genes, did also not completely meet 
the expectations of being expressed equally. While PPIA, as expected, was expressed 
equally in both patient and control kidney 240, for CDH1 the opposite effect was observed 
with less expression in the patient. CDH1 encodes for E-cadherin, one of the major 
adhesion molecules crucially involved in cell-cell adhesion in renal epithelial tissue 241. It 
forms a multiprotein complex with polycystin-1, polycystin-2 and β-catenin, which is 
disrupted in polycystic kidney disease cells. In ADPKD for example, it was shown that E-
cadherin expression was significantly reduced and not part of the protein complex 
anymore affecting cellular stabilisation 242. Due to its interaction with β-catenin, E-
cadherin is also a modulator in signal transduction having an impact on transcriptional 
regulation and cell cycle control. β-catenin is heavily involved in regulation of cell 
proliferation, apoptosis and tumorigenesis (e.g. via Wnt signalling pathway). This 
indicates a direct correlation of reduced E-cadherin synthesis with uncontrolled cell 
growth and metastasis as β-catenin dissociates from E-cadherin to exert its 
transcriptional activity under normal circumstances 243, thus likely contributing to cyst 
formation. As the patients’ kidney was in its end-stage, traversed by cysts with functional 
renal tissue replaced by fibrotic scar tissue at the time of nephrectomy, CDH1 gene 
expression was likely seriously reduced in the HIPKD patient sample due to the loss of 
epithelial integrity 244. Moreover, as the RNA used was obtained from a heterogeneous 
sample (containing fibroblasts besides renal epithelial cells) of primary renal cells, grown 
in different wells, this likely contributed to the variability. Further, RNA extraction was 
done partly after different passages, which can also alter gene expression patterns 245. 
All these potential contributors need to be kept in mind when analysing the data.  
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Other factors influencing qPCR outcome are technical hurdles as variability increases if 
experimental performance is lacking accuracy 233. The efficiency of RT PCR based cDNA 
synthesis is the most important but also potentially inaccurate step in expression 
analysis. It can introduce errors generated by effects of mRNA secondary and tertiary 
structures, variation in priming efficiency, and properties of the reverse transcriptase 246. 
It is crucial to always use the same amount of RNA and ideally generate cDNA in the 
same reaction, to keep results comparable. Varying mRNA degradation processes are 
considered being major control points of gene expression, significantly contributing to 
gene regulation in eukaryotes 247,248. Different stimuli from developmental- (proliferation), 
environmental- (e.g. temperature) or such of disease-related origin like fibrosis, as it was 
likely the case in the patients’ kidney, can influence mRNA degradation.  
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Chapter 5: Insulin secretion studies with human 
pancreatic islets  
5.1 Introduction  
To investigate a possible impact of the PMM2 promoter mutation on insulin secretion, 
two sets of experiments (Assay 1, Assay 2) were performed to test whether 
deglycosylation affects the functionality of -cells within the pancreatic islets cell cluster. 
For these experiments it was necessary to mimic a dysfunction of the PMM2 protein, 
which normally acts at an early state within the protein glycosylation pathway during 
posttranslational modification. In our experiments, however, we opted for deglycosylation 
of glycoproteins, using commercially available recombinant deglycosylation enzymes 
(glycosidases) which are able to remove sugar residues attached to various proteins.  
To investigate the effect of deglycosylation on insulin secretion, two batches (Batch 1 
and 2) of human pancreatic islets were kindly provided by the Oxford Consortium for Islet 
Transplantation (OXCIT) and used in two differently designed deglycosylation assays. 
Secreted (extracellular) and intracellular insulin concentration produced by these islets 
were measured with a human insulin ELISA assay.  
ELISA represents a suitable and common method to detect a protein of interest in a liquid 
sample based on the principle of immunobiochemistry: Insulin is captured by an 
immobilised specific mouse monoclonal anti-Human Insulin antibody and can be 
detected due to the addition of an enzyme (Streptavidin-Horseradish Peroxidase 
Conjugate) and an enzyme-linked secondary detection antibody (Biotinylated 
Monoclonal Mouse anti-Human Insulin Antibody), which builds a complex with the 
antigen (Insulin). The addition of a chromogenic enzyme substrate (TMB, 3, 3’,5,5’-
tetramethylbenzidine) causes a chromogenic enzyme-substrate reaction resulting in a 
colour change (blue). The addition of HCl (acidification) stops the reaction and turns the 
blue colour into yellow allowing to measure the ELISA reaction colorimetric in an 
appropriate spectrophotometric plate reader at an absorbance of 450 nm. The colour 
intensity is directly proportional to the insulin concentration in the samples allowing the 
detection and quantification of the insulin content. Therefore, the unknown insulin 
concentrations (µU/mL) could be extrapolated by interpolation of the absorbance values 
from a standard curve (standards: 5, 20, 50 100 and 200 µU/mL) generated in the same 
assay.  
The first batch of human pancreatic islets (Batch 1) received was used to conduct a 
glucose-stimulated insulin secretion (GSIS) with a subsequent Peptide N-Glycosidase F 
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(PNGase F) treatment series (2.3.1). The experimental set up was based on the standard 
operating procedure of the National Institute of Health (NIH) applied for the functional 
assessment of purified human pancreatic islets within the clinical islet transplantation 
consortium and adjusted to the purposes of this experiment. PNGase F 
(Amidohydrolase) is a commonly and widely used deglycosylation enzyme purified from 
Flavobacterium meningosepticum. It cleaves the GlcNac-ASN bond of all three major N-
Glycans, regardless of the oligosaccharide class attached 249,250.  
With the second batch of human pancreatic islets (Batch 2) the impact of deglycosylation 
on insulin secretion was approached differently by conducting the experiment (2.3.2) 
according to the protocol used by a collaborating group which addressed this question 
in a deglycosylation experiment with MIN6 mouse -cells 209. In this setting the 
deglycosylation of human pancreatic islets took place prior to glucose stimulation. In 
addition to PNGase F, a second deglycosylation enzyme, Endoglycosidase H (Endo H), 
was used. Endo H is a recombinant glycosidase which specifically cleaves at the dimer 
core (chitobiose) of high mannose and some hybrid types of N-linked sugars 251. To 
enhance the predicted effect of an increased insulin release, the protein kinase C (PKC) 
activator PMA (phorbol- 12 myristate-13 acetate) was added to the high glucose solution 
as a third condition. PMA mimics the function of GLP-1 (incretin hormone glucagon-like 
peptide), a hormone produced in the distal intestine that stimulates insulin secretion in 
response to meals. Effectively, like GLP-1, PMA-dependent PKC activation via 
diacylglycerol (DAG) stimulates insulin secretion by activating L-type Ca2+ channels and 
the increasing Ca2+ concentration eventually leads to insulin synthesis and secretion 
155,252.  
5.2 The aims of this chapter  
▪ Study insulin secretion in human pancreatic islets  
▪ Mimic PMM2 dysfunction using glycosidases (PNGase F and Endo H)  
▪ Study the effect of deglycosylation on beta cells within human pancreatic islets  
▪ Investigate whether deglycosylation increases insulin secretion  
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5.3 Results  
5.3.1 Insulin measurement of glucose-stimulated and 
PNGase F treated human pancreatic islets (Assay 1)  
To investigate the effect of deglycosylation on insulin secretion, human pancreatic islets 
were treated with 2,000 U of PNGase F after a series of glucose stimulation (GSIS) with 
low (2.8 mM) and high (28 mM) concentrated glucose solutions to further measure Insulin 
secretion using ELISA (2.3.3). The GSIS series was performed to test the eligibility of 
the islets used for the experiment and to investigate whether PNGase F treatment 
induces insulin secretion to the same or even a higher level.  
The experiment was performed twice using the same islets batch. After equilibration, all 
samples were incorporated into the GSIS series. The final PNGase F treatment was 
done with three of the samples and one served as a control only treated with the enzyme 
buffer (Na3PO4, 50 mM final concentration).  
Insulin secretion was determined measuring the accumulated insulin in the test medium 
(KRBB) using the human insulin ELISA assay. For this, the medium samples before (T0) 
and after incubation (T60) of each test condition were collected during the experiment. In 
addition, the islets were harvested in RIPA buffer immediately at the end of each 
experiment for lysis. The islets lysates were also measured in the ELISA assay to assess 
the intracellular insulin content of each sample.  
Insulin concentrations measured in ELISA were converted into µU/mL using the standard 
equation obtained from the standard curve measured in each ELISA assay. To evaluate 
the response of the islets to the GSIS and PNGase F treatment the ratio reflecting the 
difference (increase or decrease) of the secreted insulin concentration between T0 and 
T60 of each condition was calculated for each sample and the means were taken. One-
way ANOVA and a post hoc Bonferroni test were used to assess statistical significance.  
The measurement of intracellular insulin from islets lysates and also the absolute 
concentrations (µU/mL) of means and single values of secreted insulin are provided in 
the appendix for both experiments (see appendix Figure 72, Figure 73, Table 16, Table 
17) 
The temporal difference between the two experiments was seven days and analyses 
were therefore kept separately. The results of both experiments are shown in Figure 40 
and Figure 41.  
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The difference in insulin secretion during glucose induced insulin secretion series (GSIS) 
in the first experiment (Figure 40) turned out not to be statistically significant. However, a 
trend of a higher increase in insulin release when treated with 28 mM glucose (Ratio 
T60/T0 7.91±3.77) compared to low glucose incubation (Ratio T60/T0 1.51±0.26) was 
observed. Likewise, a decrease of insulin secretion by reducing the glucose 
concentration back to 2.8 mM (Ratio T60/T0 1.15±0.18) seems to be likely. When treated 
with PNGase F in 0 mM glucose KRBB, the change in insulin concentration over 60 
minutes was not significant compared to the control sample (Ratio T60/T0 1.67). There 
was a trend of an increase, which was based on one out of the three samples with a very 
low T0 concentration compared to the other two (Table 16). This explains the strong 
Figure 40: Assay 1: Experiment 1 human pancreatic islets Batch 1.  
Differences of Glucose-stimulated insulin secretion (GSIS) and subsequent PNGase F treatment 
for deglycosylation are shown. The ratios (T60/T0) of secreted insulin are plotted and were 
calculated from absolute concentrations obtained from ELISA. The ratio reflects the change in 
insulin secretion per condition over an incubation period of 60 minutes. The entire experiment 
lasted for 240 minutes. The experiment was performed in 24-well-plates. Four islets samples 
were included in the experiment. For each sample 300 IEQ (theoretical number) were seeded in 
one well. In total, four different conditions were tested and completed in KRBB (Krebs Ringer 
bicarbonate buffer). All four islets samples were included in the GSIS series (n=4) and stimulated 
with 2.8 mM, 28 mM and 2.8 mM glucose (Black bars). After GSIS three of the samples were 
incubated with 2,000 U PNGase F pre-prepared in its enzyme buffer (Na3PO4, 50 mM final 
concentration) in 0 mM glucose (n=3, chequered bar). One sample was used as a control only 
incubated with enzyme buffer (Na3PO4, 50 mM final concentration) also in 0 mM glucose (n=1, 
white bar). Standards were measured from 5-100 µU/mL (data not shown). Values are 
means±SEM when applicable. Statistical significance (P<0.05) was tested using a one-way 
ANOVA followed by a Bonferroni correction for multiple comparisons to compare between the 
different conditions 
PNGase F
2.8 mM 28 mM 2.8 mM No glucose
240 minutes 
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variation with ratios of a range from 2.67 to 42.27 (16±13.15). Similarly, compared to the 
high glucose stimulation and also both low glucose stimulation, no significant difference 
was observed when islets were treated with PNGase F due to the high fluctuation.  
The absolute concentrations of single values ranged between approximately 900 and 
2,000 µU/mL for secreted insulin, whereas this was higher in islets lysates with insulin 
concentrations of 13,500 to 46,000 µU/mL (see appendix Figure 72, Table 16).  
The quality controls of the assay were within the predefined range (2.3.3) and accounted 
for 8.53 µU/mL and 25.86 µU/mL for low and high quality control, respectively.  
 
 
Figure 41: Assay 1: Experiment 2 human pancreatic islets Batch 1.  
Repetition of experiment 1 seven days later. Differences of Glucose-stimulated insulin secretion 
(GSIS) and subsequent PNGase F treatment for deglycosylation are shown. The ratios (T60/T0) of 
secreted insulin are plotted and were calculated from absolute concentrations obtained from ELISA. 
The ratio reflects the change in insulin secretion per condition over an incubation period of 60 
minutes. The entire experiment lasted for 240 minutes. The experiment was performed in 24-well-
plates. Four islets samples were included in the experiment. For each sample 300 IEQ (theoretical 
number) were seeded in one well. In total, four different conditions were tested and completed in 
KRBB (Krebs Ringer bicarbonate buffer). All four islets samples were included in the GSIS series 
(n=4) and stimulated with 2.8 mM, 28 mM and 2.8 mM glucose (Black bars). After GSIS three of the 
samples were incubated with 2,000 U PNGase F pre-prepared in its enzyme buffer (Na3PO4, 50 mM 
final concentration) in 0 mM glucose (n=3, chequered bar). One sample was used as a control only 
incubated with enzyme buffer (Na3PO4, 50 mM final concentration) also in 0 mM glucose (n=1, white 
bar). Standards were measured from 5-200 µU/mL (data not shown). Values are means±SEM when 
applicable. Statistical significance was tested using a one-way ANOVA followed by a Bonferroni 
correction for multiple comparisons to compare between the different conditions. “a” indicates a 
significant difference (P<0.05) of the PNGase F-treated sample group to 2.8 mM, “b” to 28 mM and 
“c” to again 2.8 mM glucose.  
PNGase F
2.8 mM 28 mM 2.8 mM No glucose
a, b, c
240 minutes 
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Experiment 2 (Figure 41) represents the repetition of experiment 1 (Figure 40). Rising 
insulin secretion (Ratio T60/T0) during GSIS was still measurable but overall to a lower 
extent (Ratios 1.62±0.33 to 2.76±0.07) compared to experiment 1 (Ratios 1.15±0.18-
7.91±3.77). Moreover, the trend of an increasing insulin concentration when stimulated 
with 28 mM glucose compared to 2.8 mM glucose could not be observed anymore. 
Similarly, the expected drop in insulin secretion when returning the islets back into 2.8 
mM glucose failed to appear.  
Even though the rise of insulin secretion during the 60-minute PNGase F treatment was 
significantly higher, with a factor of 28.40±6.64 compared to the GSIS series, PNGase F 
influence did not significantly alter insulin secretion compared to the control, which 
showed a 32.1-times increase after the 60-minute incubation.  
Overall, the extra- and intracellular insulin concentrations measured in experiment 2 
were much lower compared to experiment 1. The absolute values for both, secreted and 
intracellular insulin can be reviewed in the appendix (Figure 73, Table 17). The quality 
controls of the assay were again within the predefined range (2.3.3) and accounted for 
8.06 µU/mL and 20.81 µU/mL for low and high quality control, respectively.  
5.3.2 Response of deglycosylated human pancreatic islets 
to glucose and PMA stimulation (Assay 2) 
A second, differently designed assay (Assay 2) was conducted to continue investigating 
the influence of deglycosylation on insulin secretion from human pancreatic islets. In this 
setting, islets were treated with two deglycosylation enzymes (PNGase F and Endo H) 
prior to glucose and PMA stimulation and the results were compared to a non-
glycosylated control group. In total, three conditions were tested. The glucose 
concentrations changed from 2.8 mM to 2 mM for the low glucose condition and from 28 
mM to 20 mM for the high glucose condition. In a third condition, islets were treated with 
500 nM PMA in addition to 20 mM glucose.  
As before, insulin concentrations measured in ELISA were converted into µU/mL using 
the standard equation obtained from the standard curve measured in each ELISA assay. 
The full experiment was conducted twice within two days and the results were combined. 
The response of the islets to the different treatments was expressed in fold over basal 
(fold change during treatment to the basal level of insulin secretion) and the means were 
plotted. The basal level of insulin secretion was calculated from values measured for 
non-glycosylated control samples at 2 mM glucose. To assess statistical significance, a 
two-way ANOVA and a post hoc two-tailed, unpaired student’s t-test were applied to the 
data. The resulting bar chart is shown in Figure 42.  
                         Chapter 5 
 130 
The absolute concentrations (µU/mL) of means and single values of secreted and 
intracellular insulin are provided in the appendix for both experiments (see appendix 
Figure 74, Table 18, Table 19).  
 
 
 
 
Within the control group, increasing insulin secretion was significant with rising glucose 
concentrations and additional PMA treatment. Insulin concentrations measured, 
changed by 1.18-fold (20 mM) and 1.42-fold (20 mM plus PMA) during the 60-minute 
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Figure 42: Assay 2: Insulin secretion from human pancreatic islets Batch 2.  
Deglycoylated (black bars) vs. non-deglycosylated (control, white bars) samples from two 
experiments. Each experiment was performed in 24-well-plates. Twelve islets samples were 
included per experiment. For each sample 150 IEQ (theoretical number) were seeded in one 
well. Six samples were treated with PNGase F and Endo H for deglycosylation and six were 
kept glycosylated in a first incubation step at 2 mM glucose (120 minutes). In total, three 
different conditions, 2 mM glucose, 20 mM glucose and 20 mM glucose plus 500 nM PMA were 
tested and completed in BSS (Balanced salt solution) in a second step (60 minutes incubation). 
Two islets samples were included per condition per experiment. The data shown represent the 
mean±SEM from both experiments per condition (n=4) and group (control samples, 
deglycosylated samples). In total two outliers were omitted from the deglycosylated group and 
n-numbers reduced accordingly. One value from the 2 mM glucose stimulation (n=3) and one 
from the 20 mM glucose plus PMA treatment (n=3) were omitted. Standards were measured 
from 5-200 µU/mL (data not shown). Statistical significance was tested using a two-way 
ANOVA followed by a two-tailed, unpaired student’s t-test to compare between the different 
conditions and groups. “a” indicates a significant difference (P<0.05) of the 2 mM treatment 
compared to the other conditions. “b” indicates a significant difference (P<0.05) of the 20 mM 
treatment compared to the other conditions.  
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incubation compared to the basal level (2 mM non-glycosylated control). A similar trend 
was observed within the group of deglycosylated islets between the different conditions. 
However, changes were not significant compared to the basal level nor between the 
three conditions. Compared to the control group, deglycosylated islets appear to secrete 
slightly more insulin within each condition but this was not significant. In particular, when 
treated with PMA the response of deglycosylated islets did not show a distinct increase 
compared to the control as hypothesised a priori.  
The quality controls accounted for 8.53 µU/mL (low QC) and 25.86 µU/mL (high QC) and 
therefore were within the defined range indicating appropriate performance of the assay 
(2.3.3).  
5.4 Discussion  
Glucose–induced insulin secretion (GSIS) is commonly used for the assessment of 
quality and viability of human pancreatic islets in islets transplant centres 253. Although 
the islets used for Assay 1 were of relatively poor quality (Batch 1), the data obtained in 
the first experiment provide initial evidence that the islets have responded to the GSIS 
(Figure 40), reflected by a trend of increased insulin secretion when stimulated with 28 
mM Glucose. Yet, this was not statistically significant. This pattern changed in the second 
experiment conducted seven days later, indicating no distinct stimulation of insulin 
release during the GSIS series. The differences in insulin secretion levels during GSIS, 
when comparing experiment 1 and 2 of Assay 1 (Figure 40, Figure 41), are likely a result 
of decreasing islets viability due to the interval of seven days between the experiments. 
Islet quality decreases with time and even more rapidly when they are not in good 
condition after isolation, as it was the case for the batch used as pointed out before 254. 
Islet quality during and after isolation at transplant centres is regularly being tested 
extensively in vitro and in vivo in order to assess islets identity, purity, viability, and 
potency to predict post-transplant functional performance 255. In this respect, it has also 
been reported, that islet viability suffers when physical, chemical or temperature stress 
is applied 256, also indicating that the experimental setting applied may needs 
improvement to address a reduction of these stress factors. Changing the experimental 
set up as done for Assay 2 indeed has partially improved islets response during GSIS. 
The non-deglycosylated control group showed a significant increase of insulin secretion 
with rising glucose concentration and also additional PMA treatment as it was expected 
initially. The batch of islets used here was also of better quality compared to the previous 
batch (please see 2.1.2.1) and this might explain the difference here.  
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Overall, the results of both assays reflect, that insulin secretion was measurable using 
human pancreatic islets and those seem to potentially be a suitable model to study β-
cell-dependent insulin secretion in human disease.  
The purpose of this study was to investigate the impact of the PMM2 mutation and 
related impairment of N-glycosylation on insulin secretion. As detailed previously (1.6.1), 
key proteins for insulin secretion are the sulfonylurea receptor 1 (SUR1) and the ATP-
dependent potassium channel KCNJ11 and previous work has shown that mutations 
affecting N-glycosylation of SUR1 and KCNJ11 can cause hyperinsulinism 257,258.  
The treatment with deglycosylation enzymes was meant to induce deglycosylation of 
membrane proteins to assess the effect on insulin secretion. However, deglycosylated 
islets did not respond with a significant increase in insulin release in both settings (Assay 
1, Assay 2) compared to the control samples not treated with PNGase F or Endo H. 
Either the variations within the deglycosylated sample group were too high or the non-
glycosylated control behaved similarly as was the case in Assay 2, so that a distinct 
effect could not be observed. Although PMA did enhance insulin release in Assay 2, a 
significant difference between deglycosylated and non-deglycosylated sample groups 
was not observed and the expected effect of increased insulin release due to impaired 
N-glycosylation was not proven. Furthermore, instead of working with PMA 
concentrations within the physiological range, PMA was added in way higher 
concentrations within the nanomolar range to mimic GLP-1 stimulated insulin secretion. 
As outlined in the introduction of this thesis, differing GLP-1 concentrations stimulate 
insulin secretion through different pathways which might change the levels of insulin 
secretion. However, the reason why GLP-1 employs different pathways depending on 
concentration is still not completely understood 154.  
It has to be noted, that the experimental set up is difficult and results therefore have to 
be analysed with caution. First of all, a problem occurred whilst performing Assay 1. A 
white precipitation was observed both times after adding the PNGase F in its enzyme 
buffer and also whilst adding the enzyme buffer only to the control. This was likely a 
result of salt formation between components of the KRBB solution and the enzyme 
buffer. The latter was a highly concentrated Na3PO4 solution which yielded a final 
concentration of 50 mM. It is very likely, that the phosphate ions have formed a salt with 
the calcium and/or magnesium ions from the KRBB solution and either Ca3(PO4)2 and/or 
Mg3(PO4)2 did precipitate. This phenomenon is explained by the Le Chatelier principle, 
which states that when stress (e.g. temperature-, pH-, concentration-change) moves the 
reaction away from equilibrium, the reaction will try to adjust to get back to equilibrium. 
Whether a precipitate will form depends on the relation of reaction quotient (Q) and 
solubility constant (Ksp). This can be determined by comparing Q and Ksp of the predicted 
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precipitate formed: If Q is greater than Ksp, excess product will precipitate 259. This is 
what likely has happened in our experiment. The solubility of Ca3(PO4)2 and Mg3(PO4)2 
in aqueous solution is very low; whereas sodium-salts are highly soluble resulting in the 
precipitation observed due to the highly concentrated Na3PO4 solution.  
Associated with the enzyme buffer addition, islets clusters dissociated within the 
precipitate and cells appeared to be swollen as observed by microscopy (data not 
shown), potentially altering their secretory function. Consequently, for Assay 2 the 
deglycosylation enzymes were added directly to the wells without the enzyme buffer this 
has solved the problem of precipitation. Disintegration of islets structure changes insulin 
secretion negatively as it is a multicellular process dependent on the interplay of many 
cell types rather than the performance of -cells only. This was tested in experiments 
looking at the effect of islets dispersion on insulin secretion showing that reaggregation 
of islets resulted in a rapid improvement of insulin release 260. The 3D architecture and 
cellular coordination of those “microorgans” is of vast importance, enabling 
communication and cross-talk between the different cell types, crucial for appropriate 
islets function. Besides communicating in an indirect way through, for example 
hormones, neurotransmitter and other signalling molecules, which do not require cells to 
be within close proximity, also direct cell-to-cell communication is essential for -cells to 
release insulin and relies on the distinct islets 3D organisation. Many different adhesion 
glycoproteins called CAMs (cell adhesion molecule) maintain cell cohesion and mediate 
direct cell-to-cell communication between neighbouring cells within pancreatic islets 
261,262. This implies that deglycosylation of the membrane-bound cell surface proteins 
likely alters islets structure and consequently -cell behaviour and response to glucose 
stimulation. This may explain that no distinct effect was observed in all three experiments 
conducted when islets were deglycosylated.  
A major issue whilst conducting these assays was a large variation in insulin 
measurement within the sample groups. Increasing the sample number would be one 
option to try to overcome the problem and reduce errors. However, some technical 
issues related to the handling of the islets are contributing to variation, which are not 
easy to solve. Those variables possibly affecting experimental data are:  
 
1) Difficulties to control equal numbers of islets seeded per well  
2) Islet quality might differ across wells  
3) Distribution of -cells per islet  
4) Number of -cells per islet likely varies  
5) Activity of -cells per islet  
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All these factors likely have an impact on insulin measurement. Moreover, particularly in 
Assay 1, insulin might have been transferred from one well to the other between the 
different conditions. It is likely that secreted insulin accumulated within the islets cluster 
and simply diffused into the solution after transfer to the next well.  
Some additional issues are also related to the enzyme addition itself to facilitate 
deglycosylation of the islets. First of all, for both assays the enzymes have not been 
tested for their functionality beforehand and also using different concentrations of the 
enzymes were not compared. Moreover, adding the enzymes effectively changes the 
surrounding environment the islets are situated in, which the non-glycosylated control 
groups do not experience, this might have a general impact on islets behaviour and 
physiology, which is not related to an effect of deglycosylation. This can be either 
inhibition but also the enhancement of insulin release as different stressors have different 
effects on -cell function 263. Some disintegration was also observed when treating the 
islets in Assay 2 without the addition of the enzyme buffer. As pointed out before, this 
does have an impact on islets and in particular -cell function. The natural environment 
of -cells is living in these cell clusters with four other endocrine cell types. If this 
changes, -cells behaviour and function very likely changes as well. In addition, this also 
causes an error within the experimental set up as the non-deglycosylated control group 
did not experience such changes. Effectively the conditions both sample groups were 
exposed to were technically different, thus unfavourable for a proper comparison.  
Pancreatic islets are quite sensitive and prone to stress in general. During the islets 
isolation procedure, for example elevated apoptosis and necrosis rates are measurable 
as studies have shown: Two major cellular stress-induced pathways, NF-κB (Nuclear 
Factor kappa-light-chain-enhancer of activated B cells) and PARP (poly(ADP-ribose) 
polymerase) are active during isolation and related signalling molecules such as 
interleukin-6 and -8 (proinflammatory cytokines) are still detectable days after isolation. 
Significant numbers of islets die post isolation, thus lowering the yield of functional islets 
dramatically and this still represents a major obstacle to overcome for islets transplant 
therapy 264.  
In conclusion, glucose-stimulated insulin secretion (GSIS) overall has worked nicely, and 
this shows that human pancreatic islets are a possible model to investigate insulin 
secretion. However, due to the restricted availability of human pancreatic islets 
conducting appropriate experiments will remain difficult. Moreover, the experimental 
settings itself require significant improvement in order to generate reliable data as the 
settings as such are too error prone and this likely affects insulin measurement (see 8.3).  
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Chapter 6: Development of the HIPKD HepG2 
cell model with CRISPR-Cas9  
6.1 Introduction  
This chapter describes the generation of an HIPKD cell model, which harbours the 
disease-causing mutation (c.-167G>T) in homozygous state. The HepG2 cell line from 
ATCC (ATCC® HB-8065™) was chosen to be directly targeted at the PMM2 promoter 
with CRISPR-Cas9 and the c.-167G>T SNP aimed being integrated by providing a 
ssODN (homologous DNA repair template) allowing the cell’s naturally occurring DNA 
repair mechanism to follow the HDR pathway after Cas9 cleavage. HepG2 cells are 
derived from a hepatocellular carcinoma of a 15-year-old male. HepG2 is an 
immortalised, non-tumorigenic cell line with epithelial morphology and a modal 
chromosome number of 55 (hyperdiploid) 265,266.  
Two reasons explain why HepG2 cells were chosen for this purpose: 1) Based on the 
previously described bioinformatics analysis characterising the human PMM2 promoter 
region more precisely, identifying a chromatin loop and showing the chromatin 
segmentation (Figure 35) in different commercially available cell lines, HepG2 cells stood 
out being the only cell type in which the chromatin seemed to be active throughout the 
looping area. 2) As HepG2 cells are a liver-derived cell line and as liver involvement in 
HIPKD has been described 209 HepG2 cells were deemed a suitable disease model for 
HIPKD.  
In order to achieve scarless genome editing, the CRISPR-Cas9 system was used to 
generate the c.-167G>T PMM2 promoter SNP in HepG2 cells. Different formats of the 
CRISPR-Cas9 system and ways to deliver it to cells are commercially available. Those 
can be DNA expression plasmids, in vitro mRNA transcripts or ribonucleoprotein 
particles (RNPs) where the recombinant Cas9 protein and the specific sgRNA build a 
complex 267. For the purposes of this study, a DNA plasmid-based CRISPR-Cas9 
expression system was used as a starting point and delivered to the cells together with 
the ssODN using a reagent-based transfection system. The advantage here was seen 
in the nature of the CRISPR construct chosen, having a GFP expression gene integrated 
as an additional feature enabling microscopical tracking of the transfection. The 
optimisation of the transfection conditions for HepG2 cells turned out to be quite 
elaborate and time-consuming, therefore fast-growing and known to be easy to transfect 
HEK293T cells (human embryonic kidney cells 293, ATCC CRL-3216) were recruited 
to initially test the efficiency of the two differently designed CRISPR-Cas9 expression 
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plasmids (6.3.5) to find out which one was the best to use. HEK293T cells were only 
used for the purpose of assessing the overall efficiency of the two CRISPR constructs 
and were not taken further in the experimental setting, e.g. no single cell colonies were 
obtained from these cells. After the construct-assessment, CRISPR experiments were 
carried out using HepG2 cells exclusively.  
Although sufficient CRISPR activity was measured repetitively in HepG2 cells, this 
plasmid-based approach did eventually not produce any homozygous HepG2 clone after 
performing several experiments and large-scale genotyping of single cell colonies. As a 
consequence, a system switch to CRISPR-RNPs was commenced, which were shuttled 
into HepG2 cells by electroporation and again in co-transfer with the ssODN. The results 
and outcomes of both attempts to generate a homozygous HIPKD cell model are outlined 
in this chapter.  
6.2 The aims of this chapter  
▪ Design of a CRISPR gRNA which targets the PMM2 promoter with high 
efficiency and only +/- 10 bp up- or downstream to the nucleotide position of the 
desired SNP (c.-167G>T)  
▪ Assessment of cutting efficiency of CRISPR gRNA using TIDE 
▪ Co-transfection of CRISPR gRNA, Cas9 and ssODN for homology directed 
repair 
▪ Development of stable HIPKD cell model using HepG2 harbouring the desired 
SNP in homozygous state  
6.3 Results  
6.3.1 Verification of PMM2 promoter region of interest in 
HEK293T and HepG2 cells  
In order to guarantee that the PMM2 promoter region of interest in HepG2 and HEK293T 
cells harbours no SNP or other alterations to the wt sequence, gDNA was extracted and 
the PMM2 amplicon (Primers: PMM2 For3+Rev3,Table 8) sent for sequence verification. 
Figure 43 shows a representative example of the band resulting from amplification of 
gDNA from HepG2 cells on a 2% agarose gel.  
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To demonstrate what the DNA sequence of the PMM2 region of interest in hg38 (Human 
genome version 38) is like, Figure 44 illustrates a BLAT (BLAST-like alignment tool) 
search result done within the UCSC genome browser (https://genome.ucsc.edu/). The 
section shows a 100 bp stretch of the amplicon with nucleotide -167 in the centre. Within 
the input sequence for the BLAT analysis the “G” at nt -167 was replaced by the desired 
SNP (“T”) to simplify localisation of the CRISPR editing site.  
Input sequence used for BLAT analysis:  
AGAGCGCATGCTCGAATGTACAAGGCGGGCGTGATCTGCGTTGCACCCTTGGAG
TTGCGGTCCAGGAATCGTGGCTGCCGCTACTCCCAGGCGTTATGGG   
 
Figure 44: UCSC BLAT result (hg38) showing the genomic ROI within the PMM2 promoter with 
nt position c.-167G in the centre.  
Top: The 100 bp sequence matches the leading strand on chromosome 16 with 99% identity. 
Bottom: The first track shows the genomic coordinates and the base composition of the of the 
BLATed input sequence on chromosome 16. The red box highlights the transcription factor 
binding site for ZNF143 which includes nt position c.-167G marked by the green arrow. The 
second track shows the input sequence from BLAT search with the SNP (c.167G>T). The third 
track shows the GENECODE version 24 track indicating PMM2.  
Figure 43: Representative gel image of PCR 
amplicon with primer pair PMM2 For3/Rev3.  
gDNA extracted from wt HepG2 cells. Lane 1: 100 
bp Ladder (Figure 75). Lane 2: PCR product 
PMM2 For3/Rev3 (296 bp). Lane 3: Empty master 
mix, Blank control H2O only.  
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The PMM2 amplicons from both, wt HepG2 and HEK293T gDNA, were sent for 
unidirectional Sanger sequencing using the PMM2 For3 primer. Both sequencing 
reactions match the UCSC hg38 PMM2 sequence shown above to 100%. Figure 45 
shows a section of the sequenced PMM2 promoter region in both cell lines.  
 
 
6.3.2 Finding the right gRNA for a successful gene edit  
For a CRISPR HDR gene edit it is crucial to choose gRNA target regions which are as 
close to the CRISPR site as possible. To meet this requirement, gRNA target sequences 
were chosen directly from the DNA sequence around nt position c.-167G. The sequence 
was pasted into SnapGene and screened for the closest PAM motifs to the CRISPR 
site. Two gRNA target regions were chosen to start with. Both are flanking the CRISPR 
site where the SNP is planned to be introduced in ultimate proximity. One of them, 
hPMM2_1, is located on the leading strand, the other one, hPMM2_2, on the reverse 
strand of the PMM2 promoter. Figure 46 shows the genomic region of the PMM2 
promoter region of interest generated with SnapGene. Primer sequences, CRISPR site, 
gRNA sequences with corresponding PAM sites and the transcription start site within 
exon 1 are annotated.  
  
Figure 45: Sanger sequencing of PMM2 For3/Rev3 amplicon with primer PMM2 For3 in wt 
HEK293T and HepG2 cells.  
The CRISPR site (c.-167G) is highlighted in light blue, flanked by about 40 nt either side. A: 
Electropherogram showing the wt sequence of the PMM2 ROI in HEK293T cells. B: 
Electropherogram showing the wt sequence of the PMM2 ROI in HepG2 cells. 
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The gRNA target region (please see below) was put in and analysed with two 
independent frequently used CRISPR design tools, CRISPOR and CHOPCHOP v2, to 
assess uniqueness and specificity of the two gRNAs of choice. For both analyses, human 
genome hg38 was selected and the PAM motif was set to NGG referring to the specific 
PAM site for the Cas9 nuclease originated from Streptococcus pyogenes.  
The input sequence used to analyse the quality of the chosen gRNA targets was the 
following:  
ACAAGGCGGGCGTGATCTGCGTTGCACCCTGGGAGTTGCGGTCCAGGAATCGTG
GCTGCCG 
 
CRISPOR lists and ranks resulting gRNA target sequences in a table (Figure 47) 
according to their specificity from high to low. The CRISPOR scoring system ranges from 
0-100. In total seven gRNA targets were found based on the DNA sequence input 
resulting in hPMM2_1 being the best match on rank 1 and gRNA hPMM2_2 being ranked 
number six. However, both are annotated as being good gRNA targets indicated by the 
green mark on the left implying specificity scores of above 50. The score was 94 for 
hPMM2_1 and 79 for hPMM2_2. The efficiency scores predicting the cutting efficiency 
of the guides were higher for hPMM2_2, with 57 and 54 according to the algorithms from 
Doensch 2016 268 and Moreno-Mateos 269, respectively. For hPMM2_1, these were 46 
Figure 46: SnapGene sequence showing the CRISPR region within the PMM2 promoter.  
Purple arrows: PMM2 For3 and Rev3 primer pair and their binding sites limiting a 296 bp DNA 
section. Green arrow: gRNA hPMM2_1 binding site and target sequence. Green box: PAM motif 
for gRNA hPMM2_1. Magenta arrow: gRNA hPMM2_2 binding site and target sequence. 
Magenta box: PAM motif for gRNA hPMM2_2. Red box: Nucleotide position c.-167G to be edited 
to c.-167G>T. Turquoise area: Beginning of exon 1 of PMM2. Yellow box: Start codon methionine 
of PMM2 coding region. Label StyI: StyI restriction site. 
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and 44. The chance of frameshift deletions is indicated by the out-of-frame score, which 
were the same for both gRNA targets with a score of 75. Nevertheless, since a homology 
directed repair is desired for the gene edit, this is not of much importance here. In terms 
of possible off-targets, guide hPMM2_1 clearly seems to be the better option with 28 off-
targets opposed to 128 off targets with guide hPMM2_2 and this is also confirmed by the 
ranking. Out of all possible off-targets there is one with three mismatches which is within 
the seed region of the gRNA target of hPMM2_1. For hPMM2_2 none of the predicted 
off-targets falls within the seed region.  
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Figure 48 shows the result of the CHOPCHOP analysis, also indicating guide hPMM2_1 
as the best choice (green) out of in total seven possible guides for the region of interest, 
with no off-targets detected. The scoring system in CHOPCHOP ranges from 0-1. 
Differently to CRISPOR, guide hPMM2_2 was categorised as a bad guide ranked on last 
Figure 47: CRISPOR result showing seven gRNAs to target the desired PMM2 CRISPR site.  
The table is sorted by specificity score from high to low. Red arrows annotate the chosen 
gRNAs hPMM2_1 (Rank 1) and hPMM2_2 (Rank 6). Green bar on the left of each guide: 
Based on specificity score. Green indicates a good specificity score of above 50. Column 1: 
Position of the PAM on the input sequence and the strand. Column 2: gRNA target sequence 
with PAM, variants, restriction sites which overlap the three base pairs 5’ of the PAM, 
instruction for cloning and PCR primer. Column 3: Specificity score. Column 4: Efficiency 
score predicting cutting efficiency. Column 5: Out-of-Frame score. Colum 6: Off-target 
mismatch counts to up to 4 mismatches and mismatch count per off-target falling into seed 
region. Scores range from 0-100.  
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position (rank 7). In terms of its specificity it was marked red (red) as shown in Figure 48 
A.  
 
 
 
Figure 48: CHOPCHOP result showing seven gRNAs to target the desired PMM2 CRISPR site.  
A Top: Dynamic visualisation displaying all target site options with a colour code according to the 
scoring indicating specificity. Green: Best. Yellow: Okay. Red: Bad. Chosen gRNAs are numbered 
according to ranks in table (A Bottom). A Bottom: Column 1 shows the ranking of the gRNA listed. 
gRNA hPMM2_1 is on rank 1 and gRNA hPMM2_2 on Rank 7. Column 2: gRNA target sequence 
including PAM. Column 3*: Genomic location. Column 4*: Exon where target sequence is located. 
Column 5: Strand. Column 6: Self-complementarity within the gRNA and between gRNA and RNA 
backbone. Column 7: Off-target mismatch counts to up to 3 mismatches. Column 8: Efficiency 
score (0-1). B: Gene specific part for gRNA hPMM2_1 indicating genomic location, number of 
mismatches and sequence of possible off-targets including the mismatches. C: Gene specific part 
for gRNA hPMM2_2 indicating genomic location, number of mismatches and sequence of possible 
off-targets including the mismatches.  
*Here neglectable as CHOPCHOP algorithm is not able to recognise where the input sequence originates from when 
pasted manually.  
1 
 
7 
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Although revealing a higher efficiency with a score of 0.58 opposed to 0.48 for hPMM2_1. 
The self-complementarity accounted zero for hPMM2_1, whereas this was accounted 
one for hPMM2_2. Finally, nine off-targets with 3 mismatch counts each were predicted 
for hPMM2_2 making it the least specific guide RNA target out of all guides listed (Figure 
48 A and C). The GC content for both were within the range (40% - 70%) with 65% each.  
In conclusion, both CRISPR design tools predict hPMM2_1 being the better gRNA for 
the purposes of this study. Although CRISPOR indicated both as reasonable guides to 
use, CHOPCHOP clearly indicated that hPMM2_2 does not meet the requirements for a 
good guide.  
6.3.3 From transfection/electroporation to the living cell 
line  
The following workflow diagram shall provide an overview of the major steps involved 
when the HepG2 cell line was generated with CRISPR-Cas9, either plasmid- or RNP-
based, starting from delivering the system to the cells with reagent-based transfection or 
electroporation until positive clones were available to be expanded.  
 
 
 
Figure 49: Workflow of a full CRISPR experiment.  
The process starting from delivery of the CRISPR-Cas9 system to the cells with either transfection 
or electroporation to expansion of positive clones is depicted.  
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Please note, that all reagent-based transfections were performed as semi-reverse co-
transfections whilst the cells were in suspension. A traditional transfection of HepG2 cells 
would be performed when the cells are adherent on the well surface. In the following 
paragraphs the term transfection or co-transfection, rather than semi-reverse 
transfections or semi-reverse co-transfections will be used for simplistic reasons.  
6.3.4 Identification of intact CRISPR constructs  
In total, three transformed E. coli DH5 clones per CRISPR construct were used for 
plasmid preparation. To verify whether the cloning was successful, both purified CRISPR 
constructs were tested in a double restriction digest with BbsI and EcoRV and analysed 
on a 1% agarose gel (Figure 50). Either one (10 kb) or two bands (3 and 7 kb) were 
expected, as successful ligation of the guide oligos removed the BbsI restriction site in 
PX458.  
 
 
 
Restriction digest of purified plasmid all show a linearised band of about 10 kb, indicating 
successful cloning of the guide oligos into the target vector PX458. The smeary 
appearance of the bands could be due to nicks in the plasmids which are changing the 
supercoiled structure of the construct. DNA concentration of each CRISPR construct was 
assessed using the NanoDrop and those with the highest concentration were sent for 
sequence verification (U6 Forward primer) to confirm the results of the digest.  
  
Figure 50: BbsI and EcoRV restriction digest to validate CRISPR constructs after cloning.  
Constructs: PX458_hPMM2_1 and PX458_hPMM2_2. Lane 1: 1 kb ladder (Figure 76). Lanes 2-
4: Purified plasmid PX458_hPMM2_2 from three E. coli DH5 clones. Lanes 5-7: Purified plasmid 
PX458_hPMM2_1 from three E. coli DH5 clones. Sample loaded and run on a 1% agarose gel. 
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In both cases the gRNA target sequence was inserted and the two CRISPR constructs 
ready to use for transfection.  
6.3.5 Testing the efficiency of CRISPR-Cas9 constructs in 
HEK293T cells 
The first step for setting up the CRISPR-HDR experiment was, 1) to find out which of the 
two designed CRISPR constructs works best eventually and 2) under which conditions. 
A first test to find out how efficient or inefficient the two designed CRISPR constructs 
were, was done with HEK293T cells, simply because this cell line is an easy to transfect 
cell line and the transfection protocol was already optimised, whilst transfection 
optimisation with HepG2 cells was still ongoing.  
The sequence verified GFP-expressing CRISPR constructs (PX458_hPMM2_1 and 
PX458_hPMM2_2) were separately delivered to HEK293T cell using the FuGENE HD 
transfection reagent (2.1.3.1) to assess the cutting efficiency of the CRISPR-Cas9 
system with the two chosen gRNAs. To be able to estimate the proportion of transfected 
cells, the same picture was taken twice with two different channels. One was simply 
illuminated with white light to obtain the brightfield image of the cells to be able to see 
the total number of cells within the selected area. The second one was shot through the 
green fluorescence channel of the cell imager to visualise the green glowing cells due to 
the expressed GFP from the CRISPR constructs once they have reached the nucleus. 
Figure 51: Sanger sequencing of CRISPR constructs.  
A: PX458_hPMM2_1. B: PX458hPMM2_2. Highlighted in blue are the gRNA target sequences 
cloned into the CRISPR expression vector PX458. Red box: 5’-overhangs of guide oligos 
complementary to BbsI cut sites. Guanine added in front of the gRNA target sequence in B to 
initiate transcription.  
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The GFP fluorescence signal was analysed after 24 hours of transfection and pictures 
were taken as described (Figure 52).  
 
 
 
In both cases, the transfection has worked, as both transfected cell population show a 
decent fluorescence signal. Comparing the brightfield images and the corresponding 
green fluorescence pictures it seems that the majority of HEK293T cells have been 
successfully transfected with the two CRISPR constructs.  
To properly investigate this further, cells were harvested and lysed ON after 48 of 
transfection and gDNA was extracted the following day (2.4.1.2) and used to analyse the 
CRISPR site on the genomic level. The gDNA from both differently transfected cell 
populations was amplified as described previously (2.4.1.3) using the PMM2 For3/Rev3 
primer pair specific for the PMM2 promoter region of interest. The two figures (Figure 53, 
Figure 54) below display the electropherograms from Sanger sequencing and the 
Figure 52: Semi-reverse transfection of HEK293T cells with 550 ng each of the GFP-expressing 
CRISPR constructs.  
A left panel: Brightfield image of PX458_hPMM2_1 transfected HEK293T cells 24 hours after 
transfection. A right panel: Fluorescence GFP signal 24 hours post-transfection with 
PX458_hPMM2_1 in HEK293T cells. B left panel: Brightfield image of HEK293T cells shot 24 
hours after transfection with PX458_hPMM2_2. B right panel: Fluorescence GFP signal 24 hours 
post-transfection with PX458_hPMM2_2 in HEK293T cells. Pictures were taken with the ZOE 
cell imager. Scale bar (bottom right corner): 100 nM.  
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following TIDE analysis to quantify the cutting efficiency of the two CRISPR constructs 
used, each carrying one of the particular gRNAs (hPMM2_1 and hPMM2_2).  
The results of transfected cells with PX458_hPMM2_1 are shown in Figure 53. In A, the 
sequencing traces of the CRISPRed cells compared to a clean wildtype control are 
shown, both depicting the region of interest within the PMM2 promoter highlighting the 
CRISPR site (blue). Whether or not the gRNA target sequence can still be found within 
the sequence after gene editing the cells, provides a first hint to what extent the CRISPR-
Cas9 system has changed the DNA region of interest. In the case of gRNA hPMM2_1, 
the target sequence was still fully detectable, indicating that the wt sequences are 
dominating the DNA pool obtained from the transfected cell population. However, after 
the Cas9 cut site the sequence is clearly shifted to the left causing a “messy” looking 
appearance of the traces. This indicates indel formation within the DNA pool and 
confirms that the designed CRISPR construct and particularly the gRNA included, have 
worked. To measure how efficient the system has worked was analysed in TIDE (Figure 
53 B). Both sequencing traces shown in A were put in the software with the gRNA 
hPMM2_1 target sequence as a reference and differences were quantified. The top 
graph in B reflects the Indel spectrum after alignment of the two sequences in percent. 
Zero means no deletion or insertion detected, which accounted in this experiment for 
54.7% of the edited sequence. To the left are the percentages of deletions of up to 10 nt 
and to the right are the percentages of insertions of up to 10 nt. The total cutting efficiency 
of this experiment was decent with 37.2%. The indel spectrum shows that mainly two 
nucleotide deletions (16.4%) have happened during CRISPR. Some deletions of three 
(2.4%), four (3.3%) and five nucleotides (2.4%) were detected, as well as some bigger 
deletions with five to ten nucleotides were identified being deleted. Only a few insertions 
could be indicated. Mainly insertions of only one nucleotide (2.3%) at a time were spotted 
and a few insertions with six, eight and nine nucleotides were found being inserted during 
the experiment. The bottom graph in B shows the aberrant sequence signal of the two 
input sequences. Black reflects the wt sequence and green the sample sequence. And 
as seen in the electropherogram right after the cut site, the sequences differ significantly 
from each other. The increasing peaks after about 275 bp can be ignored as they reflect 
noise since the full amplicon sequenced only has a size of 296 bp.  
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Figure 53: Sanger sequencing and TIDE analysis of CRISPR region of edited HEK293T cells.  
Pooled HEK293T gDNA edited with hPMM2_1 compared to a control (wt HEK293T pooled gDNA). 
A: Sanger sequencing. Highlighted in blue are the gRNA target sequences. Green boxes mark the 
PAM sites. Red arrow indicates the Cas9 cut sites. Both sequencing traces shown are in forward 
direction previously amplified with primer PMM2 For3/Rev3 and sequenced with primer PMM2 For3. 
A Top: Electropherogram of sequenced HEK293T gDNA amplicon after transfection with hPMM2_1. 
A bottom: wt electropherogram of PMM2 promoter ROI. B: TIDE analysis comparing 
electropherograms from A. gRNA sequence hPMM2_1 was provided as a reference string. B Top: 
Indel spectrum and calculated cutting efficiency in percent. B Bottom: Aberrant sequence signal of 
the two input sequence traces and the expected cut site. Black: wt sequence. Green: Sample 
sequence. Blue: Expected cut site. 
B 
HEK PX458_hPMM2_1 
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The electropherograms in Figure 54 A reflect the result after editing the cells with 
CRISPR construct PX458_hPMM2_2 compared to the clean control wt sequence. Apart 
from the first 5 bases, the gRNA target sequence cannot be detected anymore. This 
indicates significant changes of the pooled DNA sequence after CRISPR editing these 
cells. The sequence shift to the right after the Cas9 cut site clearly demonstrates indel 
formation within the DNA pool due to CRISPR and confirms that gRNA hPMM2_2 is a 
good candidate to target the PMM2 promoter region of interest.  
Quantification of the CRISPR efficiency (Figure 54 B) when the cells were transfected 
with construct PX458_hPMM2_2, TIDE measured an overall cutting efficiency of 47.9%. 
Similarly, to guide hPMM2_1, mainly deletions of one nucleotide (21.7%) took place 
during CRISPR altering the input DNA from the HEK293T cell population. Overall, the 
edited sequence matched the control wt sequence to only 46.5%. Further deletions of 
two to ten nucleotides were measured with percentages ranging from 5.2% (two 
nucleotide deletions) to below 1.6% (three, four, five, six and ten nucleotide deletions). 
Deletions of seven, eight and nine nucleotides ranged from 1.6% to 3.6%. Only 3.3% of 
one nucleotide insertions were detected and some insertions of two, eight and ten 
nucleotides with very low percentages were found. The aberrant sequence signal clearly 
matched with what was already reflected by the two electropherograms, showing a 
significant difference in the sequencing traces after the Cas9 cut site indicating indel 
formation. This is demonstrated in the bottom graph by the high and low peaks in green 
and black, which reconstruct the CRISPRed DNA and wt sequences, respectively. As 
said previously, the noisy peaks after about 275 bp in the diagram are irrelevant and can 
be ignored.  
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Figure 54: Sanger sequencing and TIDE analysis of CRISPR region of edited HEK293T cells.  
Pooled HEK293T gDNA edited with PX458_hPMM2_2 compared to a control (wt HEK293T 
pooled gDNA). A: Sanger sequencing. Highlighted in blue are the gRNA target sequences if 
possible. Green boxes mark the PAM sites. Red arrow indicates the Cas9 cut sites. Both 
sequencing traces shown are in forward direction previously amplified with primer PMM2 
For3/Rev3 and sequenced with primer PMM2 For3. A Top: Electropherogram of sequenced 
HEK293T gDNA amplicon after transfection with PX458_hPMM2_2. A bottom: wt 
electropherogram of PMM2 promoter ROI. B: TIDE analysis comparing electropherograms from 
A. gRNA sequence hPMM2_2 was provided as a reference string. B Top: Indel spectrum and 
calculated cutting efficiency in percent. B Bottom: Aberrant sequence signal of the two input 
sequence traces and the expected cut site. Black: wt sequence. Green: Sample sequence. Blue: 
Expected cut site.  
A 
B 
HEK PX458_hPMM2_2 
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In conclusion, the CRISPR-Cas9 system seems to work better with gRNA hPMM2_2 in 
HEK293T cells, as the cutting efficiency after TIDE analysis was 10% higher, with 47.9% 
compared to the construct carrying gRNA hPMM2_1, with 37.2%. Hence, all further 
CRISPR transfections and co-transfections to finally generate the desired HepG2 cell 
line were done with CRISPR construct PX458_hPMM2_2.  
6.3.6 A first attempt of targeting HepG2 cells with the 
CRISPR-Cas9 system  
Before being able to perform a CRISPR-HDR experiment, the transfection conditions to 
deliver PX458_hPMM2_2 into HepG2 cells had to be optimised (For details see section 
2.1.3.2). After testing different amounts of plasmid DNA (550ng, 880 ng, 1µg, data not 
shown) to get an optimal outcome, delivering 1 µg of the CRISPR construct 
PX458_hPMM2_2 resulted in the best transfection efficiency in HepG2 cells. This was 
in first place indicated by the number of green fluorescent cells as shown in Figure 55.  
 
 
By comparing the two images in Figure 55, it becomes obvious that the number of 
transfected cells was quite low in relation to the high cell density present in the well. This 
indicates an overall low transfection efficiency reached by the setting used. However, it 
was deemed sufficient to proceed and the cells were FACS-sorted after 72 hours post 
transfection. This helped to separate the green GFP-expressing cells from the non-
transfected cells. The green fluorescent cells form all wells were collected in one. This 
guaranteed an enrichment of transfected cells to increase the chances of a better overall 
Figure 55: Semi-reverse transfection of HepG2 cells with 1 µg of the GFP-expressing CRISPR 
construct PX458_hPMM2_2.  
Left panel: Brightfield image of PX458_hPMM2_2 transfected HepG2 cells 48 hours after 
transfection. Right panel: Fluorescence GFP signal 48 hours post-transfection with 
PX458_hPMM2_2 in HepG2 cells. All pictures were taken with the ZOE cell imager. Scale bar 
(bottom right corner): 100 nM. 
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outcome of the experiment. The gDNA was extracted from a portion of these cells and 
the pooled gDNA was analysed by Sanger sequencing, after amplification of the region 
of interest (PMM2 For3/Rev3 primer pair). Figure 56 shows the result of the sequencing 
reaction.  
 
 
 
The electropherogram of the edited gDNA in Figure 56 A shows the desired “messy” 
appearing sequencing traces as expected after targeting the cells with the CRISPR-Cas9 
system. Indels have formed right after the Cas9 cut site and have shifted the sequence 
to the right to an extent the gRNA target sequence cannot be identified anymore. This 
indicates, that the majority of the cells have been edited, which was confirmed performing 
a TIDE analysis (Figure 57). B shows the clean wt control sequence in comparison.  
  
Figure 56: Electropherograms of pooled gDNA from transfected HepG2 cells with CRISPR 
construct PX458_hPMM2_2 (1 µg) compared to a wt control.  
Both sequencing traces shown are in forward direction previously amplified with primer PMM2 
For3/Rev3 and sequenced with primer PMM2 For3. Highlighted in blue are the gRNA target 
sequences if possible. Green box marks the PAM site. Red arrow indicates the Cas9 cut site. A: 
Electropherogram of sequenced HepG2 gDNA amplicon after transfection with 
PX458_hPMM2_2. B: Wt electropherogram of PMM2 promoter ROI from HepG2 cells. 
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TIDE measured an overall cutting efficiency of 61.8% within the pooled sample of FACS-
sorted HepG2 cells when transfected with PX458_hPMM2_2. As previously seen and 
again shown by the indel spectrum, mainly deletions of one nucleotide (36.3%) were 
detected. In addition, deletions of five to nine nucleotides were found with lower 
percentages, ranging from 5% to below 2%. The total number of insertions was 
significantly lower with 3.3% and less of insertions with two to six nucleotides. The 
aberrant sequence signal nicely reflects the result of the Sanger sequencing (Figure 56), 
by reconstructing the significant alterations between the CRISPRed and the wt DNA 
samples right after the Cas9 cut site demonstrated by the high green peaks (CRISPR 
sample) opposed to the short black ones (wt) in the bottom graph.  
 
The concentration of the “green” transfected HepG2 cells has worked quite well as 
demonstrated by the high cutting efficiency obtained using PX458_hPMM2_2. This 
experimental setting was then kept for further experiments optimising the co-delivery with 
Figure 57: TIDE analysis comparing and quantifying the alterations of sequencing traces from 
PX458_hPMM2_2-edited HepG2 cells to a wt control.  
sgRNA sequence hPMM2_2 was provided as a reference string. Top: Indel spectrum and 
calculated cutting efficiency in percent. Bottom: Aberrant sequence signal of the two input 
sequence traces and the expected cut site. Black: Wt sequence. Green: Sample sequence. Blue: 
Expected cut site. 
HepG2 cells PX458_hPMM2_2 
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the ssODN – the second step necessary to create the desired HepG2 cell line harbouring 
the c.-167G>T SNP causative for the HIPKD phenotype.  
6.3.7 Optimisation of co-delivering CRISPR construct and 
ssODN  
The first co-transfection was done using the same conditions as previously described 
and the ssODN was added. To get a first impression on how the cells handle the 
additional DNA input, a standard volume of 0.5 µL (2.1 µg) of the 100 µM ssODN were 
used. The result is illustrated in Figure 58 showing a portion of the transfected cells.  
 
 
 
Many cells survived the transfection procedure as demonstrated by the high cell density 
shown in the brightfield image (left). However, only a few cells showed GFP expression 
(right picture) indicating insufficient uptake of the CRISPR construct in the majority of 
cells. In a next experiment, different amounts of the ssODN DNA were delivered to the 
cells, to find the right balance between the already optimised amount set for the CRISPR 
construct (1 µg) and the ssODN. Figure 59 shows the transfected cells 72 hours after 
co-transfection.  
  
Figure 58: Optimisation of semi reverse co-transfection of HepG2 cells.  
1 µg of the CRISPR construct PX458_hPMM2_2 and 2.1 µg of the ssODN were used. Left panel: 
Brightfield image of transfected HepG2 cells 72 hours after transfection. Right panel: 
Fluorescence GFP signal in HepG2 cells 72 hours post-transfection. Images were taken with the 
ZOE cell imager. Scale bar (bottom right corner): 100 nM.  
                         Chapter 6 
 155 
 
 
Images A-B show the total cell density (brightfield, left images) and the density of GFP-
expressing cells (right images) when co-transfected with 210 ng, 340 ng, 425 ng and 850 
ng of the ssODN DNA, respectively. Compared to the result shown in Figure 58, an 
overall increase of the transfection efficiency was observed in all four cases but did not 
differ substantially between the different conditions. However, the number of GFP-
expressing cells seemed to be slightly higher when co-transfected with either 210 ng 
(Figure 59 A) or 425 ng (Figure 59 C) of the ssODN compared to B (340 ng) and D (850 
ng). In order to compensate for partial degradation, 425 ng instead of 210 ng of the 
ssODN were finally chosen for further experiments in order to insert the desired SNP in 
the PMM2 promoter via the CRISPR HDR pathway.  
 
6.3.8 Successful co-delivery of the CRISPR-Cas9 system 
and ssODN in HepG2 cells  
The following experiment has been performed a few times. The results in Figure 60 show 
HepG2 cells after co-delivery of PX458_hPMM2_2 (1 µg) together with 425 ng of the 
Figure 59: Optimisation of semi reverse co-transfection of HepG2 cells testing different amounts of 
ssODN.  
CRISPR construct: PX458_hPMM2_2 (1 µg). All images were taken 72 hours post-transfection. A: 
Brightfield and GFP expression of HepG2 cells transfected with 210 ng of ssODN. B: Brightfield and 
GFP expression of HepG2 cells transfected with 340 ng of ssODN. C: Brightfield and GFP 
expression of HepG2 cells transfected with 425 ng of ssODN. D: Brightfield and GFP expression of 
HepG2 cells transfected with 850 ng of ssODN. All pictures were taken with the ZOE cell imager. 
Scale bar (bottom right corner): 100 nM. 
                         Chapter 6 
 156 
ssODN, which finally caused a sufficient gene edit at the CRISPR target site (see also 
Figure 61 and Figure 62).  
 
 
 
 
In total six 24 wells with 250,000 cells each were co-transfected during this experiment. 
The outcome was similar to what was observed previously. The number of transfected 
GFP-expressing cells (Figure 60, right) was not very high but enough for being separated 
from the non-transfected ones in a FACS cell sorting session. All “green” cells were 
collected in the same tube to get the maximum cell concentration possible. Only a few 
thousand (7,000) cells were collected, therefore the sorted cells were kept in culture for 
nine days for recovery and to obtain more cells to work with. After this period, the cells 
were harvested and divided in three parts: One portion was used for gDNA extraction, 
some cells were seeded in low density to obtain single cell colonies and the other portion 
was put in cryopreservation at -80C to be stored as a backup. From the extracted gDNA, 
the PMM2 promoter region of interest was amplified as described before and the 
amplicon sent for Sanger sequencing. The sequencing result is shown in Figure 61.  
 
 
 
 
  
Figure 60: Successful CRISPR co-transfection of HepG2 cells.  
Semi reverse co-transfection of CRISPR construct PX458_hPMM2_2 (1 µg) together with 425 ng 
of the HDR oligo donor template. Left panel: Brightfield image of transfected HepG2 cells 72 
hours after transfection. Right panel: GFP expression from PX458_hPMM2_2 in HepG2 cells 72 
hours post-transfection. Images were taken with the ZOE cell imager. Scale bar (bottom right 
corner): 100 nM. 
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Compared to the clean wt sequence (Figure 61 Bottom), the CRISPRed cells clearly 
have been edited as demonstrated by the shifted sequencing traces becoming apparent 
after the Cas9 cut site (Figure 61 top) due to indel formation. Furthermore, the gRNA 
target sequence was not detectable anymore within the sample sequence (Top), 
indicating the number of edited cells exceeded the number of non-edited cells. To 
analyse this precisely and as done before, the electropherograms were both put in the 
TIDE analysis software to quantify alterations between the two sequences and to assess 
the cutting efficiency of PX458_hPMM2_2. TIDE is not able to detect and quantify HDR 
events in a pooled sample, therefore the result represents the overall performance of the 
CRISPR-Cas9 system during this experiment only. Figure 62 shows the TIDE analysis 
performed.  
 
 
 
 
  
Figure 61: Electropherograms of successful CRISPR co-transfection of HepG2 cells.  
Pooled gDNA samples from co-transfected HepG2 cells with CRISPR construct PX458_hPMM2_2 
(1 µg) and 425 ng of the ssODN compared to a control (pooled gDNA wt HepG2 cells) were used. 
Both sequencing traces shown are in forward direction previously amplified with primer PMM2 
For3/Rev3 and sequenced with primer PMM2 For3. Highlighted in blue are the gRNA target 
sequences if possible. Green box marks the PAM site. Red arrow indicates the Cas9 cut site. A 
Top: Electropherogram of sequenced HepG2 gDNA amplicon after transfection with 
PX458_hPMM2_2 and ssODN. A bottom: wt electropherogram of PMM2 promoter ROI from 
HepG2 cells.  
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The result of the TIDE analysis coincided with a presumed strong performance of the 
CRISPR-Cas9 system as the total cutting efficiency within the pool of FACS-sorted cells 
turned out being quite high with 67%. The indel spectrum, represented by the top graph 
in Figure 62, again indicates deletions of one nucleotide as being the most prominent 
change introduced after DNA repair. But also, deletions of two to 10 nucleotides have 
been detected by the software with percentages ranging from 9.4% (2 nt deletion) to 
below 3.5% (four nt deletion) with seven nucleotide deletions being the least present. On 
the side of the insertions, those with one nucleotide being inserted were most dominant 
with 8.8%. However, some insertions of two, three, four, five and seven nucleotides with 
very low quantities were detected as well. As previously seen and expected, the aberrant 
sequence signal indicates significant changes after the Cas9 cut site indicated by the 
high green (sample sequence) and the low black peaks (control sequence) depicted in 
the bottom graph (Figure 62) and coincides with the altered sequence seen in the 
electropherogram of the CRISPRed cells.  
Figure 62: TIDE analysis comparing and quantifying the alterations of sequencing traces from 
HepG2 cells transfected with PX458_hPMM2_2 and the ssODN to a wt control.  
sgRNA sequence hPMM2_2 was provided as a reference string. Top: Indel spectrum and 
calculated cutting efficiency in percent. Bottom: Aberrant sequence signal of the two input 
sequence traces and the expected cut site. Black: wt sequence. Green: Sample sequence. Blue: 
Expected cut site. 
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In order to get an idea whether the HDR repair has worked in some of the edited cells, a 
test restriction digest (2.4.8) with the same PMM2 amplicon used for Sanger sequencing 
was performed (data not shown). The desired SNP creates an additional restriction site 
for StyI (Alias Eco130I), therefore the band patterns of digested DNA with and without 
the SNP should differ from each other on an agarose gel, if a sufficient number of cells 
have been repaired according to the ssODN (2.4.4). However, this was not detected on 
the basis of this experiment. To investigate, whether HDR events have happened within 
this population of cells, the single cell colonies seeded in low density underwent 
genotyping.  
6.3.9 Genotyping of CRISPRed single cell colonies  
In total 200 single cell colonies were picked from the low-density plates (2.4.7) and 
further expanded separately on 96-well plates for genotyping. They were split 
asymmetrically (70% and 30%) and cells were lysed and gDNA extracted when the 
majority of the clones on the 70% plate reached a confluency of above 70%, usually no 
longer than 3-5 days after splitting (2.4.7). To screen the clones for the desired mutation, 
first the PMM2 promoter region of interest was amplified as usual using the PMM2 
For3/Rev3 primer pair and on the basis of the gDNA obtained from each clone. The PCR 
was analysed on a 2% agarose gel and the amplicon further used for digestion with StyI 
to identify HDR-positive clones (2.4.8). Figure 63 shows a representative example of the 
analytical agarose gels after PCR and StyI digest of the first 31 clones.  
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The resulting DNA band after PCR was expected to run at 300 bp for both, wt and HDR-
positive clones. Although this was the case for the majority of clones, in some of them 
(clones 3, 8, 12, 13, 14, 19, 27, 28, and 30) the DNA band pattern differed significantly, 
with additional bands appearing for example at 1,000 bp (e.g. clones 3 & 19) and/or 450 
bp, 500 bp and 600 bp (e.g. clones 12, 13 and 28). It is possible, that in these cases a 
partial insertion of the CRISPR construct has happened explaining the larger DNA 
bands. Clone 8 stands out with only one additional DNA band just below the expected 
300 bp PCR product, which could be due to a bigger indel formation. Although these are 
no candidates for a positive HDR-clone, they at least indicate CRISPR activity during 
this experiment once more.  
The StyI restriction digest was meant to indicate whether the 300 bp PCR amplicons 
were simply expected to be wt clones or HDR-positive clones, with either two DNA bands 
at 246 bp and 50 bp or three bands of 144 bp, 102 bp and 50 bp, respectively (see 
section 2.4.8). Analysing the result after gel electrophoresis (Figure 63 B), none of the 
Figure 63: Genotyping of 31 single cell clones after co-transfection with 
PX458_hPMM2_2 and the homologous ssODN (representative for all 200 
clones screened).  
2% agarose gels showing the PCR amplicons before (A) and after StyI 
restriction digest (B). A and B: M: 100 bp DNA ladder. Lanes 1-8: Clones 1-
8. Lanes 9-14: Clones 9-14. Lanes 15-22: Clones 15-22. Lanes 23-30: 
Clones 23-30. Lanes 31-32: Clone 31 and wt control. Lane 33 (A only): 
Master mix only (negative control). Lane 34 (A only): H2O only (negative 
control). C: 100 bp DNA standard used for A and B (Figure 75).  
C 
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candidate clones (Lanes: 1-2; 4-7; 9-11; 14-18; 20-26; 29; 31) showed the DNA band 
pattern (144 bp, 102 bp and 50 bp) resulting from StyI digest when the desired c.-167G>T 
SNP was present. Comparable results were observed whilst screening the following 170 
single cell colonies (data not shown).  
Even though the chances of a positive HDR-clone faded after the StyI digest, clones 1, 
2, 4, 5 and 10 were sent for Sanger sequencing to spot-check the genomic nature of the 
present clones form this experiment. Three out of the five sequenced clones indeed did 
show sequence alterations and therefore were clearly edited – that counts for 60% and 
agrees with the expected cutting efficiency of 67% quantified by TIDE (Figure 62). This 
confirms a strong activity of the delivered CRISPR-Cas9 system and in particular the 
gRNA. However, the electropherograms (data not shown) of edited clones only show 
shifted sequencing traces indicating indels but not the distinct repair according to the 
provided ssODN which was desired.  
In conclusion, the CRISPR-Cas9 system on PX458 has worked sufficiently in HepG2 
cells as several clones were identified being edited by the system. However, there was 
no evidence of clones which were repaired after the HDR repair pathway and therefore 
a change of strategy for creating the HepG2 HIPKD cell model was decided.  
6.3.10 Successful co-delivery of Cas9 protein, sgRNA and 
ssODN in HepG2 cells – a CRISPR RNP approach  
In order to increase the chances of the HDR repair in CRISPR-edited HepG2 cells to 
happen, further experiments were carried out using Cas9 protein and sgRNA (RNPs) 
together with the homologous ssODN. The three components were delivered to the cells 
by electroporation rather than reagent-based transfection. For this purpose, gRNA 
hPMM2_2 was to be synthesised in sgRNA format (see section 2.4.5.2).  
After a few days of recovery, the electroporated cells were divided in three parts. The 
majority of cells was put in cryopreservation at -80C to save a backup population in 
stock. Three times 5,000 cells were seeded in low density using 10 cm cell culture dishes 
to obtain single cell colonies for genotyping later on. These were kept in culture for 14 
days at 37C and 5% CO2 and the medium was replaced every five days. The remainder 
of cells was used to extract gDNA in order to validate the overall outcome of this 
experiment and the pooled gDNA sample was used as a template for PCR amplification 
under familiar conditions (2.4.1.3). As a first quality control, the 300 bp amplicon was 
digested with the restriction endonuclease StyI to pre-check whether some HDR events 
have happened amongst the pool of CRISPR-targeted cells. The digested sample and 
an equally treated wt control were put on an 2% agarose gel for analysis (Figure 64).  
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The digested wt control sample shows the expected DNA band pattern, with products of 
246 bp and 50 bp in size (Figure 64, Lane 2). Differently, the restriction digest of gDNA 
from the experimental cells resulted in four DNA bands appearing after electrophoresis. 
Besides the two bands (246bp, 50 bp) from cutting at the wt site, an additional StyI site 
was generated and restriction resulted in two extra DNA bands, at 144 bp and 102 bp, 
as a consequence of HDR repair due to introduction of the desired HIPKD SNP.  
To further confirm mutagenesis in HepG2 cells the same pooled gDNA sample was sent 
for Sanger sequencing (Figure 65).  
 
 
 
 
 
 
 
 
 
  
Figure 64: StyI restriction 
digest of pooled electroporated 
HepG2 cells with Cas9 protein, 
sgRNA hPMM2_2 and the 
homologous ssODN compared 
to a wt control.  
Lane 1: 100 bp DNA ladder 
(Figure 75). Lane 2: Wt control. 
Lane 3: CRISPR-Cas9 edited 
sample. 2% agarose gel 
electrophoresis.  
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Compared to the clean wt sequence (Figure 65 B), a clear sequence shift as seen in the 
electropherogram showing the sequencing traces of the edited cells (Figure 65 A) 
indicates sufficient CRISPR activity and indel formation. The CRISPR site highlighted in 
blue shows a double peak for two nucleobases, guanine “G” and thymine “T”. Hence, 
both the wt and the mutant version, HepG2 cell pool as the desired SNP is a guanine to 
thymine substitution (c.-167G>T).  
The overall efficiency and quality, the CRISPR-Cas9 induced mutagenesis has worked 
with, was analysed in TIDE as usual (Figure 66).  
 
  
Figure 65: Electropherograms of pooled gDNA from electroporated HepG2 cells with Cas9 
protein, sgRNA hPMM2_2 and the homologous ssODN.  
A: CRISPRed DNA. B: wt. Both sequencing traces shown are in forward direction previously 
amplified with primer PMM2 For3/Rev3 and sequenced with primer PMM2 For3. The green box 
marks the PAM site. The red arrow indicates the Cas9 cut site. A: Electropherogram of 
sequenced HepG2 gDNA amplicon after electroporation. Highlighted in blue is the CRISPR site 
c.-167G. B: Wt electropherogram of the PMM2 promoter ROI from HepG2 cells. Highlighted in 
blue is the sgRNA target site.  
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The calculated cutting efficiency of the CRISPR-Cas9 system under guidance of sgRNA 
hPMM2_2 amounted to 40% in this experiment. As seen previously, the majority of 
changes were due to deletions of one nucleotide (10.6%), followed by deletions of two 
and nine nucleotides of above 4%. Deletions of sizes in between occurred with lower 
percentages, not defined numerically within the Indel spectrum (Figure 66, top graph). 
Some insertions of one nucleotide were detected with a frequency of 3.3% and others 
from two to ten nucleotides were acknowledged with lower percentages. About 50% of 
the compared sequences were identical with 0% changes. The reconstruction of the 
aberrant sequence signals in the bottom graph (Figure 66) matches with the appearance 
of the two electropherograms, showing a significant difference in the sequencing traces 
after the Cas9 cut site. This indicates indel formation and is demonstrated by the high 
and low peaks in green and black, representing the edited and wt DNA sequences, 
respectively.  
Figure 66: TIDE analysis comparing and quantifying the alterations of sequencing traces from 
HepG2 cells edited with Cas9 protein, sgRNA hPMM2_2 and the homologous ssODN.  
Comparison to wt control. sgRNA sequence hPMM2_2 was provided as a reference string. Top: 
Indel spectrum and calculated cutting efficiency in percent. Bottom: Aberrant sequence signal of 
the two input sequence traces and the expected cut site. Black: Wt sequence. Green: Sample 
sequence. Blue: Expected cut site.  
                         Chapter 6 
 165 
6.3.11 Genotyping of single cell HepG2 colonies to obtain a 
homozygous HIPKD clone  
In total 144 single cell HepG2 clones CRISPRed with RNPs, which all had gone through 
the entire editing process were included in the screening to identify the precise 
genotypes needed for further experiments. For a full set of desired clones, it was of 
interest to find at least and most importantly one positive HIPKD clone homozygous (c.-
167G>T/c.-167G>T) for the desired SNP within the PMM2 promoter and additionally at 
least one homozygous wt (c.-167G/c.-167G) clone. In order to find these clones, the 
gDNA of each clone was extracted, the region of interest amplified in a standard PCR 
(2.4.1.3) and the amplicons used as a template for restriction digest with StyI. As 
described previously (see section 6.3.9) to do this, single cell colonies were picked, kept 
separated in 96 well plates and split asymmetrically with different cell densities (70% and 
30%). gDNA of each clone was extracted after a few days of growth (70% 96 well plate) 
and amplified with the PMM2 For3/Rev3 primer pair. Each amplicon then was digested 
with StyI, to enable the identification of HDR events within the population of screened 
HepG2 clones (see Figure 26). The results obtained from 29 clones after gel 
electrophoresis of the samples are shown in Figure 67 which depicts a representative 
example for both, the PCR reaction and the StyI restriction digest.  
The backup plate (30% 96 well plate) was kept in culture to keep every clone included 
in the screening alive.  
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The majority of all clones included in the genotyping PCR resulted in the expected 
amplicon running at 300 bp as seen on the example in Figure 67 A. About 12% of all 
clones included in the screening showed additional bands of larger sizes between 400 
and 1,200 bp likely as a result of large indel formations. This is reflected by clones 14, 
16, 20, 22 and 25 (Figure 67 A). However, all 144 samples were incorporated in the StyI 
restriction digest, resulting in a variety of band patterns emerging as seen in Figure 67 
B, thus indicating a mixed population of genotypes amongst all the single cell HepG2 
clones screened (here represented by 29 clones). Table 14 lists the combinations of DNA 
band patterns and the frequency they appear with, within the population of all 144 edited 
HepG2 clones screened as a result of StyI restriction.  
 
 
 
 
 
 
 
Figure 67: Genotyping PCR and StyI restriction digest of 29 HepG2 single 
cell colonies edited with Cas9 protein, sgRNA hPMM2_2 and the 
homologous ssODN.  
Representative example for all 144 clones screened. 2% agarose gels 
showing the PCR amplicons before (A) and after StyI restriction digest (B). 
A and B: M: 100 bp DNA ladder (Figure 75). Lanes 1-8: Clones 1-8. Lanes 
9-16: Clones 9-16. Lanes 17-24: Clones 17-24. Lanes 25-29: Clones 25-
29. Red circles indicate clones with DNA band patterns particular for a 
homozygous HDR. C: 100 bp DNA standard used for A and B (Figure 75). 
C 
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Table 14: Six different categories of DNA band patterns observed after StyI restriction digest.  
144 single cell HepG2 clones electroporated with CRISPR-Cas9 RNPs and ssODN were 
screened. Column 2: Different DNA band patterns present. Column 3: DNA band sizes according 
to pattern. Column 4: Possible genotype(s). Column 5: Number of clones per category. Wt: c.-
167G/ c.-167G. HDR: c.-167G>T/ c.-167G>T. Indel: Random insertions and deletions at the 
CRISPR target site.  
 # DNA bands DNA band sizes (bp) Interpretation # of clones 
1 2 246, 50 wt/wt; wt/Indel; Indel/Indel 38 
2 3 246, 230, 50 wt/Indel 9 
3 3 144, 102, 50 HDR/HDR 8 
4 4 246, 150, 100, 50 HDR/wt; HDR/Indel 39 
5 5 246, 230, 150, 100, 50 HDR/Indel 10 
6 multiple 50 – 1,200 Indel/Indel; wt/Indel; HDR/Indel 27 
Total number of clones count: 131* 
* Variation in total number of clones due to empty (no DNA) samples or results not clearly interpretable  
 
 
For further experiments, the aim was to ideally identify three homozygous HDR clones 
and three clean wt clones to provide a control group which has gone through the same 
experimental process. In total, eight out of all these clones showed the HDR specific 
band pattern and therefore seemed to be homozygous for the c.-167G>T mutation, here 
represented by clones 11 and 19 (Figure 67 A, red circles). The majority of genotyped 
HepG2 clones showed DNA band patterns indicating indel formation after StyI digest. 
However, according to their DNA band pattern 38 clones (category 1, Table 14) 
theoretically remained wt and although the presence of small indels could not be 
excluded, these were considered to be potential candidates for the control group. In order 
to identify the desired clones all eight clones appearing homozygous for the c.-167G>T 
mutation and five seemingly clean wt clones were included in Sanger sequencing 
analysis for confirmation.  
Figure 68 depicts the electropherograms of positive homozygous HDR clones and clean 
wt clones only. 
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Figure 68: Sanger sequencing of positive HepG2 homozygous HDR (c.-167G>T/c.167G>T) and 
wt clones obtained from CRISPR-Cas9 editing and HDR repair.  
Nucleotide position c.-167 to be edited is highlighted in blue. Green boxes mark the PAM sites. 
Red arrow indicates the Cas9 cut sites. All sequencing traces shown are in forward direction 
previously amplified with primer PMM2 For3/Rev3 and sequenced with primer PMM2 For3. A: 
Electropherograms of three homozygous clones (Clone 1, Clone 2, Clone 3) showing the c.-
167G>T SNP. B: Electropherograms of three clean wt clones (WT Clone 1, WT Clone 2, WT Clone 
3) with no SNP included. C: Electropherogram of non-edited HepG2 wt cells. Blue arrow marks 
the gRNA target site. 
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In the case of the electropherograms in Figure 68 no indels were expected in these 
sequencing traces and therefore performing a TIDE analysis was not relevant here. 
However, Figure 69 depicts the TIDE analysis for homozygous Clone 3 exemplary for all 
homozygous clones for the purposes of illustration.  
 
 
 
TIDE quantifies sequence alterations by aligning the two input sequencing traces and 
then calculates the overall efficiency of CRISPR-Cas9 of a particular experiment. 
Therefore, it is not surprising that the cutting efficiency was determined 0% or nearly 0% 
in the case of the verified clones, as those compared sequences differ at one 
(homozygous HIPKD clones) or none (wt clones) nucleotide position only. In addition, as 
expected, no insertions or deletions were detected by the software as seen in the top 
graph (Figure 69). The aberrant sequence signal by contrast nicely confirms sequence 
equality of both, wt and mutant, apart from one large peak indicating the desired SNP in 
the test sample sequence (green) due to CRISPR editing and HDR repair, appearing 
just before the Cas9 cut site (blue) and matching the expectation thoroughly.  
Figure 69: TIDE analysis comparing and quantifying the alterations of sequencing traces of 
positive HDR Clone 3 homozygous for the c.167G>T SNP to a wt control.  
sgRNA sequence hPMM2_2 was provided as a reference string. Top: Indel spectrum and 
calculated cutting efficiency in percent. Bottom: Aberrant sequence signal of the two input 
sequence traces and the expected cut site. Black: wt sequence. Green: Sample sequence. Blue: 
Expected cut site.  
                         Chapter 6 
 170 
All six clones (3x HDR positive (c.-167G>T/c.167G>T), 3x wt) were expanded in cell 
culture and their genotypes reconfirmed with gDNA obtained from each clone afterwards 
(Data not shown). Unfortunately, wt clones 1 and 2 were not clean anymore after 
expansion as indels have appeared in the sequence (data not shown).  
For further experiments, stocks of each clone, homozygous and wt, were prepared for 
cryopreservation at -80C.  
6.3.12 Testing positive homozygous HepG2 HIPKD clones for 
off-targets  
Homozygous HIPKD clones were only screened for the most likely off-target effects as 
calculated by CRISPOR and CHOPCHOP, the tools used for gRNA design. Only one 
off-target with two mismatches was predicted by CRISPOR and chosen to be screened 
for. All the other ones had three or more mismatches and were not incorporated in the 
analysis as those off-target effects are very unlikely to happen. The off-target chosen to 
look at in the homozygous HIPKD clones is located within the first intron of the gene 
TTTY14 on chromosome Y. The sequence variations between gRNA hPMM2_2 and the 
off-target are shown below (Table 15).  
 
Table 15: Difference between gRNA hPMM2_2 and off-target sequence.  
Mismatches are marked in red. 
 Gene Sequence PAM 
gRNA hPMM2_2 PMM2 TTCCTGGACCGCAACTCCCA GGG 
Off-target ChrY TTTY14 TTCCTGGCCCGTAACTCCCA TAG 
 
 
The Sanger sequences of all homozygous HIPKD clones after amplification with specific 
primers were compared to a wt control HepG2 sequence of the same region. No 
difference between the sample and control sequence was observed. Hence, gRNA 
hPMM2_2 did not induce the predicted potential off-target effect of on chromosome Y 
(data not shown).  
6.4 Discussion  
The CRISPR-Cas9 system has rapidly become the gold-standard method for genome 
editing projects over the past five years within the fields of biomedical and biotechnical 
sciences to create model organisms to study human disease. Moreover, it us used by 
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the industry sector to improve crops and livestock breeding. It has surpassed the 
advantages of similar techniques, such as ZNFs (zinc finger nucleases) and TALENs 
(transcription activator-like effector nucleases) due to its ease of use, cost-effectiveness 
and its efficiency in nearly any cell type. ZNFs and TALENs are site-specific 
endonucleases fused to a DNA binding domain (Protein-DNA binding) which need 
elaborate engineering and cloning for every single locus to reach specificity. The 
CRISPR-Cas9 system by contrast, only needs the individual gRNA for targeted gene 
editing and functions after the RNA-DNA hybridisation principle – thus, providing a much 
simpler option in terms of design and synthesis 270,271.  
Cong et al. and Mali et al. are the pioneers in demonstrating that CRISPR-Cas9 system 
can be used to successfully genome edit mammalian cells. Since then, the system has 
been extensively used in biomedical research and contributed to the generation of 
multiple model systems in eukaryotic cells and animals, such as zebrafish, mice and 
monkey 272-274. Moreover, the first trials applying CRISPR in humans to correct disease-
causing mutations are ongoing since 2016 275,276.  
For the reasons and advantages mentioned above, its preciseness and reliability, the 
CRISPR-Cas9 system was chosen for this study to generate a HIPKD cell model with 
HepG2 cells having the PMM2 promoter mutation incorporated in homozygous state. 
However, and despite its simplicity and reliability opposed to other genome editing 
methods there are still some challenges involved, especially when genome engineering 
a cell line for the first time. First of all, it is essential to find and chose a strong gRNA with 
high specificity and minimum risk of producing off-target effects at the same time, as 
those can have severe effects on the genome. To simply knock-out a genes’ function 
following the NHEJ repair, various regions within the coding region of the gene of interest 
are possibly suitable to be targeted with CRISPR 277. Scientist have created libraries with 
highly efficient predesigned gRNAs commercially available which are specific for a broad 
range of genes with often more than one appropriate gRNA per gene. Aiming for HDR 
to introduce a change at a particular site within the DNA, the search for an optimal gRNA 
target sequence is far more limited. It is essential that the specific gRNA binds close to 
the site to edit. Ideally, within a distance of no more than 10 nt up- or downstream of the 
desired genome edit, as with increasing distance between gRNA target-site and site of 
modification the editing efficiency decreases significantly 278. A successful CRISPR-HDR 
gene edit is therefore highly dependent on PAM motifs being in very close proximity to 
the target site. In the case of the HIPKD HepG2 cell line, two potential gRNA target 
sequences just adjacent of position PMM2 c.-167G were chosen and first tested for their 
efficiency in HEK293T cells. Prior to transfection they were assessed for their specificity 
in silico with CHOPCHOP and CRISPOR. Yet, our experience demonstrates, that such 
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in silico tools are still limited: according to both those CRISPR web tools, gRNA 
hPMM2_1 seemed the better candidate to use, reaching higher specificity scores 
compared to gRNA hPMM2_2. Moreover, in CHOPCHOP gRNA hPMM2_2 was not 
even categorised as being a reasonable gRNA to use. However, after transfections and 
subsequent TIDE analysis gRNA hPMM2_2 gave the better result (Figure 53, Figure 54) 
with a higher cutting efficiency and was therefore chosen to proceed with in the actual 
experiment with HepG2 cells to generate the desired HIPKD cell model.  
Such difficulties with the different web-based search tools arise for example due to 
variation of parameters the developers include to predict unwanted off-target effects of 
the gRNAs observed and the number of mismatches they consider 274. CHOPCHOP for 
instance developed its own unique method which only searches for potential off-targets 
with maximum three mismatches and limits potential off-targets to the 20 bp upstream of 
the PAM without for example taking possible DNA “bulges”(unpaired short DNA which 
can loop-out) 279 into account, which are also prone to cause off-target effects 279. A 
general restriction is also, that many tools rely solely on prediction of sequence homology 
between the gRNA and the targeted genome, often resulting in inaccurate rankings due 
to the lack of actual experimental data. The first version of CHOPCHOP is such an 
example 280. But as new experimental methods are on the rise, generating unbiased 
data, this helps to improve predictions and to identify “true” off-targets by providing more 
insights into the molecular mechanisms of the CRISPR-Cas9 system and its affinity to 
the targeted DNA. CRISPOR has been developed more recently and aims for collecting 
all such experimentally confirmed off-targets known so far to provide a more elaborate 
service and to improve the assessment of off-target effects when designing a CRISPR 
experiment. In addition, it includes off-targets with up to four mismatches and provides 
also the numbers of off-targets which are not within the seed region 215. The seed region 
is the first 10 bp of the 3’ gRNA target sequence just adjacent to the PAM, to which the 
gRNA begins to anneal to its target. Homology between the gRNA and DNA seed 
sequences is crucial because only if they match properly the gRNA will continue to 
anneal completely to mediate Cas9 cleavage. The gRNA first scans potential target sites 
to ensure specificity, a safety mechanism which prevents cutting of the host genome, 
considering that the CRISPR system is a defence mechanism in prokaryotes. In 
research, this capability of the gRNA helps to minimise unwanted off-target effects. In 
the case of mismatches within the seed region the system likely abolishes cleavage and 
therefore the risk of causing off-targets is significantly reduced. It is the mismatches 
outside the seed region, distal of the PAM that are responsible for the risk of off-targets, 
as the gRNA is more likely to tolerate those 281. That explains why tools like CRISPOR 
distinguish between potential off-targets within and outside the seed region to estimate 
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a gRNAs specificity. Overall, CRISPOR seems to be a reliable tool to trust and therefore 
the poor ranking of gRNA hPMM2_2 in CHOPCHOP was not pivotal. Although CRISPOR 
identified 128 potential off-targets (opposed to 9 in CHOPCHOP) for gRNA hPMM2_2, 
none of them included mismatches outside the seed region and therefore those off-
targets were unlikely to happen (Figure 47). This was confirmed by looking into one of 
the potential off-targets to be introduced by gRNA hPMM2_2 in the homozygous HIPKD 
HepG2 clones (data not shown). CRISPOR predicted one off-target effect with two 
mismatches on chromosome Y, this was the most likely one to happen as the other off-
targets predicted had three or more mismatches. The rule of thumb here is, the more 
mismatches within the sequence the less likely the off-target effect to happen 282. PCR 
and subsequent Sanger sequencing of the off-target region on chromosome Y showed 
that no off-target had been introduced.  
Additional issues getting the CRISPR experiments with HepG2 cells to work were related 
to the transfection itself, the delivery method and the format in which the system was 
supplied. The efficiency of transfection heavily depends on the cell line of choice as some 
cell lines are easy and others hard-to-transfect for various reasons. HepG2 is known to 
be a difficult-to-transfect cell line. This is also demonstrated by the lower amount of GFP 
expression in HepG2 cells compared to HEK293T cells (Figure 52, Figure 55). The first 
attempts to transfect HepG2 cells overall failed (data not shown) and a lot of optimisation 
in terms of culture conditions, subculturing and handling prior to transfection was 
needed. HepG2 cells are hard-to-transfect mainly due to their disposition to grow in 
clumps. This significantly reduces the accessibility of the cell membrane, affecting the 
transfection efficiency. Overall, several external factors have their influences on the 
success or failure of transfection and need to be addressed 283: It is essential that the 
cells to transfect are healthy and actively dividing. Different seeding densities were also 
tested as this also varies across cell types. Changing the procedure from traditional 
transfection (adherent cells) to the semi-reverse transfection (cells in suspension) made 
a big difference and improved the uptake of the CRISPR system. In order to advance 
the overall health state of the HepG2 cell population used for this study, the frequency 
of subculturing was increased, and passage numbers were kept below 15 passages. 
Furthermore, the composition of the culture medium was improved by adding additional 
growth factors to promote cell growth (personal communication). To prevent HepG2 cells 
from clumping a lot of effort was put into the separation of the cells, which has contributed 
to increase transfection efficiency.  
Chemical, reagent-based transfection was used initially to deliver the CRISPR-Cas9 
system on a plasmid, as well as the HDR repair template to HepG2 cells. After some 
optimisation this protocol gave a good overall cutting efficiency after FACS-sorting the 
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GFP-expressing (the transfected) cells. However, after genotyping about 200 single cell 
colonies (Figure 63) and although it induced sufficient mutagenesis as demonstrated by 
clones being repaired through the NHEJ pathway, this approach did not provide any 
evidence for clones being repaired through the HDR pathway. Hence, we initially did not 
witness the inclusion of the desired SNP within the PMM2 promoter. It is recognised that 
there is a significant difference in terms of efficiency between NHEJ and HDR, with HDR 
being by far the rarer event, which shows its impact here 274,284 One major reason surely 
is that an HDR is restricted to late S- and G2-phase, when DNA-replication is completed 
during the cell cycle and a repair template is required. The NHEJ can take place during 
G1, S- and G2-phase, hence competes with the HDR pathway 285,286. Plasmid-based 
delivery of the system holds some limitations disadvantageous for CRISPR. Part of the 
plasmid for example can be integrated in the host genome randomly at the on- and also 
off-target sites, with the latter being difficult to recognise 287. Such events were observed 
in the clones screened with large additional bands appearing after PCR of the CRISPR 
target region (Figure 63). Another obstacle of using CRISPR plasmid DNA is its 
translocation into the nucleus through the nuclear pore complex (in non-dividing cells) to 
allow transcription of the system. As CRISPR expression plasmids are quite big, this is 
limiting their ability to move smoothly through the cytoplasm with the potential to 1) not 
reaching the nucleus at all and 2) getting degraded by cytoplasmic nucleases, thus 
reducing CRISPR efficacy. The half-life of plasmid DNA within the cytoplasm amounts 
to 50-90 minutes 288. Moreover, aiming for an HDR event by delivering a ssODN (DNA 
repair template) in parallel, part of it might got degraded already before Cas9 protein and 
sgRNA were synthesised and active, as HepG2 cells were quite slow with only a few 
“green” glowing cells being observed after 24 hours post transfection. Finding the desired 
homozygous HIPKD clone seemed very unlikely continuing with the plasmid-based 
approach. For this reason, the experimental set-up was changed to using CRISPR 
ribonucleoproteins (Cas9 protein and sgRNA complexes, RNPs). Those RNPs were 
delivered to the cells via electroporation as it significantly enhances the frequency of 
CRISPR compared to reagent-based delivery, demonstrated by different studies. This 
approach was successfully applied resulting in three homozygous HIPKD clones (Figure 
67, Figure 68). The big advantage of using CRISPR RNPs is that once within the 
cytoplasm, the system is ready and active to immediately cleave the targeted DNA. 
Simultaneously, RNPs get degraded rapidly within the cytoplasm, therefore contributing 
to reduced off-target mutations compared to CRISPR plasmids 274,289,290. In conclusion, 
this CRISPR experiment provides a nice example demonstrating the power of CRISPR 
RNPs compared to a traditional plasmid-based approach. CRISPR RNPs are more 
efficient as they are active once within the cell and are also more reliable due to reduced 
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off-target effects compared to CRISPR plasmids and the risk of large plasmid insertions 
at on- and off-target sites is also prevented.  
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Chapter 7: General Discussion  
The goal of this study was to gain insights into the disease mechanisms of HIPKD. In the 
beginning, the patients presented with an ARPKD-like polycystic phenotype with 
additional appearance of hyperinsulinism. They were initially tested for mutations in the 
key genes known to be responsible for those rare disorders under the assumption that 
they may be affected by two separate disorders. However, the causative mutation could 
not be identified. Thus, the combination of these two phenotypes without the involvement 
of any known mutations plus the subsequently noted presence of liver cysts in some 
patients strongly suggested that the patients presented a novel disorder, limited to 
kidney, pancreas and liver which had not been described before. This motivated us to 
investigate the genetic cause of this unknown rare disease. The identification of the 
PMM2 promoter variant (c.-167G>T) implicated the exact same gene that triggers CDG-
1a, a multisystem disorder which is caused by defective protein N-glycosylation due to 
loss-of-function mutations in PMM2. This prompted the question of what mechanisms 
underlie the difference between the restricted HIPKD phenotype and CDG-1a.  
In vitro and in silico studies helped us to identify some important key findings suggesting 
a dysfunctional PMM2 gene regulation as the major point of the HIPKD disease 
mechanism, which is restricted to the three affected organs due to presumably altered 
tissue-specific transcription (hypothesis). This study shall contribute to a better 
understanding of the underlying disease mechanisms of HIPKD and to work towards the 
proof of this hypothesis.  
7.1 The PMM2 promoter mutation and gene pleiotropy  
As outlined before, mutations in the PMM2 gene are related to the severe multisystem 
disorder CDG-1a 180. However, careful clinical observations excluded this diagnosis in 
our patients. This was in particular demonstrated by 1) a normal glycosylation pattern of 
transferrin which is altered in CDG-1a and a typical indicator for the disease and 2) the 
restricted HIPKD phenotype. While renal cysts and hyperinsulinism have been described 
as part of the spectrum of manifestations of CDG-1a, consistent with impaired 
glycosylation as the common underlying basis, the classification of HIPKD as a mild form 
of CDG-1a was excluded as neurological features, an invariable characteristic in CDG-
1a patients, were absent in our HIPKD patients. In CDG-1a the brain is most sensitive to 
the loss of PMM2 function 291, whereas there is no evidence that the brain is affected in 
HIPKD. The non-coding PMM2 mutation somehow shifts the organ-sensitivity related to 
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PMM2 dysfunction and limits the disease manifestations distinctively to kidney, pancreas 
and liver, while PMM2 activity remains apparently sufficient in the rest of the body. The 
impact of the promoter mutation results in an organ-specific impairment and thereby 
distinguishes HIPKD from CDG-1a. Hence, our findings clearly indicate PMM2 pleiotropy 
– the ability of one gene to cause different phenotypes – which has not been reported 
before. Such gene pleiotropies are common phenomena of central evolutionary origin 
when complex organisms have formed from a restricted group of genes 292. Although 
known for more than 100 years now, mechanisms of pleiotropies and how they develop 
are poorly understood. The effects of gene pleiotropies are quite versatile as some result 
in only two different disorders whilst others cause multiple different abnormalities. 
Different mutations in TRPV4 are the genetic cause for at least nine syndromes with 
phenotypes ranging from neuromuscular disorders to skeletal dysplasia 293. Another 
example are allelic variants in IL-10, which form a complex group of different autoimmune 
and inflammatory disorders, such as asthma, psoriasis, tuberculosis or Bowel disease 
which are either the result of enhanced IL-10 function or its deficiency due to genetic 
alterations (dinucleotide repeats, SNPs) 294.  
The classic example within the renal field are mutations in the OCRL1 gene, either 
causing the systemic Lowe syndrome which presents with oculocerebrorenal features or 
Dent disease. Dent disease is exclusively limited to the kidneys and specifically the 
proximal renal tubules. It is categorised as one cause of renal Fanconi syndrome and 
presents characteristic features such as low-molecular weight proteinuria, glycosuria, 
and phosphaturia. It was first linked to mutations in the CLCN5 gene before OCRL1 was 
discovered as a second disease gene 222,295. As a potential disease mechanism, another 
enzyme with similar function as the one encoded by ocrl1 might compensate for ocrl1 
disruption as it has been observed in mice. If this or a similar mechanism applies in 
human, variation in terms of the expression of the compensating enzyme amongst 
different tissues could explain the restricted Dent phenotype seen in some patients with 
particular OCRL1 mutations, which differ from Lowe syndrome 296.  
Studies characterising pleiotropic genes, SNPs and proteins helped to identify their 
contribution and impact on human disease 297: About 12% of disease-causing proteins 
are considered of pleiotropic nature and typically involve rare rather than common 
genetic variation, as it is the case also for HIPKD. Interestingly, the majority of pleiotropic 
SNPs are coding mutations within exonic areas of the affected genes – in contrast to 
HIPKD. Thus, HIPKD is a rare example of genetic pleiotropy with involvement of a non-
coding variant causing human disease.  
The mechanisms of pleiotropic effects are not well understood but are likely highly 
versatile depending on the molecular and metabolic involvement of the encoded protein. 
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For HIPKD we expect the PMM2 promoter mutation to cause a problem on the gene 
regulatory level that results in dysfunctional PMM2 expression with an impact in the three 
affected organs, kidney, liver and pancreas only, thus implying a tissue-specific 
dysregulation of the gene. Tissue-specific enhancer-promoter interactions indeed have 
been described to promote pleiotropic effects during development with both enhancer 
and gene promoters enclosed within distinct highly conserved chromatin structures 
called topologically associating domains (TADs) or chromatin loops which are also 
described as “regulatory landscapes”: for example, the regulators of the vertebrate gene 
Hoxd13, which is needed for the development of digits or external genitals, are organised 
in such a TAD. Deletions of parts of this TAD have reduced the transcription rates of 
Hoxd13 in digits compared to genital tubercles, thus validating 1) TADs as a gene 
regulatory unit for tissue-specific transcription and also 2) reduced gene expression due 
to altered transcriptional regulation 298. Similar principles for the disease mechanism are 
assumed to be the case in the HIPKD cell types.  
Recently, two interesting cases which describe pleiotropic diseases with parallels to 
HIPKD were reported. Gabbay et al. describe PTF1A pleiotropy: Homozygous truncating 
coding mutations in the PTF1A gene are known to cause pancreatic and cerebellar 
agenesis. However, they identified novel compound heterozygous mutations in the same 
gene, a truncating one on one allele and the other one in a pancreatic enhancer element. 
Together, these lead to the manifestation of pancreatic agenesis only 299. The second 
study reported how a novel homozygous SNP creates a neo-ARE (a new AU-rich 
element) at the 3’-UTR of the SLC4A4 gene which significantly reduces the expression 
of the gene and results in an isolated ocular phenotype whereas coding mutations in 
SLC4A4 cause a systemic phenotype which manifests in the eyes and the kidney and 
often induce also intellectual and growth abnormalities. They suggest that the neo-ARE 
interacts with a mRNA decay protein which destabilises the SLC4A4 mRNA tissue-
specific in the eye only due to the involvement of tissue-specific transcription factors of 
yet unknown identity 300.  
In both cases pleiotropic effects 1) are based on non-coding mutations with 2) distinct 
disease phenotypes, due to 3) tissue-specific alteration of the regulation of the affected 
gene. It will be interesting to follow future investigations on the disease mechanisms of 
these two cases.  
7.2 HIPKD and tissue-specific transcription  
Various factors have their influence on the complex development of mammals. As 
outlined above, one of them is gene pleiotropy but also protein modification and diverse 
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splicing patterns contribute to differentiation during development and later on. However, 
a major part influencing such processes relies on the genome and genomic regulation 
itself 301. Although the genetic material within the nucleus of every single cell of an 
organism is virtually identical, the spatiotemporal gene expression amongst different 
tissues is highly versatile to allow the development of unique functions in each tissue. 
Such tissue-specific transcription is crucial for the development of multicellular 
organisms when stem cells actually differentiate into particular tissues and organs 302. 
Transcriptional processes are highly organised and controlled by different regulatory 
elements (e.g. enhancer, repressors, activators, insulators, silencer, enhancing RNAs) 
which can be bound by transcription factors, epigenetic modifications (DNA methylation, 
histone modification) and also the chromatin landscape of particular regulatory TADs 
mentioned earlier 303. It is thus not surprising that abnormalities of transcriptional 
regulation that change gene expression are often associated with human disease, as it 
is the case for HIPKD, for example, in cancer 304. The involvement of such non-coding 
SNPs in human disease are well recognised since the early 2000’s 305, however the 
association of gene regulation and disease-phenotypes and their mechanisms, in 
particular on the cell-specific level, raises many questions still to answer 306. Thus, our 
study of HIPKD and our ambition to decipher its pathomechanism will shed light onto the 
molecular actions of non-coding disease-causing variants.  
More than 1 million enhancer elements exist which are responsible to regulate about 
20,000 protein-coding genes only. On average, that accounts for at least four enhancer 
elements which interact with a single gene in each cell type of the human body 307,308. 
Hence, genetic variation and complex morphology is not predominantly driven by the 
variety of genes and their promoters but by their transcriptional control instead 309. About 
98% of the entire genome is occupied by non-coding DNA and around 40% of it are 
predicted to be of regulatory nature 310. So-called gene deserts can stretch over 
distances in the megabase range and indeed long-range promoter interactions with distal 
elements are not unusual, forming transcriptional networks. Chromatin conformation 
studies have identified more than 1,000 of such long-range interactions independently in 
three different human cell lines 308. Due to their high abundance, such regulatory regions 
are prone to disease-causing SNPs which can alter the expression level of the allele on 
which a transcription factor binding site is disrupted. This is easily measurable when such 
mutations appear in heterozygous state and was demonstrated for example in B-cells 311 
and is also supported by our data with a significantly reduced expression of the allele 
controlled by the mutant promoter in the compound heterozygous HIPKD promoter 
variant. Hence, our HIPKD case provides an example of a SNP which co-localises with 
a regulatory element which is disease-associated in a tissue-specific fashion. However, 
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it is not a long time ago when the non-coding part of the human DNA, which occupies a 
remarkable 98% of the entire human genome, was majorly ignored by scientists and 
declared as “Junk” DNA 312. Nowadays, we are aware of its importance and the 
completion of the human genome project in 2003 eventually has allowed scientists to 
vastly explore the entire human DNA and generate huge sets of data for analysis, made 
processable thanks to modern genetics 313. Since then SNPs have been identified to be 
the most common unit of genetic variation. The study of millions of such SNPs 314 and 
their integration in genome-wide association studies (GWAS) has helped to rapidly 
identify disease-associated variants and have shown that 93% of such variants indeed 
lie within the non-coding formerly called “Junk” DNA regions.  
Maurano et al. performed elaborate GWAS-SNP analyses on disease-causing variants 
in the non-coding regulatory DNA 306: In this respect, they found that multiple disease-
causing variants predominantly enrich in transcription factor binding sequences and 
exert rather small effects – at least that is the case for common variants. Such variants 
are defined as small or weak effect variants which modulate the chromatin conformation 
in distinct areas rather than influencing entire regulatory networks. In addition, they have 
demonstrated the selective enrichment of disease-associated variants in particular cell 
types and tissues related to common diseases, for example the T-cell subtype Th17 in 
Crohn’s disease. Moreover, on the basis of DNAse I mapping to explore DNAse I 
hypersensitivity sites (DHSs; marker for regulatory DNA regions), they noted a distinct 
cell-specific localisation of multiple independent GWAS SNPs in disease-relevant cell 
types or tissues for many common diseases, suggesting a tissue-specific regulatory 
effect of such variants. They also pick up on what we today call TADs and how these are 
modified by transcription factor binding which results in “alterations of chromatin 
structure” as it was already reviewed and described in 1988 by Gross and Garrard, at 
the time termed “nucleosomal substructures” 315. In this context, they also point out that 
the “weak” variants can change the “local chromatin architecture”. Although these 
observations are related to common variants the concept however is in favour of our 
hypothesis of an altered tissue-specific loop formation in HIPKD caused by the PMM2 
promoter variant in the ZNF143 binding site.  
A recent study on how tissue-specific gene regulation works was performed by 
Sonawane et al., profiling genotype-tissue expression in 38 tissues 316: They concluded 
that tissue-specific transcription is not so much dependent on individual tissue-specific 
transcription factors but rather on entire transcription networks formed of network edges 
(connections between transcription factors and target genes), network nodes (genes) 
and regulatory nodes (transcription factors). Knowing that only 2,000 genes encode for 
transcription factors it is unlikely that the multiple tissue-specific processes and functions 
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rely solely on this small number of transcriptional active proteins. Instead, their data 
support the existence of global core networks shared by common and tissue-specific 
biological processes which are adjusted and tailored particularly to those unique 
processes by building “tissue-specific regulatory paths”. They postulate that it is the 
target-pattern which makes transcription factors exert their tissue-specific role rather 
than their differential expression. In conclusion, both tissue and non-tissue-specific 
transcription factors seem to mediate specific biological processes according to their 
data. This should be kept in mind whilst further investigating the HIPKD 
pathomechanism.  
7.3 HIPKD and chromatin loop formation  
Only a few years ago a more substantial analysis on the higher order of the organisation 
of the 3D genome within the nucleus was performed based on the Hi-C methodology 317: 
These data sets have helped to identify TADs as frequent and fundamental chromatin 
structures which form large (megabase-sized) interactive, gene regulatory regions that 
allow for distinct interactions between gene promoters and their regulatory elements 
which otherwise were too far away from each other within the linear genome 318. These 
TADs are highly conserved structures suggesting their early development during 
evolution 317. Typically, these TAD and sub-domains are limited by CTCF motifs 
(CCCTC) which are bound by CTCF zinc finger proteins. CTCFs colocalise with TAD-
stabilising cohesin ring structures 319 and are architectural proteins which separate 
chromatin regions and hence chromatin interactions. They function as insulators within 
gene regulation but also support distinct regulatory interactions within the TAD they are 
anchoring – they build regulatory hubs within the genome in which regulatory elements 
are enriched to facilitate promoter-enhancer interaction across long distances rather than 
just blocking unwanted interactions 224. TADs can be further subdivided into smaller 
chromatin loops and sub-TADs which often form tissue-specific regulatory units. This 
was seen in a mouse model, where novel enhancer-promoter interactions formed after 
disturbing CTCF binding within such a sub-TAD 225. Dysregulation of gene expression 
due to derangement of CTCF binding indeed has been observed in many different cell 
types and also as a cause for human disease 320,321.  
This indicates the importance of TAD formation for gene regulation, in addition to 
enhancer elements and transcription factors and also reflects the complexity of the 3D 
chromosomal organisation 322.  
We have identified that PMM2 lies within a structural chromatin loop 220 kb in size which 
is limited by CTCF motifs in the HIPKD-relevant tissues as revealed by our in silico 
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analysis for HepG2 cells (Figure 35). The interaction of CTCF with other architectural 
proteins has been well observed to form a variety of sub-loops or sub-TADs (also called 
“functional loops”), which facilitate tissue-specific interactions 323.  
One such key architectural protein is ZNF143, which, as our results suggest, plays a key 
role in the HIPKD pathomechanism, as the PMM2 promoter SNP is located right in the 
ZNF143 DNA binding site (Figure 31). Interestingly, Bailey et al. have identified ZNF143 
as a novel chromatin-looping factor which is majorly involved in discrete chromatin 
formation to facilitate interactions between promoters and distal regulatory elements 226: 
They have shown that ZNF143 directly binds to gene promoters to stimulate chromatin 
interactions. This agrees with our EMSA data which demonstrated that ZNF143 binds to 
the intact PMM2 promoter 209. Although it is ubiquitously expressed 324, this suggested 
that ZNF143 may also play a role in tissue-specific chromatin conformation. Indeed, this 
was confirmed by studying chromatin interactions of the same locus in different cell lines 
in a 3C chromosome conformation capture analysis. Moreover, and in favour of our 
hypothesis of altered chromatin loop formation, modifications within ZNF143 binding 
sites through SNPs have indeed been shown to significantly change its DNA-binding 
affinity with consequent altered chromatin interaction patterns 226. This suggests the 
potential formation of disease-associated chromatin interactions when conformational 
control through ZNF143 is impaired. This, we suspect, is the case in HIPKD and is 
underpinned by our EMSA data indicating substantial impairment of ZNF143 binding to 
the defective PMM2 promoter. Thus, transformation of the structural chromatin loop into 
a functional sub-loop by ZNF143 binding would enable normal PMM2 regulation, 
whereas this would be prevented in the presence of the promoter mutation. Additional 
data on ZNF143 interaction with other factors also support this model of PMM2 regulation 
228: ZNF143 highly colocalises with CTCF and cohesin. All three factors are expressed 
globally and are highly enriched at TAD boundary regions. Although the exact molecular 
mechanisms of the ZNF143/CTCF/cohesin interplay are not yet fully understood these 
findings do implicate their mutual function on 3D chromatin conformation and associated 
specific gene regulation 228.  
Back to our HIPKD hypothesis, such a relationship between ZNF143, CTCF and cohesin 
would support the necessity of ZNF143 “pulling” the loop down through binding to the 
intact PMM2 promoter and CTCF/cohesion. This would facilitate proximity of the PMM2 
promoter with a set of distinct regulatory elements at the anchors of the loop to enable 
specific spatiotemporal regulation of the gene.  
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As mentioned earlier, one such regulator facilitating tissue-specific PMM2 expression 
could be the transcription factor HNF4A. HNF4A is an attractive candidate due to its 
predominant expression in kidney, liver and pancreas – the three organs affected in 
HIPKD 325. As clusters of HNF4A sites have been found within the loop in silico this could 
explain the tissue-specific PMM2 expression, which is impaired in HIPKD patients and 
responsible for the restricted phenotype.  
The concept of specific promoter-enhancer interactions and related individual chromatin 
conformations as a key mechanism of tissue-specific gene expression was already 
proposed in 2000 and reviewed by Kleinjan et al. 326,327. The model of such “functional 
gene expression modules” is shown in Figure 71.  
Figure 70: Tissue-specific chromatin loop formation suspected in healthy state (A) and HIPKD (B). 
Grey arrows mark the genes considered within the loop including PMM2.  
A 
B 
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A question remains whether the expression of the other three genes located in the 
structural loop, TMEM186, ABAT and CARHSP1, might also be altered and thus 
potentially could also have an effect on HIPKD. This would be easiest to consider for 
TMEM186, which is regulated by the same promoter. Yet, the ABAT gene is also 
interesting, as it encodes the gamma-aminobutyrate transaminase which converts GABA 
(gamma-aminobutyric acid), a neurotransmitter into succinic semialdehyde. 
Interestingly, GABA enhances insulin secretion under low glucose conditions (as in 
HIPKD) in murine INS-1 cells 328. Hence, one could speculate that altered loop formation 
in HIPKD could reduce ABAT expression, which in turn would increase GABA levels and 
thus enhances insulin secretion. However, an insulin-related phenotype has not been 
reported in patients with GABA-transaminase deficiency, a severe autosomal recessive 
disorder caused by biallelic mutations in the ABAT gene which damage the brain 329.  
Unfortunately, the gene expression studies on all genes in the loop did not provide us 
with convincing results we trust due to poor input material and thus requires repetition in 
Figure 71: Putative model for the individual tissue-related regulation of different genes located in 
the same DNA region after Dillon and Sabattini 2000.  
Three genes are located in the same DNA region. Gene X (eye) and gene Y (brain) are tissue-
specific, gene Z (housekeeping gene) is ubiquitously expressed. The transcription of the genes X 
and Y depends on chromatin formation and different active enhancer elements interacting with 
gene promoters in eye and brain that are bound by different transcription factors. The 
housekeeping gene is transcribed in all tissues. Figure taken from Kleinjan 2005.  
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the future. This was outlined in chapter-specific discussion analysing the gene 
expression studies (4.4). However, the results obtained should not be ignored 
completely, especially for CARHSP1 – the only gene for which the expression was 
significantly reduced in the compound heterozygous patient (Figure 39). With its two 
RNA binding domains, CARHSP1 is able to regulate crucial processes within protein 
biosynthesis, such as the regulation of ribosomal translation, mRNA degradation and the 
rate of transcription termination. Studies on TNF-α have demonstrated 1) CARHSP1 
binding to the 3’UTR of TNF-α as well as 2) reduced protein production and mRNA levels 
of TNF-α when CARHSP1 was knocked down 231. This example reflects the negative 
effect impaired CARHSP1 expression can have on the expression of other genes, which 
theoretically could also apply in the HIPKD case. However, insights regarding the distinct 
function of CARHSP1 are limited as most research has been conducted on the signalling 
pathways which phosphorylate and dephosphorylate CARHSP1 330. Thus, extensive 
research on this particular involvement of CARHSP1 on transcriptional and translational 
processes is needed in general and also specifically concerning a major role within the 
HIPKD disease mechanism.  
Furthermore, altered or reduced expression of the additional looping genes could 
potentially be caused by the predicted 3D conformational change of the chromatin loop 
in the HIPKD patient. As it was discussed in section 7.3, the 3D architecture of the 
genome indeed has an important influence on transcriptional regulation and could affect 
the expression of all genes in the loop. Imagining such a scenario, certain regulatory 
elements might not be able to interact with each other in the case of HIPKD to properly 
control gene expression in the three affected organs. So, one could theoretically argue 
that the phenotype seen in the patients may not or at least not solely be a result of 
impaired protein N-glycosylation due to reduced PMM2 expression but also 
dysregulation of additional genes, e. g. CARHSP1. However, a substantial contribution 
of these genes is unlikely, considering that most patients are compound heterozygous 
for the promoter mutation and a coding PMM2 mutation. Thus, expression of the other 
genes would only be changed from one allele and if this would be sufficient to cause 
disease, then the heterozygous carriers of the promoter mutation, without a coding 
mutation in trans (e.g. a parent) would be expected to also exhibit a phenotype. Hence, 
if the PMM2 promoter mutation initiated reduced expression of CARHSP1 in our assay 
(Figure 39), triggered by an altered chromatin loop formation and this results in the 
HIPKD phenotype, the heterozygous carriers of the c.-167G>T SNP must express the 
phenotype too – but they don’t exhibit any medical restrictions. Therefore, in the 
compound heterozygous patients, PMM2 is the only gene with clearly impaired function: 
a) by decreased expression from the allele with the promoter mutation and b) by the loss-
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of-function mutation on the other allele. Organ-specific PMM2 dysfunction thus is still 
considered to be the critical mechanism causing HIPKD.  
To finalise, additional interesting findings on how the shape of the genome contributes 
to gene regulation with its conformation were made quite recently: Studies on the 
molecular dynamics within the nucleus have demonstrated that most of the time, 
transcription factors actually remain in search mode before they find and bind to their 
respective site within the regulatory hubs. This diffusion along the chromatin fibres is 
apparently highly dependent on the conformation of the genome and is prone to changes 
in dependence of alterations in the genomic architecture 331. This supports the idea that 
tissue-specific gene regulation can be impaired due to the rearrangement of the 
regulating chromatin induced by disease-causing SNPs, simply preventing transcription 
factors (like ZNF143) to find their targets.  
The HIPKD cell model generated with CRIPSR-Cas9 during this PhD (see Chapter 6:) 
will help to further investigate the impact of dysregulated PMM2 expression and hopefully 
enable investigation of the hypothesis of altered tissue-specific loop formation in HIPKD 
as a result of the PMM2 promoter SNP as the key mechanism of this rare disease.  
7.4 HIPKD and glycosylation  
Knowing PMM2 is involved early during posttranslational protein N-glycosylation 185, we 
clearly link the occurrence of HI and cystogenesis to defective N-glycosylation in the 
HIPKD patients. As almost half of all naturally occurring proteins are N-glycosylated 194, 
there are potentially multiple proteins which have their function in the physiology of the 
nephron and insulin secretion pathway that are affected by PMM2 dysfunction. Hence, 
when improperly N-glycosylated many of those proteins are presumably involved in cyst 
formation and the excess secretion of insulin. Indeed, HI and cystic kidneys have been 
associated with deficient N-glycosylation within the broad range of multisystemic 
manifestation in CDG-1a. Renal involvement as one of multiple features within CDG was 
first described in detail in 1993 when five patients were examined, partially presenting 
multiple renal microcyst but also distinct larger cysts as observed by ultrasound and 
histology 332. Additional cases describing renal involvement in CDG-1a have followed 
and kidney features have been added to the long list of organ manifestations seen in 
CDG 183.  
HI is related to many types of developmental syndromes and its association with defects 
in N-glycosylation has been linked to three subtypes of CDG 333. Three cases with 
persistent HI either in combination with additional typical features of CDG-1a or in one 
of the cases also in isolated format have been reported in 2009 334. The clinical 
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phenotypes of all three patients during infancy was dominated by HI. However, all three 
individuals showed the serum transferrin pattern typical within CDG-1a caused by 
deficient PMM2 function. Of note, in the patient with isolated HI, only a heterozygous 
mutation was identified, hence PMM2 activity was reduced, but not absent. whether 
PMM2 deficiency in this patient was truly the cause of HI is unclear and thus this case 
does not contradict the obligate neurological involvement in CDG-1a.  
Regardless, the awareness of HI as a leading symptom of CDG-1a, prompted the 
inclusion for testing of CDG in all cases with HI to reduce the risk of misdiagnoses. HI as 
a symptom has also been noted in two other types of CDG namely CDG-1b 335. and 
CDG-1d 336,337. The molecular mechanisms of HI within CDG are not fully understood but 
are likely related to the membrane-bound KATP channels in β-cells as both major 
components of the channel, SUR1 (ABCC8 gene) and Kir6.2 (KCNJ11 gene) are N-
glycosylated 333 and mutations in the encoding genes are responsible for congenital HI 
338. Indeed, mutagenesis studies on SUR1 have shown that when SUR1-N-glycosylation 
sites are mutated this impairs SUR1 trafficking to the β-cell membrane and retains the 
protein at the ER where it is assembled. This suggests direct involvement of defective 
SUR1 N-glycosylation in CDG due to reduced cell surface expression which causes HI 
339. In contradiction to these findings are the observations that many CDG patients and 
also the HIPKD patients do respond to diazoxide treatment to lower the amounts of 
insulin secretion which suggests that KATP channels are intact in those cases 336. Other 
proteins heavily involved in glucose homeostasis and insulin secretion are the glucose 
transporters GLUT1 and GLUT2, both membrane-bound proteins which are N-
glycosylated. However, solid scientific evidence for this theory to date is missing but 
depletion of N-glycosylation sites of GLUT1 resulted in a significant increased uptake of 
glucose in rodents which theoretically could promote enhanced insulin release 340. 
Further genes and their protein products which evidently have significance in HI are not 
N-glycosylated and therefore unlikely to be targets of defective PMM2 function. However, 
it should be kept in mind that around 40-50% of HI cases are of unknown genetic cause 
338.  
Several other studies have linked renal cystogenesis and defective N-glycosylation of 
key proteins: Rare cases of GANAB mutations for example which cause ADPKD and 
also autosomal dominant polycystic liver (ADPLD) have been described in 2016 341: 
Mutations in GANAB affect the encoded protein glucosidase IIα subunit (GIIα) which is 
crucial for maturation and correct intracellular localisation of PC-1 and PC-2 to the cell 
surface and cilia of the proximal renal tubular epithelial cells. If GIIα is intact, it trims 
immature proteins in the ER by cleaving off glucose residues to transform them into 
their mature format. Missense mutations in GANAB negatively affect the maturation of 
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PC-1 and reduced amounts of mature PC-1 have been observed in GANAB+/- cells. 
Thus, incorrect glycosylation patterns of PC-1 prevent it to exert its full function within 
the nephron which often leads to cyst formation. Dysfunctional PC-1 is a major cause 
for ADPKD and cystogenesis as outlined in the introduction of this thesis.  
Aberrant PC-1 glycosylation as a cause for kidney cysts in mice has also been observed 
and was linked to mutations in the Aqp11 gene. Furthermore, PC-2 levels, its localisation 
and stability are highly dependent on its N-glycosylation status. Thus, inadequate N-
glycosylation of PC-2 is likely an additional reason for cystogenesis in ADPKD 223. 
In conclusion, key proteins involved in cystic kidney disease, such as PC-1 (PKD1), PC-
2 (PKD2) and also fibrocystin (PKHD1) are N-glycosylated and therefore are all potential 
candidates to be incorrectly glycosylated in HIPKD. In addition, the genetic causes for 
glomerular cyst are quite heterogeneous as discussed earlier, expanding the list of 
proteins which could be affected, uromodulin for example is one of them. Furthermore, 
considering that many signalling pathways and regulatory processes involved in renal 
development are affected in PKD and also the different pathways regulating insulin 
secretion, this further extends the number of proteins which might be potential targets of 
glycosylation defects in HIPKD.  
A novel devastating subtype of CDG was also reported in 2016 342: Truncating mutations 
in the ALG9 gene triggered a severe phenotype similar to the one seen in the Gillessen-
Kaesbach-Nishimura syndrome presenting with multiple malformations, skeletal 
dysplasia and renal cysts. ALG9 encodes the alpha-1,2-mannosyltransferase – an 
enzyme which is involved in the lipid-linked precursor oligosaccharide assembly during 
the N-glycosylation pathway.  
The key proteins causative for polycystic liver disease, Glucosidase IIβ subunit (GIIβ, 
PRKCSH) and translocation protein SEC63 (SEC63), are involved in the N-glycosylation 
pathway in the ER. Thus, mutations in the respective genes result in dysfunctional 
SEC63 and GIIβ which affects the correct glycosylation of proteins important for liver 
development 343.  
Evidence for the glycosylation defect we postulate for HIPKD has been observed in a 
mouse β-cell line: We have shown that insulin secretion seemed to be enhanced when 
mouse β-cell proteins were deglycosylated 209. However, we could not confirm this effect 
with deglycosylated human pancreatic islets because variations in insulin measurements 
were too high to draw distinct conclusions. Thus, studies on defective insulin secretion 
based on the deficient PMM2 expression in HIPKD will be subject for future 
investigations (8.3).  
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7.5 HIPKD cell line – improvement and alternatives  
As outlined in section 6.4, the use of HepG2 cells involved some difficulties whilst 
performing the CRISPR-Cas9 experiments. Apart from those technical issues, we were 
aware that HepG2 is surely not an ideal cell line for the purpose of this study as it is a 
cancer cell line knowing to be aneuploid (55 chromosomes on average) and genomically 
instable. Indeed, there is evidence that almost the entire chromosome 16 underwent a 
copy number gain in HepG2 and therefore the targeted locus likely is present more than 
twice in HepG2 344. Luckily, this would not hinder a sufficient performance of a chromatin 
conformation study, as long as CRISPR-Cas9 introduces the c.-167G>T SNP in 
homozygous state (personal communication). However, as we were restricted to work 
either with a human kidney, β-cell or at least a liver cell line, HepG2 was the best choice 
to start with as we were not aware of a reliable human β-cell line. While there are human 
kidney cell lines, the difficulty is that we do not know which kidney cells are affected by 
the promoter mutation: there are numerous different cell types in the kidney, ranging 
from highly specialised glomerular and tubular epithelial cells to mesenchymal cells and 
we currently do not know, which of these are affected. Without this information, choosing 
a specific cell line is impossible. Obviously, a similar problem arises for liver cells, as the 
liver also contains multiple different cell types. But, in support for the HepG2 cells was 
also the result of the in-silico analysis (Figure 35) reflecting HepG2 to be the only cell 
line in which the chromatin seems to be active throughout the predicted loop on 
chromosome 16. Unfortunately, no data from a human kidney or β-cell line were 
available to include in this chromatin segmentation analysis, therefore HepG2 was the 
best candidate cell line to use at this stage.  
Other options to consider are the use of human iPS cells or to isolate the particular cell 
type (e. g. glomerulus) needed from the primary renal cell culture of the control kidney 
used in this study. Both versions could then be CRISPRed to generate the desired 
disease model. This would also allow to overcome the issues related to the gene 
expression studies outlined above when using end-stage kidney material form the 
compound heterozygous patient (4.4). However, the disadvantage of primary cells is 
their limited lifespan and ability to proliferate before they reach senescence 345. A solution 
could be to immortalise the isolated cells from primary culture to keep the cell cycle active 
and cells dividing. As primary cells are difficult to transfect, an immortalisation is most 
efficient through viral infection to introduce certain genetic changes to guarantee for 
example consistent telomerase activity. But genetically modifying a genome always 
bears the risk of changing the phenotype of the targeted cells whilst going through the 
immortalisation process, which could impact on the experimental outcome 346.  
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Another time-saving alternative instead of editing human iPS cells or for example 
glomerular cells from primary culture is the use of stem cells obtained directly from one 
of the patients. This would save the labour of gene editing completely. These stem cells 
then could be programmed into iPS cells and afterwards differentiated into β-cells for 
insulin secretion studies and kidney cells for gene expression analysis and a capture C 
analysis to study whether altered chromatin conformation of the PMM2 loop is the case 
in HIPKD. However, this approach will not solve the issue of limited cell proliferation once 
the cells are differentiated. This in particular is a problem to sufficiently conduct a capture 
C analysis which requires incredibly large cell populations (at least 10 million cells per 
sample per experiment) to generate solid and reproducible interaction maps with high 
resolution 347. Thus, generating 3C libraries (the first crucial step in capture C) from rare 
tissues and cell types is nearly impossible. However, recent advances from the pioneers 
in the field of chromatin conformation capture produced high quality interaction profiles 
from only 10,000 – 20,000 cells 348. This is of immense use for the scientific community 
to explore how structural interactions influence gene activation und could be an option 
to study the potential chromatin conformation change suggested in HIPKD (Figure 36).  
The use of CRISPR RNPs and electroporation has tremendously improved the outcome 
of the tedious process producing this HIPKD cell model which failed using CRISPR-Cas9 
expression plasmids and reagent-based transfection (Chapter 6:). What initially failed for 
6 months worked out in the end within 1.5 months (electroporation to identification of 
homozygous single cell HIPKD clone) after changing the format of the system. Clearly, 
this indicates CRISPR RNPs as the better choice to perform a successful CRISPR 
knock-in through the HDR repair pathway, which is known to be a very inefficient 
process. Scientist are continuously working on improving the CRISPR technology to 
overcome such restrictions and are in particular keen on solving the problem of the yet 
inefficient CRISPR knock-in process. Big advances have been made at least at the stage 
of directed single base pair substitutions. “CRISPR base editors” catapult modern gene 
editing to its next level 349,350: A catalytically inactive so called “dead” Cas9 (dCas9) fused 
with nucleobase deaminases is capable to convert A·T to G·C and G·C to A·T base pairs 
allowing programmable base editing without creating a double strand break and the use 
of an HDR donor template. The efficiency of those adenine (e.g. ABE7.10) and cytidine 
(e.g. BE4) base editors is reported to be an impressive 50% and reveals high product 
purity in human cells. In addition, the system significantly reduces the formation of indels 
to 0.1%. This approach demonstrates a powerful tool to precisely correct disease-
causing point mutations and can be used to efficiently generate disease models for 
monogenic diseases, such as HIPKD. To date, the system is tied to some limitations as 
it is only able to perform base pair transitions (change of purine base to other purine 
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base or pyrimidine to other pyrimidine base) but not transversions (purine changed to 
pyrimidine and vice versa). Therefore, only the four base pair transitions C-to-T, G-to-A, 
A-to-G, and T-to-C are yet possible to achieve with the system. Hence, in the case of 
HIPKD, the base editors available would only introduce a G-to-A instead of the desired 
G-to-T SNP at position -167 within the PMM2 promoter due to the 
purin→purine/pyrimidine→pyrimidine restriction. Therefore, such base editors are not 
advantageous to use in the particular HIPKD case. However, vast enhancements on the 
base pair editing system are emerging and scientists work hard to improve efficiency and 
precision of the system and foremost to reduce or ideally eliminate the risk of unwanted 
off-target single base substitutions 351. Surely, there is more exciting development within 
the field of cutting-edge genome editing technology to come in the near future which will 
help us to conquer current restrictions to the CRISPR technology.  
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Chapter 8: Future work  
8.1 Gene expression studies with HIPKD cell line  
The expression levels of all four genes (PMM2, TMEM186, CARHSP1, ABAT) within the 
predicted chromatin loop plus the expression of two control genes (PPIA, CDH1) were 
analysed in a dPCR setting on the basis of primary renal cells obtained from one of the 
HIPKD patients. However, the interpretation of the results appeared to be difficult and 
the analysis needs repetition. All six gene expression assays used in the digital PCR 
setting should be repeated using the new HIPKD cell model which was generated in this 
study and the results compared to a control. This will exclude the issues related to the 
quality of the cell material used in the previous setting (4.4).  
8.2 Verification of the glycosylation status of proteins 
in HIPKD  
A simple test to assess the overall glycosylation status in HIPKD could be performed 
with quantitative proteomic for example within an IEF assay. Isolated proteins taken from 
HIPKD and wild type control cells could be used for such an assay. If N-glycosylation is 
significantly affected in HIPKD this should be visible due to a different migration pattern 
of this sample within the electric field.  
To focus on the glycosylation status of particular proteins, for example the SUR1 and 
Kir6.2 subunits of the KATP channel, potential differences could be observed with SDS-
PAGE and Western blotting using specific antibodies. A shift in the migration pattern 
between mutant and control sample should be noticeable if the N-glycosylation pattern 
clearly differs.  
8.3 Continue studying the impact of defective 
glycosylation on insulin secretion in HIPKD 
The functional consequences of a potentially altered protein glycosylation in HIPKD is 
still questionable and needs further investigation. Although the use of human pancreatic 
islets seems to be a promising approach to measure insulin secretion, the experimental 
settings would require significant improvement in order to generate reliable data to 
overcome the errors which are related to the work with pancreatic islets (5.4). To prevent 
those errors a reliable approach is to generate a HIPKD β-cell line. This would allow 
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insulin measurement without having to manipulate the cells with the deglycosylation 
enzymes to mimic a glycosylation effect. Such a cell line can be generated after the same 
principle as it was successfully applied to HepG2 cell using the CRISPR-Cas9 system. 
As we did not produce reliable data with commercially available human β-cell lines in 
previous studies, a good alternative to use would human inducible pluripotent stem cells 
(iPSC). The HIPKD promoter mutation could be introduced in those iPSC which then 
could be differentiated into β-cells 352,345. Changes in insulin secretion could then be 
assessed in a glucose-induced insulin secretion assay exposing the HIPKD β-cells to 
low and high glucose concentrations and compare the result to a control group.  
It could also be considered to go one step further and try to re-aggregate engineered β-
cells into pseudo islets so that they would be closer to their natural environment. Studies 
on re-aggregated islets have shown that this has improved β-cells performance 354,355.  
8.4 Validation of the HIPKD cell model  
Prior to proceeding work with the new CRISPR engineered HIPKD cell model, its 
suitability should be verified. A ChIP-qPCR assay could help to assess ZNF143 binding 
to its binding site within the PMM2 promoter in the HIPKD cell line compared to a wild 
type control 356. This would quantify ZNF143 interactions with the PMM2 promoter and 
would indicate significant differences in the mutant if there are some.  
8.5 3D chromatin conformation in HIPKD  
Tissue-specific altered chromatin loop formation due to the impaired binding of ZNF143 
based on the PMM2 promoter SNP was suggested to be the disease mechanism in 
HIPKD. This hypothesis needs to be validated and a Capture C analysis could 
investigate this further to eventually shed light onto the 3D architecture within HIPKD. 
This method has been successfully applied to analyse interactions between gene 
promoters and regulatory elements in detail at any given locus to understand the 3D 
folding-characteristics of the human genome. Its high throughput capacities allow to look 
at multiple specific interactions within only one experiment to 1) clarify the principles by 
which gene expression is controlled which is highly depended on inter- and intragenic 
interactions and 2) to enable scientists to investigate the functional effects of SNPs 
located in regulatory elements which are related to human diseases 347.  
The new HIPKD cell model can be used in such an analysis to investigate the interactions 
of the PMM2 promoter with regulatory elements, especially HNF4A, and differences 
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compared to a wild type control can be assessed. In addition, this experiment should 
also be done with cells which originate from a tissue which is not affected by HIPKD to 
validate the tissue-specific loop formation enclosing PMM2 expected in kidney, liver and 
pancreas.  
8.6 Conclusion  
This study provides evidence that the PMM2 promoter mutation clearly reduces the 
expression of the PMM2 gene at the allelic level in HIPKD patients. This finding 
contributes to the overall assumption that disrupted ZNF143 binding results in 
dysfunctional PMM2 expression in HIPKD which is thought to be associated with 
impaired tissue-specific PMM2 gene regulation in particular in the three affected organs. 
To be able to investigate this further, a HIPKD cell model was successfully generated 
with CRISPR-Cas9 and HepG2 cells which have the c.-167G>T SNP stably introduced 
in homozygous state. Preliminary data were obtained addressing a glycosylation defect, 
which causes raised insulin secretion in HIPKD. A trend supporting this expectation of 
increased insulin secretion in HIPKD has been observed but needs approval in the 
future.  
Overall, the findings of this study and the discovery of HIPKD extent the genetic cause 
for HI and PKD and also provide an additional example of how non-coding mutations 
have their impact in human disease. In addition, the study reflects the importance of 
including non-coding variants in the genetics of human disease. Furthermore, it creates 
awareness on how appropriate gene regulation and expression substantially relies on 
the higher organisation of the human genome in the 3-dimensional space.  
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Appendix 
 
1. Insulin sceretion assay (Assay 1) human pancreatic islets 
Batch 1 (absolute values 
 
Table 16 APPENDIX: Single values, means and SEM (abs. values; µU/mL) measured and 
calculated for experiment 1, Assay 1 (islets Batch 1). 
Secreted insulin and intracellular insulin (cell lysates).  
*excluding sample 4/control 
  2.8 mM = 2.8 mM glucose 
  28 mM = 28 mM glucose 
  0 mM = 0 mM glucose 
  PNGase F = 500 nM PNGase  
 
Experiment 1 (µU/mL) 
Condition Sample 1 Sample 2 Sample 3 Sample 4/Control Mean SEM 
2.8 mM 0 min 173.80 343.56 330.44 378.45 350.82 45.40 
2.8 mM 60 min 366.07 585.82 424.86 351.26 432.0 53.68 
28 mM 0 min 181.50 32.62 98.16 14.93 81.80 37.75 
28 mM 60 min 444.93 287.17 209.95 272.32 303.59 50.00 
2.8 mM 0 min 385.95 421.3 472.09 280.06 389.85 40.64 
2.8 mM 60 min 366.0 637.46 356.48 382.15 435.52 67.52 
0 mM + 
PNGase F 0 
min 
199.69 173.51 7.84 / 127.01 60.06 
0 mM + 
PNGase F 60 
min 
587.03 463.87 331.42 / 460.77 73.80 
0 mM 0 min 
(Control) 
/ / / 318.08 / / 
0 mM 60 min 
(Control) 
/ / / 532.57 / / 
Cell lysates 421.15 2640.97 455.71 480.37 (Control) 1172.61* 734.25* 
  212 
Figure 72: APPENDIX. Assay 1, experiment 1. Extra- and intracellular insulin measurement.  
Absolute insulin concentrations (µU/mL) for time points T0 and T60 are shown. All four islets samples were included in the GSIS series (n=4) and stimulated with 2.8 mM, 28 
mM and 2.8 mM glucose (Grey bars). After GSIS three of the samples were incubated with 2,000 U PNGase F pre-prepared in its enzyme buffer (Na3PO4, 50 mM final 
concentration) in 0 mM glucose (n=3, black bar). One sample was used as a control only incubated with enzyme buffer also in 0 mM glucose (n=1, white bar). After passing 
all 4 conditions islets were lysed. Values are means±SEM when applicable. Statistical significance (P<0.05) was tested using a one-way ANOVA followed by a Bonferroni 
multiple comparisons test to compare between the different conditions.  
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Table 17: APPENDIX. Single values, means and SEM (abs. values; µU/mL) measured and 
calculated for experiment 2, Assay 1 (islets Batch 1). Secreted insulin and intracellular insulin 
(cell lysates). 
*excluding sample 4/control 
  2.8 mM = 2.8 mM glucose 
  28 mM = 28 mM glucose 
  0 mM = 0 mM glucose 
  PNGase F = 500 nM PNGase F 
 
 
 
 
 
 
Experiment 2 (µU/mL) 
Condition Sample 1 Sample 2 Sample 3 Sample 4/Control Mean SEM 
2.8 mM 0 min 25.14 37.35 35.24 80.52 44.56 12.28 
2.8 mM 60 min 74.16 100.98 97.74 209.99 120.72 30.35 
28 mM 0 min 37.74 15.26 113.66 93.64 65.07 23.10 
28 mM 60 min 40.98 46.92 68.18 285.91 110.5 58.76 
2.8 mM 0 min 96.08 105.58 216.20 102.55 130.10 28.77 
2.8 mM 60 min 188.16 152.38 169.19 237.17 186.73 18.33 
0 mM + 
PNGase F 0 min 
4.99 4.43 10.54 / 6.65 1.95 
0 mM + 
PNGase F 60 
min 
157.97 168.61 164.61 / 163.54 2.95 
0 mM 0 min 
(Control) 
/ / / 5.55 / / 
0 mM 60 min 
(Control) 
/ / / 178.12 / / 
Cell lysates 283.72 257.3 299.72 290.61* 280.25 12.37 
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Figure 73: APPENDIX. Assay 1, experiment 2. Extra- and intracellular insulin measurement.  
Absolute insulin concentrations (µU/mL) for time points T0 and T60 are shown. All four islets samples were included in the GSIS series (n=4) and stimulated with 2.8 mM, 
28 mM and 2.8 mM glucose (Grey bars). After GSIS three of the samples were incubated with 2,000 U PNGase F pre-prepared in its enzyme buffer (Na3PO4, 50 mM final 
concentration) in 0 mM glucose (n=3, black bar). One sample was used as a control only incubated with enzyme buffer also in 0 mM glucose (n=1, white bar). After passing 
all 4 conditions islets were lysed. Values are means±SEM when applicable. Statistical significance (P<0.05) was tested using a one-way ANOVA followed by a Bonferroni 
multiple comparisons test to compare between the different conditions.  
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2. Insulin sceretion assay (Assay 2) human pancreatic islets 
Batch 2 (absolute values) 
 
Table 18:  APPENDIX. Insulin secretion from Assay 2 with islets Batch 2. Single values, means 
and SEM (abs. values; µU/mL) measured and calculated.  
Secreted Insulin (µU/mL) 
Group Condition Experiment 1 Experiment 2 Means SEM 
Without 
PNGase F and 
Endo H  
2 mM glucose 
914.55 
977.08 
1003.6 
1025.23 
980.12 23.97 
20 mM glucose  
1273.01 
1081.01 
1077.76 
1202.16 
1158.48 47.91 
20 mM glucose 
+ 500 nM PMA 
1489.49 
1278.67 
1377.89 
1420.35 
1391.6 44.11 
With PNGase 
F and Endo H  
2 mM glucose 
11697.72* 
988.48 
1112.72 
1041.06 
1047.42 
 
36.01 
20 mM glucose  
1150.47 
1106.69 
1400.16 
1357.33 
1253.66 73.29 
20 mM glucose 
+ 500 nM PMA 
1375.72 
1369.24 
1943.95 
3899.25* 
1562.97 190.50 
*omitted 
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Table 19: APPENDIX. Intracellular insulin from Assay 2 with islets Batch 2. Single values, means 
and SEM (abs. values; µU/mL) measured and calculated.  
Intracellular Insulin (Lysates) (µU/mL) 
Group Condition Experiment 1 Experiment 2 Means SEM 
Without 
PNGase F and 
Endo H  
2 mM glucose 
26729.45 
50507.07 
16674.79 
25997.29 
22477.15 2380.86 
20 mM glucose  
40018.63 
37073.25 
13760.08 
17090.49 
26985.61 6735.78 
20 mM glucose 
+ 500 nM PMA 
30457.48 
27376.21 
15443.09 
17529.09 
22701.47 3667.95 
With PNGase 
F and Endo H  
2 mM glucose 
43204.21 
46066.01 
1500.19 
14473.35 
34581.19 10087.81 
20 mM glucose  
38633.77 
40741.23 
15688.22 
17322.04 
28096.32 6714.28 
20 mM glucose 
+ 500 nM PMA 
21523.8 
35140.43 
26863.72 
16178.61 
24926.64 4043.32 
*omitted 
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Figure 74: APPENDIX. Assay 2. Extra- and intracellular insulin measurement.  
Absolute insulin concentrations (µU/mL) for each condition for non-glycosylated control (white bars) and deglycosylated samples (black bars) are shown. Six samples were 
treated with PNGase F and Endo H for deglycosylation and six were kept glycosylated in a first incubation step at 2 mM glucose (120 minutes). In total, three different conditions, 
2 mM glucose, 20 mM glucose and 20 mM glucose plus 500 nM PMA were tested and completed in BSS (Balanced salt solution) in a second step (60 minutes incubation). Two 
islets samples were included per condition per experiment. After incubation islets were lysed (hatched bars). Values are means±SEM when applicable. Statistical significance 
(P<0.05) was tested using a one-way ANOVA followed by a Bonferroni multiple comparisons test to compare between the different conditions. 
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3. 100 bp and 1 kb DNA standards (NEB) 
 
100 bp standard:  
 
 
 
1 kb standard:  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 75: APPENDIX. 100 bp DNA standard.  
A number of proprietary plasmids are digested to 
completion with appropriate restriction enzymes to 
yield 12 bands suitable for use as molecular weight 
standards for agarose gel electrophoresis. The 
digested DNA includes fragments ranging from 100-
1,517 base pairs. The 500 and 1,000 base pair bands 
have increased intensity to serve as reference points. 
The approximate mass of DNA in each of the bands 
is provided (assuming a 0.5 μg load) for 
approximating the mass of DNA in comparably 
intense samples of similar size. 100 bp DNA Ladder 
visualised by ethidium bromide staining on a 1.3% 
TAE agarose gel. Mass values are for 0.5 µg/lane. 
Information taken from NEB.  
Figure 76: APPENDIX. 1 kb DNA standard.  
A number of proprietary plasmids are digested to 
completion with appropriate restriction enzymes to 
yield 10 bands suitable for use as molecular weight 
standards for agarose gel electrophoresis. The 
digested DNA includes fragments ranging from 0.5-
10.0 kilobases (kb). The 3.0 kb fragment has 
increased intensity to serve as a reference band. 
The approximate mass of DNA in each of the bands 
is provided (assuming a 0.5 μg load) for 
approximating the mass of DNA in comparably 
intense samples of similar size. 1 kb DNA Ladder 
visualized by ethidium bromide staining on a 0.8% 
TAE agarose gel. Mass values are for 0.5 µg/gel 
lane. Information taken from NEB. 
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4. Ethical considerations 
DNA and tissue samples (if applicable) were obtained after written consent from the 
patient and/or parents according to protocols approved by the Institute of Child 
Health/Great Ormond Street Hospital Research Ethics Committee (REC reference 
number: 05/Q0508/6).  
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